



EXHIBIT F

IN THE CIRCUIT COURT OF MONTGOMERY COUNTY, ALABAMA

THE LEAGUE OF WOMEN VOTERS)
OF ALABAMA, et al.)
))
Plaintiffs,)
))
v.)
))
JOHN MERRILL, in his official capacity)
as Alabama Secretary of State, et al.)
))
Defendants.)

Case No. 03-CV-2020-900702

AFFIDAVIT OF DR. MICHAEL SAAG

STATE OF ALABAMA

COUNTY OF JEFFERSON

My name is Dr. Michael Saag. I am a resident of Jefferson County, Alabama. I am above the age of 19 years, and I am competent to make this affidavit.

1. I am Associate Dean for Global Health, Infectious Diseases, and Director of the UAB Center for AIDS Research at the University of Alabama at Birmingham. I received my B.S. in chemistry with honors from Tulane University in 1977 and my medical degree with honors from the University of Louisville in 1981. I completed my residency and infectious disease and molecular virology fellowship training at the University of Alabama at Birmingham, completing all of the above by 1987. I am board certified in Infectious Diseases and Internal Medicine. I am a full Professor of Medicine with tenure

in the Division of Infectious Diseases at the University of Alabama at Birmingham School of Medicine. Among other responsibilities over my career, I have served on the Board of Directors of the American Board of Internal Medicine and as Chair of the Infectious Disease Subspecialty Board. A copy of my current CV reflecting my education, experience, accomplishments, and publications is attached to my affidavit.

2. As a physician who specializes in infectious diseases, I am very familiar with many of the infectious diseases that have been in our midst during the course of my 35+ year career, including Ebola, SARS, MERS, and AIDS. I have been involved in research and clinical studies and trials as well as the treatment, diagnosis, and care of many patients with viral infections as well many other infectious diseases. In my entire career, I have never seen a virus like SARS CoV-2, the coronavirus that causes COVID-19. This is a brand-new and novel infection which, based on the information we have to date, has never been transmitted into the human population until very recently.
3. COVID-19, the disease caused by SARS CoV-2, has many disturbing characteristics that cause those of us in the medical and public health community great concern. First, we continue to learn more about this virus at a rapid pace. Second, it is respiratory and transmitted primarily via airborne routes. Third, it is highly contagious from human to human. Fourth, it is associated with a considerable degree of morbidity and mortality. Fifth, we now know that a person is most contagious in the 24-hour period before that person becomes symptomatic.
4. Equally concerning is the growing literature of the number of people who have the virus but are asymptomatic. That means they are infected with the virus but have no symptoms. Despite having no symptoms they still are able to spread the virus to others

but do so without knowledge that they are carriers or transmitters of the disease. This means that they can infect countless people with whom they cross paths without ever realizing they are doing so. The presence of asymptomatic, yet highly-contagious, carriers of COVID-19 is a significant public health concern.

5. According the Alabama Department of Public Health (<https://covid19.alabama.gov/#live-updates>), as of June 16, 2020, in the state of Alabama alone there have been 26,524 confirmed positive COVID-19 cases with an additional 388 probable cases and 779 confirmed COVID-19 deaths and 6 additional probable deaths resulting from the virus. There were 7,986 new cases in the last 2 weeks alone. According to the CDC COVID Data Tracker as of June 16, 2020 there have been 2,104,346 total cases of the virus and 116,140 deaths resulting from the virus nationwide (<https://www.cdc.gov>). In contrast, the CDC estimates during the 2019-2020 flu season there were 24,000-62,000 deaths from the flu (<https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm>).
6. During the month of May 2020, daily reported cases in Alabama increased at an average higher rate than in any prior month since we began keeping track of the COVID-19 infection rate. Specifically, as of May 1, 2020, the average daily incidence of new COVID-19 cases in Alabama was 180 cases / day; on June 16, 2020, the average number of new cases was 764 per day, the highest per day average ever reported in Alabama. (<http://91-divoc.com/pages/covid-visualization/>). We have no indication that transmission will decrease during the summer and fall months. Indeed, every indication is that the number of cases will continue to rise during the summer and into the fall. This opinion is based on the knowledge that the virus is present within the community, it is

very contagious (more contagious than seasonal influenza), the at-risk population is made up of > 90% of the total population (i.e., those who have never been infected remain 'at-risk'), and the population is tired of staying at home and want to re-engage now back into the activities they were doing before the epidemic hit Alabama. For all of these reasons, the virus is very likely to continue its aggressive transmission rate for the foreseeable future until an effective vaccine is developed, mass produced, and made fully available to and utilized by > 50% of the general public. In other words, this virus is not going to magically disappear. The likelihood is that the rate of transmission will continue to increase as time goes on, into the fall and winter months of 2021.

7. The prevailing medical viewpoint, based on my research, study, and discussions with other infectious disease and public health experts, is that the best-case scenario for developing a vaccine, making it available to the general public, and seeing it widely implemented, is at least a year or more away.
8. The virus is definitely in our midst here in Alabama and transmission from person to person is inevitable, including transmission among susceptible populations who are more prone to develop significant morbidity and mortality if they become infected. What types of people constitute susceptible populations? The elderly, people with underlying conditions that are prevalent in our state such as hypertension, diabetes, heart disease, obesity, and pulmonary issues, and those with compromised immune systems (e.g., those on potent immune suppressive agents to treat autoimmune disorders, malignancies, or those who have had organ or bone marrow transplants). According to estimates based on the 2010 US Census (<https://www.census.gov/quickfacts/AL>), an estimated 828,638 (16.9%) Alabamians are 65 years of age or older. That said, transmission certainly is not

limited to people in these higher risk categories. This virus attacks all; no one is safe or protected from transmission and infection. Indeed, I contracted the virus in March 2020, and was far sicker than I have ever been in my life. I am in my 60s and I am hypertensive, but otherwise I do not have underlying conditions that should make me particularly vulnerable to the effects of COVID-19.

9. Based on my experience and expertise, it is my opinion that the people of Alabama should be extremely cautious about their interactions in public settings until a vaccine is widely distributed and utilized. We Alabamians should be on high alert right now, because I believe we are under a great public health threat, the magnitude of which we have never before encountered.

10. In my opinion, as it relates to COVID-19, the people of Alabama are not even into the woods yet, much less out of the woods. I am extremely concerned about the health and welfare of the people of our state. I believe that this virus will not only continue to escalate in Alabama, but this epidemic will be raging at a worse level into the fall and likely beyond. If the current trends hold, the death rates of ~ 1000 deaths / day across the United States, minimally, will continue as is. In a worst-case scenario, both the death rates and new case rates will continue to rise into autumn, with a potential 'spike' in cases as people return indoors for activities. This potential spike, if it occurs, would occur in late October or early November, right around the time of the election.

Complicating matters in the fall is the return of seasonal influenza, which will create a major diagnostic dilemma for physicians to determine if symptoms are due to influenza or COVID-19. This will cause confusion in both the healthcare settings and the general public.

11. Because we have no widely available treatment or an effective vaccine to protect us against this virus, we must take significant precautions to reduce the risk of exposure leading to infections. These include: (a) frequent hand washing, (b) avoiding crowds, (c) wearing a mask, (d) social distancing of a minimum of 6 feet (determined by estimating the distance aerosolized droplets travel during speech), assuming no one in the crowd is yelling, singing, exercising, or engaging in other activities that cause virus particles to project into the air at a greater distance than 6 feet, (e) physical separation, and (e) common sense avoidance of high transmission or hot spot locations. Even when these precautions are followed, exposure and resulting infection could still occur. Additionally, and unfortunately, some people simply do not follow these recommendations, which increases the risk for all of us.

12. Medical recommendations as well as common sense dictate that health and safety precautions must be put into place to protect our citizenry while they are exercising their constitutional right to vote in the general election. As Secretary of State Merrill said on March 15, 2020, in a statement concerning the need to postpone the Alabama runoff elections that were originally scheduled for March 31, 2020:

“The health and well-being of the people of this state are of paramount importance In order to effectively practice social distancing, as recommended by the President of the United States, the Centers for Disease Control & Prevention (CDC), the Alabama Department of Public Health, etc., the March 31 Runoff Election must be postponed.”
 Brian Lyman, *Alabama Secretary of State John Merrill seeks postponement of March 31 runoffs*, MONTGOMERY ADVERTISER, Mar. 15, 2020,

<https://www.montgomeryadvertiser.com/story/news/2020/03/15/alabama-secretary-state-seeks-postponement-march-31-runoffs/5056510002/>

I agree with what Secretary Merrill said in the quoted sentences. The concerns he raised about the need to postpone the runoff election remain true today and will be even more applicable in the fall, at the time of the November 3, 2020 general election. We must take precautions well in advance of an election date to protect the health and well-being of our citizenry as they exercise their constitutional right to vote.

13. The CDC has made recommendations for election officials to consider in advance of election day. These recommendations, found at <https://www.cdc.gov/coronavirus/2019-ncov/community/election-polling-locations.html>, provide as follows:

- a. “Encourage voters to use voting methods that minimize direct contact with other people and reduce crowd size at polling stations.
- b. Encourage mail-in methods of voting if allowed in the jurisdiction.
- c. Encourage early voting [i.e., before election day], where voter crowds may be smaller throughout the day. This minimizes the number of individuals a voter may come in contact with.
- d. Encourage drive-up voting for eligible voters if allowed in the jurisdiction.
- e. Encourage voters planning to vote in-person on election day to arrive at off-peak times. For example, if voter crowds are lighter mid-morning, advertise that in advance to the community.
- f. Encourage relocating polling places from nursing homes, long-term care facilities, and senior living residences, to minimize COVID-19 exposure among older individuals and those with chronic medical conditions.


g. Consider additional social distancing and other measures to protect these individuals during voting.”

14. In my view, the CDC recommendations are appropriate and, indeed, necessary to minimize as much as possible the transmission of this disease to citizens as they exercise their right to vote. The fact that this highly-contagious virus is airborne raises very significant public health concerns about public interaction of the type and nature that I have personally experienced when I have exercised my right to vote, and that issue is made all the more concerning when people fail to follow the recommendations concerning social distancing, wearing of masks in public, and the other precautions I have referenced.

Respectfully submitted, this 17th day of June, 2020.


Michael Saag, MD

Sworn to and subscribed before me this 17th
Day of June 2020, in and for the
County of Jefferson
State of Alabama


Notary Public
My Commission Expires: 9-21-20



Revised 01/14/2020

Michael S. Saag, MD



20 Jan 2020

**UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE**

PERSONAL INFORMATION

Name: Michael Switow Saag, M.D.

Citizenship: USA

Social Security #: *Available Upon Request*Home Address: 4963 Cold Harbor Drive
Birmingham, AL 35223

Phone: 205-951-2672

RANK/TITLE Professor of Medicine and Public Health
Associate Dean for Global Health, UAB School of Medicine
Director, University of Alabama at Birmingham Center for AIDS Research

Department: Medicine

Business Address: University of Alabama at Birmingham, School of Medicine
UAB Center for AIDS Research
845 19th Street South, BBRB 256D
Birmingham, Alabama 35294-2170

Phone: 205- 934-7349

Fax: 205-934-1640

Email: msaag@uab.edu

HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS

1987 - 2010 Staff Physician, Medical Service Infectious Diseases, Department of
Veterans Affairs Medical Center, Birmingham, Alabama

1987 - 2010 Consulting Physician, Cooper Green Hospital, Birmingham, Alabama

1987 - Present Attending Physician, Department of Medicine, University of Alabama at Birmingham,
School of Medicine, Birmingham, Alabama

2009 - Present Secondary Appointment to Epidemiology, University of Alabama at Birmingham
School of Public Health, Birmingham Alabama

Revised 01/14/2020

Michael S. Saag, MD

EDUCATION

- 1977 Chemistry, Tulane University
New Orleans, LA
Bachelor of Science, Cum Laude - Chemistry
- 1981 University of Louisville
Louisville, Kentucky
Doctor of Medicine, Cum Laude

LICENSURE

- 1982 State of Alabama Registration #10505

BOARD CERTIFICATION

- 1982 Diplomate, National Board of Medical Examiners
1985 Diplomate, American Board of Internal Medicine, Certificate #103723
1988 Diplomate, American Board of Internal Medicine, Subspecialty Infectious Diseases, Certificate #103723

POSTDOCTORAL TRAINING

Internship and Residencies:

- 6/1981 - 1982 Intern, Department of Medicine, University of Alabama at Birmingham, School of Medicine Birmingham, AL
- 6/1982 - 1984 Resident, Department of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham, AL
- 6/1984 - 1985 Chief Medical Resident, Department of Medicine, University of Alabama at Birmingham, School of Medicine, Birmingham, AL

Fellowships:

- 6/1985 - 1987 Clinical Fellow, Infectious Diseases and Molecular Virology, University of Alabama at Birmingham, School of Medicine, Birmingham, AL
- 6/1985 - 1987 Post Doctoral Research Fellowship in Virology and Molecular Biology, University of Alabama at Birmingham, School of Medicine, Birmingham, AL

ACADEMIC APPOINTMENTS

- 6/1984 - 1985 Chief Resident and Instructor in Medicine, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, AL
- 6/1985 - 1987 Research Fellow in Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL
- 6/1985 - 1987 Clinical Fellow in Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL
- 7/1987 - 1992 Assistant Chief, Medical Service, Birmingham Veterans Affairs Medical Center Birmingham, AL
- 10/1987 - 1992 Assistant Professor of Medicine, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, AL

Revised 01/14/2020

Michael S. Saag, MD

1/1988 – 7/2004	Founding Director, UAB AIDS Outpatient Clinic, University of Alabama at Birmingham, School of Medicine Birmingham, AL
7/1988 - 1999	Associate Director, General Clinical Research Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL
7/1988 - 2002	Senior Scientist/Associate Director for Clinical Care and Therapeutics, UAB AIDS Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL
10/1992 - 1997	Associate Professor of Medicine and Award of Tenure, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL
10/1997 - Present	Professor of Medicine and Award of Tenure, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, AL
7/2002 - 7/2004	Deputy Director, UAB AIDS Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL
02/2002 - Present	Senior Scientist, Center for Outcomes and Effectiveness Research and Education, University of Alabama at Birmingham School of Medicine, Birmingham, AL
3/2004 - Present	Senior Scientist, Minority Health and Research Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL
04/2004 - 08/2004	Interim Director, UAB Center for AIDS Research, Birmingham, AL
08/2004 - Present	Director, UAB Center for AIDS Research, Birmingham, AL
1/2007 - 3/2010	Director, Division of Infectious Diseases and International Health, UAB Department of Medicine, Birmingham, AL
01/2008 - Present	Senior Scientist, Center for Aging, University of Alabama at Birmingham, Birmingham, AL
06/2008 - Present	Senior Scientist, Center for the Study of Community Health, University of Alabama at Birmingham, Birmingham, AL
06/2009 – Present	Professor, Department of Epidemiology, University of Alabama School of Public Health
04/2009 - Present	Senior Scientist in the Virology Program, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
07/2012 – Present	Senior Scholar, Center for Palliative and Supportive Care, University of Alabama at Birmingham, Birmingham, AL
01/24/13 – Present	Senior Scientist, Center for Exercise Medicine, University of Alabama at Birmingham, Birmingham, AL
04/02/15 – Present	Associate Dean for Global Health, UAB School of Medicine
11/01/17 – Present	Investigator in the McKnight Brain Institute of Medicine, UAB School of Medicine, Birmingham, AL

AWARDS/HONORS

1976	Omicron Delta Kappa, Zeta Beta Tau, President
1978	Student Research Day - First Place, Medical School Division
1978 - 1981	Medical School Admissions Committee
1980	Alpha Omega Alpha
1981	Presley Martin Memorial Award for Excellence in Clinical Medicine
1984	Aesculapian Award for Excellence in the Clinical Practice of Medicine (given to

Revised 01/14/2020

Michael S. Saag, MD

best internal medicine resident at Cooper Green Hospital)

1986 - 1987 The Walter B. Frommeyer Fellowship Award in Investigative Medicine

1991 Honorary Citizen of Louisville, Louisville, KY

1992 Outstanding Medical Research Achievement Award, AIDS Task Force of Alabama

1993 Southern Society for Clinical Investigation

1993 - Present Board of Directors, International AIDS Society - USA

1994 *International Health and Medical Film Festival* Freddie Award Winner for "Be Careful Out There", a film for resident physicians regarding universal precautions

1994 - Present Listed in *The Best Doctors in America*, Woodward/White publishers

1996 - Present Tinsley Harrison Teaching Scholar

1996 Listed as one of the Best Doctors in America by *American Health*, a member of the Reader's Digest Special Interest Publications

1996 Myrtle Wreath Award, Hadassah (awarded for significant contributions to Medical Care)

1996 Chair, IAS-USA Guidelines Panel on the Use of Viral Load in Clinical Practice

1996 - 2006 IAS-USA Antiretroviral Therapy Guidelines Panel

1997 American Society for Clinical Investigation

2001 Odessa Woolfolk Community Service Award, University of Alabama at Birmingham School of Medicine (awarded in recognition of outstanding community involvement and social action).

2001 - Present Listed in *America's Top Doctors*, Castle Connolly Medical, LTD publishers

2002 Birmingham Business Journal's first *Who's Who in Health Care*

2002; 2003 Recipient, The Max Cooper Award for Research Excellence; UAB Department of Medicine, University of Alabama at Birmingham School of Medicine

2002 - 2004 Subspecialty Board on Infectious Diseases, American Board of Internal Medicine

2004 - 2008 Chair, Subspecialty Board on Infectious Diseases, American Board of Internal Medicine

2004 - 2008 Member, Board of Directors, American Board of Internal Medicine

2004 Honoree, Birmingham Chapter of the National Conference on Community and Justice (NCCJ), Birmingham, Alabama

2004 - Present Member, Rotary Club of Birmingham, Birmingham, Alabama

2005 Recipient, Live the Dream Award, Birmingham Regional Chamber of Commerce, Birmingham, Alabama

2005 - Present Listed as one of the Best Doctors in Birmingham in *Birmingham Magazine*, Birmingham, Alabama

2006 Recipient, Leonard Tow Humanism in Medicine Award, The Arnold P. Gold Foundation Jonathan Lax Memorial Lecturer, Philadelphia, PA

2006 Royal College of Medicine, Lecture, London, England

2007 Recipient, Hettie Butler Terry Community Service Award, UAB Medical Alumni Association

2007 Charles C. Shepard Science Award ceremony honored guest for recognition as a co-author on the manuscript *Rapid Scale-up of ART at Primary Care Sites in Zambia*, nominated in the "prevention and control" category

2007 UAB Center for AIDS Research, Gold winner in the Non-Profit category of the 2007 Excellence in Information Integrity Award; presented by the Information Integrity Coalition

2008 *Clinical Infectious Diseases* Award for Outstanding Review of the article entitled "An Unusual Abacavir Reaction in a HLAB*5701 Negative Individual"

2008 Recipient, Best Patient, Doctor, and Society Lecturer; and Best Fundamentals II Lecturer; UAB School of Medicine 13th Annual Argus Society Awards, presented by the UAB Medical Alumni Association

2009 Recipient: Best Patient, Doctor, and Society Lecturer; and Nominated, Best Fundamentals II Lecturer; UAB School of Medicine 14th Annual Argus Society Awards, presented by the UAB Medical Alumni Association

2010 Recipient: Best Patient, Doctor, and Society Lecturer, UAB School of Medicine 15th Annual Argus Society Awards, presented by the UAB Medical Alumni Association

2010 Association of American Physicians

2010 The UAB President's Medal of Honor

2013 34th Annual Reynolds Historical Lecturer, UAB

2014 Castle Connolly Medical Ltd National Physician of the Year Award for Clinical Excellence

2014 Alabama Health Care Hall of Fame, Inductee

2014- 2017 Founding Co-Chair, Hepatitis C Guidelines Panel, AASLD and IDSA

2015 Recipient: Best Patient, Doctor, and Society Lecturer, and Nominated, Best Fundamentals II Educator; UAB School of Medicine 20th Annual Argus Society Awards, presented by the UAB Medical Alumni Association

Revised 01/14/2020

Michael S. Saag, MD

2015	Recipient: Teaching Excellence Award, UAB Tinsley Harrison Internal Medicine Residency Program
2016	Recipient: Cotlove Award, presented by the Academy of Clinical Laboratory Physicians and Scientists
2016	Recipient: William Kirby Speaker, University of Washington, Seattle
2016	Recipient: Best Educator, Patient, Doctor, and Society Lecturer, UAB School of Medicine Annual Argus Society Awards, presented by the UAB Medical Alumni Association
2017	Recipient: Best Educator, Patient, Doctor, and Society Lecturer, UAB School of Medicine Annual Argus Society Awards, presented by the UAB Medical Alumni Association
2018	UAB Department of Medicine Faculty Honors Award for Excellence in Mentorship in Infectious Diseases
2018	Recipient: Best Educator, Patient, Doctor, and Society Lecturer, UAB School of Medicine Annual Argus Society Awards, presented by the UAB Medical Alumni Association
2018	Recipient: First Annual Marchase UWIRC Endowed Award, University of Alabama at Birmingham
2018	Recipient: 2018 School of Medicine Alumni Fellow Award, University of Louisville, Louisville, KY
2019	Recipient: Best Educator, Patient, Doctor, and Society Lecturer, UAB School of Medicine Annual Argus Society Awards, presented by the UAB Medical Alumni Association

PROFESSIONAL SOCIETIES AND MEMBERSHIPS

1985 - Present	Birmingham Infectious Disease Society
1988 - 1992	Member, American College of Physicians
1988 - Present	American Federation for Clinical Research
1988 - Present	American Association for the Advancement of Science
1988 - Present	Federation of American Societies in Experimental Biology
1988 - Present	American Society for Microbiology
1989 - 2005	President, Alabama Chief Residents Society
1989 - 2001	Physicians Association for AIDS Care
1989 - Present	Infectious Diseases Society of America; Board of Directors 2004-2007; Fellow 2006
1989 - Present	International AIDS Society
1989 - 2017	International Society for Antiviral Research
1990 - 1992	VA Society for the Practice of Infectious Diseases (VASPID)
1991 - 2000	Southern Medical Association
1992 - Present	American Society of Internal Medicine
1993 - Present	Fellow, American College of Physicians
1993 - Present	Southern Society for Clinical Investigation
1997 - Present	American Society for Clinical Investigation
1998 - Present	Jefferson County Medical Society, Inc
2002 - Present	HIV Medical Association; President 2009- 2010; Board of Directors 2004-2011
2005 - Lifetime	International Association of Physicians in AIDS Care (IAPAC)
2011 - Present	Association of American Physicians
2015	American Association for the Study of Liver Diseases (AASLD)

COUNCILS AND COMMITTEES

National/International:

1989 - 1992	Vice-Chair, Systemic Mycoses Pathogen Study Group (PSG), Subcommittee of the Opportunistic Infections Committee, NIH/NIAID AIDS Cooperative Treatment Group (ACTG)
1989 - 1994	Member, Opportunistic Infections Core Executive Committee, NIH/NIAID AIDS Cooperative Treatment Group (ACTG)
1989	Ad Hoc Study Section, AZT Resistance, NIH/NIAID
1989	Ad Hoc Study Section, GCRC Site Visit, NIH/NIAID
1989 - 1990	Member, State of the Art Panel for Early Use of AZT, NIH/NIAID
1990	Ad Hoc Committee, Early Initiation of Zidovudine Therapy, NIH/NIAID

Revised 01/14/2020

Michael S. Saag, MD

1990 - 1993 Chair, Cryptococcal Subproject Committee, Mycoses Study Group (MSG), NIH/NIAID
 1990 - 1995 Member, Steering Committee, Mycoses Study Group (MSG), NIH/NIAID
 1991 Ad Hoc Study Section, Multicenter AIDS Cohort Study, NIH/NIAID
 1991 Ad Hoc Study Section, Transmission of HIV from Mother to Child, NIH/NIAID
 1992 Member, AIDS Subcommittee, Medical Knowledge Self-Assessment Program X for the American College of Physicians
 1992 - 1993 Member, Phase I/II Working Group, Subcommittee of the Primary Infection Committee, NIH/NIAID ACTG
 1992 - 1995 Member, American Foundation for AIDS Research, Scientific Advisory Committee
 1992 - 1993 Chairman, Systemic Mycoses Pathogen Study Group, Subcommittee of the Opportunistic Infections Committee, NIAID/AIDS
 1993 - 1996 Chairperson, Therapeutics Subcommittee, AIDS Research Advisory Committee, NIH/NIAID
 1993 Member, Scientific Advisory Committee, Shared Medical Research Foundation
 1993 - Present Program Executive Committee Member, International AIDS Society-USA Educational Program
 1993 - Present Board of Directors, International AIDS Society-USA
 1993 - 1994 Member, Elizabeth Glaser Pediatric AIDS Foundation Grant Review Committee
 1994 - 1997 Member, Adult ACTG Executive Committee, NIH/NIAID
 1994 - 1996 Chairman, Outside Relations Working Group, Subcommittee of the NIH/NIAID ACTG Executive Committee
 1994 Member, Institute of Medicine Fialuridine (FIAU) Committee
 1995 - 1996 Member, Institute of Medicine's Committee on Resource Sharing in Biomedical Research, National Academy of Sciences
 1995 - 1998 Member, Adult ACTG HIV Disease Research Agenda Committee, NIH/NIAID
 1995 - 1997 Member, HIV Disease Committee, Medical Knowledge Self-Assessment Program XI for the American College of Physicians
 1995 - 1996 Member, HIV Disease Research Agenda Committee Protease Inhibitor Focus Group, NIH/NIAID
 1996 Chair, HIV Disease Research Agenda Committee Pathogenesis Focus Group, NIH/NIAID
 1996 - 1998 Member, Board of Directors Forum for Collaborative HIV Research
 1996 - 1998 Member, NIH Panel to Define Principles of Therapy of HIV Infection, NIH Office of AIDS Research
 1996 - 2000 Member, Advisory Committee, Arthur Ashe Program in AIDS Care, National Medical Fellowships
 1997 - 2000 Board Member, Family AIDS Network, Inc.
 1997 - 2001 Consultant, FDA Center for Biologics Evaluation and Research Advisory Committee
 1997 - 1998 Medical Advisory Board of Directors, Ryan White Foundation for Medical Treatment, Inc.
 1997 - 1999 Member, Executive Committee, Forum for Collaborative HIV Research, DHHS
 1998 - 2001 Member, Program Committee, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
 1998 Member, National Board of Governors, Project Inform
 1998 Member, Total Physician Services Research Advisory Board
 1998 - 2000 Member, Adult ACTG Immunology Research Agenda Committee, NIH/NIAID
 1999 Member, Scientific Advisory Committee of the VA-based AIDS Network
 1999 Member, Scientific Committee of SHARE, International AIDS Society
 2000 Member, ABC News Medical Advisory Board
 2000 Member, National Advisory Board, EthicAd Council, Inc.
 2000 - 2001 Panel Member, International AIDS Society-USA Panel on Metabolic Complications of Antiretroviral Therapy
 2000 - 2004 Member, Subspecialty Board on Infectious Diseases, American Board of Internal Medicine
 2001 Member, Immunology and SIV Animal Models, STI Workshop II Working Group
 2001 Member, Observational Database (OBD) Working Group, STI Workshop II Working Group
 2001 Chairman, Ad Hoc Study Section, Veterans Administration Long-term Outcomes, NIH/NIAID
 2001 Chairman, NIH/NIAID Ad Hoc Study Section, MACS Expansion into Long-term Outcomes, NIH/NIAID
 2001 Member, NIH/NIAID Special Emphasis Panel
 2001 - 2003 Member, NIAID Adult ACTG Executive Committee
 2001 - Present Co-Chair, Ryan White Annual Clinical Update Conference
 2002 - 2003 Member, NIH/Institute of Medicine of the National Academies, Committee for Assessment of NIH Centers of Excellence Programs

Revised 01/14/2020

Michael S. Saag, MD

2003 - 2011	Member, Board of Directors, HIV Medicine Association (HIVMA)
2004	Member, Review Panel, Distinguished Clinical Scientist Award Competition, Doris Duke Charitable Foundation
2004	Member, Advisory Board, Health Action AIDS
2004 - 2007	Member, Board of Directors, Infectious Diseases Society of America
2004 - 2008	Member, Office of AIDS Research Advisory Council, Department of Health & Human Services
2004 - 2008	Chairman, Subspecialty Board on Infectious Diseases, American Board of Internal Medicine
2004 - 2008	Member, Board of Directors, American Board of Internal Medicine
2005	Member, Track B: Clinical Research, Treatment and Care Committee for the XVI International AIDS Conference Scientific Programme Committee
2006	Fellow, Infectious Diseases Society of America
2006 - 2009	Education Committee Member, Association of Specialty Professors (ASP) – Member of the Alliance for Academic Internal Medicine
2007- 2009	Member, Committee on Ambulatory and Comprehensive Internal Medicine, American Board of Internal Medicine
2007 - 2012	Chair, Therapeutics Research Working Group (TRWG), NIH Office of AIDS Research Advisory Council (OARAC)
2007 - 2013	Member, DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents
2007 -2013	Co-Chair, DHHS Panel Membership Subcommittee
2009 - 2013	Member, Scientific Advisory Board Universal Maternal Antiretroviral Therapy (UWA)
2011	NIH/NIAID - Board of Scientific Counselors Ad hoc member
2011	Association of American Physicians
2012 - 2015	Member, WHO Antiretroviral Therapy Guidelines Committee
2013 -	Member, CFAR Sub-Saharan Africa Working Group (CFAR-SSA)
2013 - 2016	Member, NIH R13 Grant Review Panel
2013 - 2017	Member, NIH NIAID/DIR Board of Scientific Counselors
2013 - 2016	Co-Chair, AASLD/IDSA/ IAS-USA Hepatitis C Guidelines Committee
2015	Institute of Human Virology Scientific AdvisoryBoard
2016- 2017	Member, United Health Council
2017 – Present	Member, HHS CDC-HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHAC)
2018-Present	Member, NIH NIAID/DIR Board of Scientific Counselors
2019-Present	Member, Presidential Advisory Council on HIV/AIDS (PACHA)

State/Local:

1988 - 1993	Member, State of Alabama Legislative Advisory Commission on AIDS
1992 - 1995	Member, Birmingham AIDS Outreach Advisory Council
1993 - 1997	Member, Hemophilia Advisory Committee for the State Hemophilia Program
1995 - 1996	Board Member, AIDS Task Force of Alabama
1997	Member, Advisory Committee, AIDS Task Force of Alabama
1997	Member, The AIDS Memorial Advisory Board, The Dances of Life Foundation, Inc.
1997 - 2003	Member, HIV/AIDS Direct Care Advisory Council, HIV/AIDS Division of the Alabama Department of Public Health
2000 - 2001	Member, State of Alabama Office of the Governor, HIV Commission for Children and Adults
2003	Member, AIDS Education and Outreach for Neighborhoods Task Force, City of Birmingham, AL

UNIVERSITY ACTIVITIES**Service Activities:**

1984 - 1985	Member, Intern Selection Committee, University of Alabama at Birmingham School of Medicine
1987 - 1992	Chairman, Infection Control Committee, VA Medical Center, Birmingham, AL
1987 - 1992	Member, Intern Selection Committee, University of Alabama at Birmingham School of Medicine
1987 - 1995	Member, University of Alabama Hospital AIDS Committee
1987 - 1995	Member, UAB AIDS Education Advisory Committee
1988 - 2002	Member, UAB General Clinical Research Center (GCRC) Scientific Advisory Committee (SAC)
1988 - Present	Executive Committee, UAB Center for AIDS Research
1989	Member, UAB Ambulatory Education Ad Hoc Committee

Revised 01/14/2020

Michael S. Saag, MD

1998 - 2001	Member, UAB Department of Medicine Clinical Practice Committee
1990 - 1995	Clinical Consultant, UAB Office of Clinical Practice Evaluation
1990 - 1991	Member, UAB Committee for Quality Assurance
1990 - 1993	Member, UAB Institutional Biosafety Committee
1990	Member, UAB Department of Medicine Clinical Research Task Force
1990	Member, UAB Medical and Dental Staff Task Force on AIDS
1990 - 1995	Member, UAB Ad Hoc Committee on Social Medicine
1990 - 2002	Faculty Advisor, UAB Medical Student AIDS Education Program in Community High Schools
1990	Alternate Member, UAB Medical Grand Rounds Advisory Committee
1990	Member, UAB Medical Student HIV Policy Committee
1992 - 1994	Member, UAB Self-Study Steering Committee of the Southern Association of Colleges and Schools (SACS)
1996 - 1998	Member, UAB Palliative Medicine Project Task Force
1996 - 1997	Member, UAB Bloodless Medicine and Surgery Program
1997	Member, Research Advisory Group - Ad Hoc Committee, UAB Central Administration Service
1998	Member, UAB Deans' Task Force for Patient Oriented Research
1998 - 2001	Member, Faculty Council Committee, UAB School of Medicine
2000 - 2002	Member, UAB School of Medicine, Clinical Research Task Force
2000 - 2001	Chair, Security Subgroup of the UAB Health Insurance Portability and Accountability Act (HIPAA) Research Subcommittee
2000	Member, Office of the President, UAB Research Compliance Steering Committee
2002	Member, Selection Committee, UAB Odessa Woolfolk Community Service Award
2003	Member, UAB Institutional Review Board Task Force
2003	Member, UAB Advisory Committee and Users Group
2004	Member, UAB Minority Health and Research Center
2004	Member, UAB Department of Medicine Research Council
2004	Member, Health Action AIDS Advisory Council, Physicians for Human Rights
2005	Member, UAB Interdisciplinary Center for Research in Women's Health Advisory Board
2005	Chair, UAB SOM, Clinical Informatics Working Group for the Strategic Planning Process
2005	Member, UAB Executive Steering Committee of the Office of Human Research
2005 - 2008	Member, UAB Conflict of Interest Review Board
2006	Member, UAB Information Services Clinical Council
2006	Member, UAB Biomedical Informatics Steering Committee
2008	Member, UAB Task Force on School of Medicine Relationships with Pharma
2009	Member, UAB Sparkman Center Campus-Wide Global Outreach Committee
2012	Senior Scholar, UAB Center for Palliative and Supportive Care
2012	Member, UAB Global Citizenship Coordinating Committee
2013 - 2015	Member, Comprehensive Cardiovascular Center (CCVC) Steering Committee
2014	Member, UAB Odessa Woolfolk Community Service Award Review Committee
2016- 2017	Member, Search Committee Chair Dept of Epidemiology, UAB SOPH

Teaching Experience:

1987 - 1993	Birmingham Veterans Affairs General Medicine Teaching Ward Service, Birmingham, Alabama
1987 - 2010	Staff Physician, Medical Service Infectious Diseases, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama
1987 - 2010	Consulting Physician, Cooper Green Hospital, Birmingham, Alabama
1987- Present	Attending Physician, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1987 - Present	Supervisor of Post-Graduate Fellows in Infectious Diseases, Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1988 - Present	Preceptor, HIV (1917) Outpatient Clinic, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1988 - Present	Teaching Faculty, Microbiology Course for Second Year Medical Students, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
1996 - Present	UAB Tinsley Harrison Clinical Scholars' General Medicine Teaching Ward Service, Birmingham, Alabama

Trainees (Infectious Diseases Fellows / Internal Medicine Residents):

1985 - 1988	Allen H. Graves, M.D.	Clinical Trials of Antiretroviral Therapy and Antifungal Therapy
1990 - 1993	Stephen Clark, M.D.	Pathogenesis of HIV Disease
1989 - 1992	Jeff Douglas, M.D.	Clinical Trials of Antiretroviral Therapy
1990 - 1993	William Lapidus, M.D.	Clinical Trials of Antiretroviral Therapy
1993 - 1996	J. Michael Kilby, M.D.	HIV Pathogenesis
1992 - 1996	David Ennis, M.D.	Clinical Trials of Antiretroviral Therapy and Antifungal Therapy
1994 - 1996	Scott Harris, M.D.	Clinical Manifestations of HIV Disease
1995 - 1998	Cathal O'Sullivan, M.D.	Natural History of CMV Disease
1996 - 1999	Craig Hoesley, M.D.	Antiretroviral Therapy
1998 - 2000	Stephanie Call, M.D.	HIV-related Outcomes Research
1999 - 2001	Michael Coghlan, M.D.	Metabolic Complications of HIV Therapy
2000 - 2003	Ray Y Chen, M.D.	HIV-related Outcomes Research
2003 - 2005	Mukesh Patel, M.D.	HIV-related Outcomes Research
2003 - 2004	Roger Bedimo, M.D.	HIV-related Outcomes Research
2004 - 2005	Davendara Sohal, M.D.	HIV-related Outcomes Research
2005 - 2008	James Willig, M.D.	HIV-related Outcomes Research
2007 - 2009	James McKinnell, M.D.	HIV-related Outcomes Research
2008 - 2010	Paula Seal, M.D.	HIV-related Outcomes Research
2009 - 2012	Greer Burkholder, M.D.	HIV-related Outcomes Research
2010 - 2013	Ricardo Franco, MD	HCV Clinical Therapeutics
2012 - 2015	Ellen Eaton, MD	HIV Health Economics

EDITORIAL BOARD MEMBERSHIPS

Editor, *AIDS*, Lippincott Williams and Wilkins, 2020 -
 Co-Editor, *The Sanford Guide to Antimicrobial Therapy*, 2008 -
 Co-Editor, *AIDS Therapy* (textbook), along with Raphael Dolin, MD & Henry Mazur, MD, 1st, 2nd, and 3rd Editions, 2000, 2003, and 2007
 Editor in Chief, Cases on the Web (COW) CME Program, International AIDS Society-USA 1995-
 Editorial Board, *Clinical Infectious Diseases* 2020-
 Senior Clinical Editor, *AIDS Research and Human Retroviruses* (1997- 2006)
 Editor, *Questions Newsletter*, UAB AIDS Center and Birmingham AIDS Outreach (1989-1995)
 Section Editor, "Clinical Investigations" section, *AIDS Research and Human Retroviruses* (1993-1998)
 Associate Medical Editor, *AIDS/HIV Treatment Directory*, published by Am Foundation for AIDS Research (1996)
 Editorial Board, *Journal of the American Medical Association Web Page on AIDS* (1996-97)
 Board Member, *Antiviral Therapy*, HIV section (1996-1999)
 Member, Editorial Board, *AIDS Care* (1997-98)
 Board Member, *The PRN Notebook* (1996-99)
 Member, Advisory Board, *HIV/HCV Coinfection Monthly* (2001-2003)
 Member, Editorial Board, *Journal of NeuroVirology*
 Member, Editorial Advisory Board, *HIV Newslines* (1995-2000)
 Member, Editorial Advisory Board, *HIV Forefront* (1995-2000)
 Member, Editorial Board, *Current HIV/AIDS Reports* (2004 – 2006)
 Member, Editorial Board, *Clinical and Translational Science (CTS)*, (2007)
 Reviewer, *The New England Journal of Medicine*
 Reviewer, *American Journal of Medicine*
 Reviewer, *Annals of Internal Medicine*
 Reviewer, *Journal of the American Medical Association*
 Reviewer, *Nature Medicine*
 Reviewer, *Journal of Infectious Diseases*
 Reviewer, *Journal of Acquired Immunodeficiency Syndrome*
 Member, Editorial Board, *Infectious Disease (2010)*
 Member, Editorial Board *AIDS* (2013-2016)
 Member, Editorial Board *HCV Next* (2014)
 Member, Editorial Board, *Infectious Diseases and Therapy* (2016-present)

MAJOR RESEARCH INTERESTS (2-3 SENTENCES)

HIV Pathogenesis (Viral Dynamics, Host-Virus Interactions, Viral Latency)
HIV Therapeutics / Clinical Trials (Special Emphasis on Phase I/II Proof of Concept Trials)
HIV Outcomes Research / Policy (Merging of Data from Electronic Medical Record / Database Systems)
Medical Informatics (Electronic Data Systems / Quality Assurance / Vocabularies / Ontology)
Hepatitis C Therapeutics (Clinical Trials, Long-term outcomes, Implementation Science)

MAJOR LECTURES AND VISITING PROFESSORSHIPS

1986 Plenary Address American Red Cross, HIV Conference, "HIV Genetic Evolution" Chicago, IL
 1986 Invited Lecture American Society of Hematology "HIV Genetic Evolution" San Francisco, CA
 1987 Invited Lecture, III International AIDS Conference, Washington, DC
 1987 Visiting Professor, Pennsylvania State University School of Medicine, Hershey, PA
 1987 Plenary Lecture, Chicago AIDS Symposium, Chicago, IL
 1988 Visiting Professor, Rush Medical Center, Chicago, IL
 1988 Keynote Address, University of Arkansas Medical Student Research Day, Little Rock, AK
 1988 Visiting Professor, University of Mississippi School of Medicine, Jackson, MS
 1988 Visiting Professor, University of Miami School of Medicine
 1989 Plenary Lecture, Annual Meeting of the South Carolina Medical Association, Charleston, SC
 1990 Invited Lecture, NIAID State of the Art Conference on ARV Therapy, Bethesda, MD

1990 Visiting Professor, University of South Alabama, Mobile, AL
 1990 Plenary lecture, NIAID ACTG Annual Meeting, "Cryptococcal Meningitis" Bethesda, MD
 1990 Plenary Lecture, 49th Meeting of the American Academy of Dermatology, Atlanta, GA
 1991 Visiting Professor, Vanderbilt University, Nashville, TN
 1991 Visiting Professor, Henry Ford Hospital, Detroit, MI
 1991 Invited Lecture, UCSF Virology Conference, "Viral Evolution", San Francisco, CA
 1991 Invited Lecture, NIAID International Conference on Antigenic Variation, Marco Island, FL
 1991 Plenary Lecture, 3rd Triennial Symposium on Antiviral Research, San Francisco, CA
 1991 Invited Lecture, Clinical Care of the AIDS Patient, San Francisco, CA
 1992 Plenary Lecture, 8th Meeting NIAID CPCRA, Washington, DC
 1992 Invited Lecture, UCSF Symposium on Use of Surrogate Markers in Clinical Trials, San Francisco, CA
 1992 Visiting Professor, Earl K. Long Hospital, Louisiana State University, Baton Rouge, LA
 1992 Invited Lecture, 32nd ICAAC, Anaheim, CA
 1992 Samuel Gross Memorial Lecture, University of Louisville, Louisville, KY
 1993 Visiting Professor, Penn State University, Hershey, PA
 1993 Visiting Professor, University of Leiden, Leiden, The Netherlands
 1993 Visiting Professor, Indiana University Medical Center, Indianapolis, IN
 1993 Plenary Lecture, Keystone Symposium on Molecular and Cellular Biology, Albuquerque, NM
 1994 Visiting Professor, Bellevue Hospital, New York, NY
 1994 Invited Lecture, Young President's Organization, West Virginia
 1994 Invited Lecture, 10th International AIDS Conference, Yokohama, Japan
 1994 Plenary Address, International Forum on HIV Medicine, Mexico City, Mexico
 1994 Plenary Address, 34th ICAAC, Orlando, FL
 1994 Visiting Professor, Rockefeller University, New York, NY
 1994 Plenary Lecture, VII International Meeting of AIDS, Bologna, Italy
 1994 Invited lecture, European HIV Congress, Glasgow, Scotland
 1995 Visiting Professor, Columbia University School of Medicine, New York, NY
 1995 Invited Lecture, 76th American College of Physicians Meeting, Atlanta, GA
 1995 Visiting Professor, Fred Hutchinson Cancer Center, Seattle, WA
 1995 Visiting Professor, St. Paul's Hospital, Vancouver, BC
 1995 Invited lecture, Institute Pasteur, "Cryptococcal Meningitis", Paris, Fr.
 1995 Visiting Professor, Aaron Diamond AIDS Institute, New York, NY
 1995 Visiting Professor, Medical College of Pennsylvania, Philadelphia, PA
 1995 Visiting Professor, Beth Israel Hospital, Boston, MA
 1995 Invited Lecture, Arizona Chapter of the ACP, Tucson, AZ
 1996 Invited Advisory, Italian Panel on Use of Viral Load, Rome, Italy
 1996 Plenary Address, Southern Society of Clinical Investigation, New Orleans, LA
 1996 Plenary Lecture, 52nd American Academy of Allergy, Asthma, and Immunology, New Orleans, LA
 1996 Visiting Professor, University of Kentucky, Lexington, KY
 1996 Invited Lecture, IAS-USA Guidelines at International AIDS Conference, Vancouver, BC
 1996 Plenary Lecture, 3rd International Conference on Cryptococcus, Paris, France
 1996 Invited Lecture, Cambridge Symposium New Insights on HIV, Hilton Head, SC
 1996 Plenary Address, 6th German AIDS Congress, Munich, Germany
 1996 Plenary Address, 8th Annual Meeting of the Australian Society for HIV Medicine, Sydney, Australia
 1996 Invited Lecture, Clinical Care of the AIDS Patient, San Francisco, CA
 1997 Visiting Professor, Medical College of Georgia, Augusta, GA
 1997 Plenary Address, IDSA Annual Meeting, "New Drugs to Treat HIV"
 1997 Invited Lecture, Winter Course in Infectious Diseases, Snowmass, CO
 1997 Visiting Professor, University of Wisconsin School of Medicine, Madison, WI
 1997 Visiting Professor, University of Arkansas School of Medicine, Little Rock, AK
 1997 Plenary Lecture, CDC HIV Post-Exposure Prophylaxis of HCW, Atlanta, GA
 1997 Plenary Lecture, 2nd Annual Institute of Human Virology Meeting, Baltimore, MD
 1997 Invited Lecture, Controversies in HIV Treatment, New York, NY
 1997 Plenary Address, AASLD Annual Meeting, Chicago, IL
 1998 Plenary Lecture, University Teaching Hospital – Ministry of Health, Lusaka, Zambia
 1998 Invited Lecture, Physicians Research Network Meeting, New York, NY
 1998 Plenary Lecture, American Society of Addictive Medicine, New Orleans, LA
 1998 Plenary Lecture, American Academy of Dermatology Annual Meeting, Orlando, FL
 1998 Invited Lecture, International Workshop on Salvage Therapy, New Orleans, LA

1998 Invited Lecture, Harvard Medical School, "Use of Viral Load in Practice"
 1998 Plenary Lecture, 25th Annual Meeting of the American Legislative Exchange Council, Chicago, IL
 1998 Invited Lecture, 38th ICAAC, San Diego, CA
 1998 Plenary Lecture, Kaiser Permanente HIV Conference, San Francisco, CA
 1998 Grand Rounds, Dept of Medicine, University of Alabama at Birmingham, Birmingham, AL
 1999 Visiting Professor, Emory School of Medicine, Atlanta, GA
 1999 Plenary Lecture, HIV Symposium, Institute Pasteur, Paris, France
 1999 Frank Polk Memorial Lecture, Johns Hopkins University, Baltimore, MD
 1999 Invited Lecture, American College of Physicians Annual Meeting, New Orleans, LA
 1999 Invited Lecture, 3rd International Cohort Meeting, Verona, Italy
 1999 Invited Lecture, Current Topics in Infectious Diseases Seminar, Naples, FL
 1999 Invited Presentation, CDC Conference on HIV Post-Exposure Prophylaxis, Atlanta, GA
 1999 Invited Lecture, Rome State-of-the-ART Conference, Rome, Italy
 1999 Chairman and Lecture, AIDS Session, 29th ICAAC, San Francisco, CA
 1999 Plenary Address, 7th European Conference on HIV Treatment, Lisbon, Portugal
 1999 Invited Lecture, 37th Annual IDSA Meeting, Philadelphia, PA
 1999 Invited Lecture, Medical Management of HIV, San Francisco, CA
 2000 Visiting Professor, University of Pennsylvania School of Medicine, Philadelphia, PA
 2000 Grand Rounds, University of Alabama at Birmingham, Birmingham, AL
 2000 Lecture, 26th Winter Course in Infectious Diseases, Vail, CO
 2000 Plenary Lecture, IX Annual Meeting of the Canadian Association HIV Research, Montreal, Canada
 2000 Invited Lecture, HRSA Clinical Meeting Update, St. Thomas, VI
 2000 Distinguished Lecturer, University of Louisville School of Medicine, Louisville, KY
 2000 Plenary Convener, 38th Meeting of the IDSA, New Orleans, LA
 2000 Plenary Lecture, Alabama Statewide AIDS Symposium, Montgomery, AL
 2000 Plenary Lecture, 5th International Congress on Drug Therapy in HIV, Glasgow, Scotland
 2000 Paul J. Galkin Lecture, Brown University, Providence, RI
 2000 Grand Rounds, NIAID, Bethesda, MD
 2000 Plenary Lecture, XIV ANL AIDS Conference, Milan, Italy
 2000 Invited Lecture, Medical Management of AIDS, San Francisco, CA
 2001 Invited Lecture, Clinical Infectious Diseases 2001, New York, NY
 2001 Grand Rounds, San Francisco General Hospital, San Francisco, CA
 2001 Chairperson, 5th International Workshop on HIV Observational Databases, Monte Carlo, Monaco
 2001 Invited Lecture, Medical Management of AIDS, Sun Valley, Idaho
 2001 Visiting Professor, University of North Carolina School of Medicine, Chapel Hill, NC
 2001 Lecture, AHRQ / HRSA Meeting on Use of Information Technology in AIDS, Rockville, MD
 2001 Invited Lecture, Medical Management of AIDS Meeting, San Francisco, CA
 2002 Plenary Address, International AIDS Congress, Barcelona, Spain
 2002 Plenary Address, 16th Annual Japan AIDS Society Meeting, Nagoya, Japan
 2002 Invited Lecture, Medical Management of AIDS Meeting, San Francisco, CA
 2003 Lecturer, Medicis Winter Skin Meeting, Snowmass, CO
 2003 Visiting Professor, Massachusetts General Hospital, Harvard Med School, Boston, MA
 2003 Congressional Briefing, Biotechnology and the Next Generation of HIV Drugs, Washington, DC
 2003 Invited Teacher, Masters in HIV / Ministry of Health, Perugia, Italy
 2003 Visiting Professor, University of California San Francisco
 2004 Invited Lecture, Harold C. Neu Infectious Diseases Conference
 2004 Plenary Lecture, 1st Caribbean CHART Meeting, Montego Bay, Jamaica
 2004 Chair, IAS-USA Case Interactive Session, IDSA 42nd Annual Meeting
 2004 Invited Lecture, Medical Management of AIDS Meeting, San Francisco, CA
 2004 Inaugural Lecture, Alex Litz Memorial Lectureship, UAB Chief Resident's Society, Birmingham, AL
 2005 Keynote Plenary, US State Dept PEPFAR International Meeting, Addis Ababa, Ethiopia
 2005 Invited Plenary, National ADAP Education Conference, Washington, DC
 2005 Plenary Lecture, 11th International Symposium on Treatment of HIV and HCV, Sitges, Spain
 2005 Mexican National AIDS Meeting, Plenary Speaker, Mexico City
 2005 Visiting Professor, Albert Einstein School of Medicine, Bronx, New York
 2006 Keynote Plenary, 16th Annual Meeting of the Society of Black Academic Surgeons, Cincinnati, Ohio
 2006 Invited Presentation - US President's Advisory Council on HIV/AIDS (PACHA). Washington, DC
 2006 Jonathan Lax Invited Lecture, Philadelphia, PA
 2006 Visiting Professor, University of Texas, Southwestern, Dallas, Texas

Revised 01/14/2020

Michael S. Saag, MD

2006 Invited Lecturer, Royal College of Medicine, London, England
 2008 Visiting Professor, Yale AIDS Colloquim Series, Yale University Center for Interdisciplinary Research on AIDS (CIRA), New Haven, CT
 2009 Guest Lecturer, Gorgas Course in Clinical Tropical Medicine, Lima, Peru
 2009 Guest Lecturer, Royal Society of Medicine Symposium in association with the National Institute of Health, USA and BASHH, London, England
 2009 Lecturer, 6th National Kaiser Permanente HIV/AIDS, Hepatitis, & STD Conference, Anaheim, CA
 2010 Gorgas Course for Tropical Medicine, Lima, Peru
 2010 Visiting Professor, University of Louisville Dept of Dermatology
 2010 Plenary Lecture (Invited), NIMH HIV Treatment Adherence Conference
 2010 UCSF CFAR Advisory Committee
 2010 University of Rochester D-CFAR Advisory Committee
 2010 IOM: Invited Speaker: Committee on HIV-related Disability
 2010 IOM Invited Speaker: Committee on HIV Workforce Capacity
 2010 Plenary Debate, Ryan White All-Titles Meeting, Washington, DC
 2010 Autumn Update: Northern California – Nevada AETC
 2010 Lecturer, Columbia University, New York, NY
 2011 Invited Speaker: American Academy of Dermatology AIDS symposium, New Orleans, LA
 2011 Emory University CFAR Advisory Board
 2011 International Workshop on HIV Observational Databases, Prague, Czech Republic
 2011 Guest Lecturer, University of Wisconsin, Madison, WI
 2011 NIH/NIAID Board of Scientific Counselors, Washington, DC
 2011 National HIV Prevention Conference, Atlanta, GA
 2011 Guest Lecturer, Case Western University, Cleveland, OH
 2011 Guest Lecturer, Dartmouth Medical School, Lebanon, NH
 2011 Bush Summit, Washington, DC
 2011 HIV Symposium at the Royal Society of Medicine, London, England
 2011 University of Pennsylvania CFAR Advisory Board
 2011 University of Washington CFAR Advisory Board
 2012 Plenary Lecture (Invited), Kwazulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa
 2012 S. Rexford Kenamer MD Distinguished Lecturer, Montgomery, AL
 2012 22nd Annual Clinical Care of the Patient with HIV Infection, Johns Hopkins, Baltimore, MD
 2012 Rotary Club Lecturer, Louisville, KY
 2012 Guest Lecturer, International Congress on Drug Therapies, Geneva, Switzerland
 2012 Guest Lecturer, Perspective in Virology HIV & Hepatitis 2012, Sydney, Australia
 2012 Guest Lecturer, Grand Rounds, Vanderbilt University ID Grand Rounds, Nashville, TN
 2012 Invited Lecturer, International Congress on Drug Therapies, Glasgow, United Kingdom
 2012 Invited Panelist, White House World AIDS Day, Washington, DC
 2013 Zambia Site Visit, Lusaka, Zambia, South Africa
 2013 Guest Faculty, Kaiser Permanente HIV, Hepatitis and STI Conference, Las Vegas, NV
 2013 Guest Speaker, Alabama Chief Residents Society Annual Conference, New Orleans, LA
 2013 President's Advisory Council on HIV/AIDS, Washington, DC
 2013 Presentation for National Health Policy Forum: Capitol Hill, Washington, DC
 2013 Invited Speaker, IDSA, Hepatitis C Virus Maintenance of Certification Update, San Francisco, CA
 2013 Guest Lecturer, Medical Grand Rounds, New York University, New York, NY
 2014 ID Grand Rounds University of Pennsylvania
 2014 Robert M. Herin Distinguished Lecture, University of Mississippi Medical Center, Jackson, MS
 2014 Keynote Speaker, Annual CROI Update, Wayne State University, Detroit, MI
 2015 Keynote Speaker, Kentucky Statewide Conference on HIV/AIDS, Louisville, KY
 2015 Guest Lecturer, UAB Huntsville Grand Rounds, UAB Huntsville Regional Medical Campus, Huntsville, AL
 2015 Invited Lecturer, ICAAC Annual Meeting, San Diego, CA
 2015 Invited Speaker, Infectious Diseases Society of Oregon, Portland, Oregon
 2015 Co-Chair, 15th Ryan White HIV/AIDS AETC program Clinical Care Conference, New Orleans, LA
 2016 Invited Speaker, UT Southwestern Medical Center, Division of Infectious Diseases, Dallas, TX
 2016 Guest Lecturer, University of Alabama Medical Student Dean's Hours, Tuscaloosa, AL
 2016 Distinguished Speaker, Henry Ford Hospital/Wayne State University, Internal Medicine Grand Rounds, Detroit, MI
 2016 Invited Speaker, HIV & Hepatitis in the Americas 2016 Congress, Mexico City, Mexico
 2016 Keynote Speaker, Medical College of Georgia, Augusta
 2016 Invited Speaker, National Association of Nurses in AIDS Care, Atlanta GA

2016 Guest Lecturer, ID and Global Health, University of California San Diego
 2017 Goldsmith Lecturer, Association of Professors of Dermatology
 2017 Guest Lecturer, IAS-USA HIV Course, New York, NY
 2017 Invited Speaker, Optimal Management of HIV Disease and Hepatitis: Clinical Conference XXV (OPMAN), Orlando, FL
 2017 Invited Lecturer, IAS-USA HIV Course, Atlanta GA
 2017 Guest Speaker, Advanced Course in HIV Illnesses (Achilles), Umbria, Italy
 2017 Guest Lecturer, IAS USA HIV Course, Chicago, IL
 2017 Invited Panelist, University of California San Francisco (UCSF) CFAR External Advisory Committee, San Francisco CA
 2017 Invited Lecturer, IAS USA HIV Course, Berkeley, CA
 2017 NCI BSA Subcommittee, Bethesda, MD
 2017 Invited Lecturer, IAS USA Webinar
 2017 NIH/SREA Reviewer for NIAID Study Section
 2017 Guest Speaker, Ryan White Clinical Conference, San Antonio, TX
 2017 Infectious Disease Review Board Course, Tysons Corner, VA
 2017 Guest Speaker, Positive Living Symposium, Fort Walton Beach, FL
 2017 Invited Lecturer, IAS USA HCV Course, Little Rock, AR
 2017 Lecturer, "This Month in HIV" Webinar
 2017 California HIV/AIDS Research Program (CHRP) Peer Review Meeting, San Francisco CA
 2017 Distinguished Lecturer, Association of Professors of Dermatology – Goldsmith Lecture, Chicago, IL
 2017 Invited Lecturer, IAS USA Hepatology Workshop, Louisville, KY
 2017 Guest Speaker, World AIDS Day, Allegheny General Hospital, Pittsburg, PA
 2018 Mentoring the Mentors, San Francisco, CA
 2018 CFAR External Advisory Committee, University of Pennsylvania, Philadelphia, PA
 2018 Invited Lecturer, University of Alabama School of Dentistry Alumni Association Annual Meeting, Birmingham AL
 2018 NIH Presentation, Washington DC
 2018 Invited Lecturer, IAS USA HIV Course, Atlanta GA
 2018 Invited Speaker, Alabama Chief Residents Society Annual Meeting, New Orleans, LA
 2018 Invited Speaker, Optimal Management of HIV Disease and Hepatitis: Clinical Conference XXVI (OPMAN), Orlando, FL
 2018 Invited Lecturer, IAS USA HIV Course, New York, NY
 2018 Invited Lecturer, IAS USA Spring HIV Course, Washington, DC
 2018 Invited Speaker, 28th Annual Conference on the Clinical Care of the Patient with HIV Infection and Care of the Patients with Viral Hepatitis, Baltimore, MD
 2018 Invited Lecturer, IAS USA HIV Course, Chicago, IL
 2018 Guest Speaker, Alabama & Mississippi Chapter of the American College of Physicians, Birmingham AL
 2018 US HIV Scientific Advisory Board, Atlanta GA
 2018 NIH/NIAID Board of Scientific Counselors, Hamilton MT
 2018 DC CFAR Scientific Advisory Committee, Washington DC
 2018 Invited Speaker, Adult Hepatitis Expert Input Meeting, Philadelphia PA
 2018 Invited Speaker, Southeast AIDS Education & Training Center, Webcast
 2018 Guest Speaker, UAB Marchase Interdisciplinary Research Centers Symposium, Birmingham AL
 2018 Invited Speaker, UAB ID Update: Update in HIV and HCV, Florentine Bldg, Birmingham AL
 2018 Invited Lecturer, Infectious Disease Board Review Course, Tysons Corner, VA
 2018 Guest Speaker, Curbsiders Internal Medicine Podcast
 2018 Invited Lecturer, Young Investigators' Masterclass Academy on HIV 2018, Tuscany Italy
 2018 Invited Lecturer, IAS USA HCV Management Workshop, New York, NY
 2018 Guest Speaker, IAS USA Hepatitis Workshop, Miramar Beach, FL
 2018 Recipient, Alumni Fellow School of Medicine Award, Louisville, KY
 2018 Guest Speaker, IAS USA Fall HCV Management Workshop, Charleston, SC
 2018 Plenary Speaker, HIV DART Plenary Session: New Drugs and Improved Formulations, Miami, FL
 2018 Guest Speaker, UAB Department of Art and Art History, Scourge: Diseases that Shaped History, Birmingham AL
 2018 Invited Speaker, National Ryan White Conference on HIV Care and Treatment, National Harbor, MD
 2019 Keynote Speaker, Medical Advocacy & Outreach (MAO)'s Breaking Barriers Summit, Montgomery, AL
 2019 IDSA Foundation Development Committee
 2019 Invited Lecturer, National HIV Prevention Conference, Atlanta GA
 2019 Guest Speaker, IAS USA Annual Update on HIV, New York, NY
 2019 Invited Lecturer, IAS USA Annual Update on HIV Disease Management, Atlanta, GA

Revised 01/14/2020

Michael S. Saag, MD

- 2019 Invited Speaker, Optimal Management of HIV Disease and Hepatitis: Clinical Conference XXVII (OPMAN), Orlando, FL
- 2019 Invited Lecturer, HIV and Aging Conference, Atlanta GA
- 2019 Invited Speaker, McKnight Brain Institute Inter-institutional meeting, Gainesville FL
- 2019 Invited Speaker, CDC/HRSA Advisory Committee on HIV, VH and STD Prevention and Treatment (CHAC), Atlanta GA

GRANT SUPPORTACTIVE Support as of October 1, 2019

5 P30-AI027767 (Saag, PI) 06/01/19-5/31/20 1.8 cm

NIH/NIAID \$1,040,404 DC

UAB Center for AIDS Research

The primary purpose of this center is to support interdisciplinary AIDS research efforts. This Center is responsible for the planning, evaluating, managing and documenting a broad array of research activities within the two institutions. The purpose of this project is linking clinical and basic science studies through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs.

1 R24 AI067039 (Saag, PI) 09/1/2016-08/31/2021 1.8 cm

PHS/NIH/NIAID \$4,006,023 DC current year

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS

The CFAR Network of Integrated Clinical Systems (CNICS) project is a multi-site, electronic medical records resource network that can substantially contribute to the contemporary HIV research agenda. As a clinic-based research network, CNICS directly reflects the outcomes of clinical decisions and management options used daily in the care of HIV infected individuals.

1 U01 AI069452 (Saag, CRS Leader) 12/01/13-11/30/20 1.8 cm

NIH/NIAID \$1,122,965 DC current year

Alabama-Clinical Trials Unit

The Alabama HIV/AIDS CTU is designed to provide an administrative infrastructure that brings Network investigators at UAB together to facilitate the conduct of high capacity, quality-assured, safety-driven clinical trials through provision of administrative support, financial support, communications, staff training, oversight, regulatory support, pharmacy services, synchronization of scientific effort, community relations, and CAB support, and coordination of study personnel in order to achieve maximal efficiency of available staff effort.

2U01AI069918-06 (R Moore, PI; Saag, Co-PI) 7/1/16-6/30/21 0.24 cm

NIH Johns Hopkins University \$54,000 DC Current year

Johns Hopkins Subcontract- North American AIDS Cohort Collaboration on Research Design-NA-ACCORD The NA-ACCORD is a regional collaboration of single-site and multi-site cohorts representing over 50 sites with greater than 60,000 patients from the United States and Canada. The NA-ACCORD provides a mechanism to combine previously collected data from classical epidemiologic and clinical HIV cohorts to address scientific questions that cannot be addressed in the individual cohorts because of limited sample sizes.

NIH/DHHS U01AA020802 (Cropsey, K) 9/1/2018-8/30/2019 0.36 cm

3/3 Alcohol Research Consortium in HIV - Intervention Research Arm (ARCH-IRA) Co-Investigator

Revised 01/14/2020

Michael S. Saag, MD

Case Western/NIH RES513806 7/1/2019-6/30/2020 0.60 cm
 Impact of Physical Activity Routines and Dietary Intake on the Longitudinal Symptom Experience of HIV+ Adults in the CNICS Cohort (PARADISE-HIV)

University Pittsburg 0061652(121408-2)/NIH (Merlin PI) 5/1/2019-4/30/2020 0.60 cm
 Evaluation of the Efficacy, Mechanisms and Cost-Effectiveness of a Novel Intervention for Chronic Pain Tailored to People Living with HIV
 Co-Investigator

University of Pennsylvania R01-HL151292 (Gross/Ashare) .24 cm
 Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
 Co-Investigator (CNICS PI)

CLINICAL TRIALS- (Saag PI on all)

Gilead GS-US-366-1216 Gilead 6/3/15-5/31/19 0.05 cm
 A Phase 3b, Randomized, DoubleBlind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically-Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Gilead GS-US-380-1489 12/1/15-5/30/20 0.05 cm
 "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/ Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected, Antiretroviral Treatment- Naïve Adults"

Recently Ended

R01HL126538 (H Crane, J Delaney, S Heckbert, PI) 09/01/2015 – 08/31/2019 0.24 cm
 NIH/NHLBI \$250,950

Cardiovascular, Pulmonary and Hematological Disease in HIV: Prevention and Treatment

We propose to rigorously assess risk factors associated with increased prevalence and incidence of myocardial infarction (MI), venous thromboembolism (VTE), and chronic anemia among persons living with HIV, and to determine risk factors associated with poor outcomes from these conditions.

Role: Co-Investigator

UAB-MISS WIHS Cohort (Saag, Co-PI) 01/01/13-12/31/18 .24 cm
 1U01AI103401-01 \$1,387,945 DC current year

The Women's Interagency HIV Study (WIHS) is a multicenter longitudinal study funded by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Drug Abuse (NIDA), and the National Cancer Institute (NCI) to investigate the impact and progression of HIV disease in women.

Creative and Novel Ideas in HIV Research (CNIHR) (Saag, PI) 6/1/14-05/31/19 0.24
 cm NIH –Supplement to P30-AI027767 \$2,675,746 DC current year

Funding mechanism to attract and mentor international and domestic young investigators from outside the field of HIV/AIDS research to bring promising ideas to this field of study.

Revised 01/14/2020

Michael S. Saag, MD

5 P30-AI027767 (Saag, PI)

06/01/14-05/31/19

1.8 cm

NIH/NIAID

\$1,177,304 DC Current year

UAB Center for AIDS Research

The primary purpose of this center is to support interdisciplinary AIDS research efforts. This Center is responsible for the planning, evaluating, managing and documenting a broad array of research activities within the two institutions. The purpose of this project is linking clinical and basic science studies through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs.

1 R24 AG044325 (K High, Wake Forest, PI; **Saag, Co-I**)
cm NIH/NIA

09/01/13-05/31/19

0.24

\$11,591 DC current year

Developing Research at the Interface of HIV and Aging

This program identifies pilot projects to forward the work being done in HIV and aging.

BIBLIOGRAPHY**MANUSCRIPTS**

1. **Saag** MS. Effects of prostaglandin synthetase inhibitors on the response to arachidonic acid infusion in the feline intestinal bed, *Honors Thesis*, Tulane University, 1977.
2. **Saag** MS, Raff MJ, Melo JC. A clinical approach to the choice of antimicrobial therapy case #22: Recurrent furunculosis. *J Ky Med Assoc* 78(12):722-25, 1980. (PMID: 7441039)
3. **Saag** MS, Reid KH. Surgical determination of the site of crossing of jaw-opening reflex evoked by tooth pulp stimulation in the cat. *Brain Res* 212(1):140-144, 1981. (PMID: 7225851)
4. **Saag** MS. Approach to the use of antimicrobial combinations. *Ala J Med Sci* 22(1): 72-75,1985. (PMID: 3883831)
5. **Saag** MS, Britz JA. Asymptomatic blood donor with a false-positive HTLV-III Western blot. *N Engl J Med* 314(2): 118, 1986. (PMID: 3510382)
6. Lyon MD, Smith KR, **Saag**, MS, Cloud GA, Cobbs CG. *In vitro* activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 30(1):25-30, 1986. (PMID: 3092731 PMCID: PMC176428)
7. **Saag** MS. Traveler's diarrhea: Minimize risks, cut losses. *Sport & Medicina* 3(4):17-20, 1986.
8. Pierce MA, **Saag** MS, Dismukes WE, Cobbs CG. Case report: Q fever endocarditis. *Amer J Med Sci* 292(2):104-106, 1986. (PMID: 3728557)
9. Lyon MD, Smith KR, **Saag** MS, Cobbs CG. Brief report: *in vitro* activity of ciprofloxacin against *Neisseria gonorrhoeae*. *Amer J Med* 82(suppl 4A):40-41, 1987.
10. **Saag** MS, Bennett JC. The infectious etiology of chronic rheumatic diseases. *Sem Arthr Rheum* 17(1):1-23, 1987.
11. Dismukes WE, Cloud G, Gallis H, Kerkering T, Medoff G, Craven PC, Kaplowitz L, Fisher J, Gregg C, Bowles C, Shadomy S, Stamm AM, Diasio B, Kauffman C, Soong S, Alsip S, **Saag** MS, Karam GH, Kaufman L, and the NIAID Mycosis Study Group. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. *N Engl J Med* 317(6):334-341, 1987. (PMID: 3299095)
12. **Saag** MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis. *Chest* 93(4):848-851, 1988. (PMID: 3280262)
13. **Saag** MS, Dismukes WE. Azole antifungal agents: Emphasis on new triazoles. *Antimicrob Ag Chemother* 32(1):1-8, 1988. (PMID: 2831809 PMCID: PMC172087)
14. **Saag** MS, Hahn BH, Gibbons J, Li Y, Parks S, Parks WP, Shaw GM. Extensive variation of human immunodeficiency virus type-1 *in vivo*. *Nature* 334(6181):440-444, 1988. (PMID: 3405290)
15. Fisher A, Ensoli B, Looney D, Rose A, Gallo RC, **Saag** MS, Shaw GM, Hahn BH, Wong-Staal F. Biologically diverse molecular variants of HIV-1 isolate. *Nature* 334(6181):444-447, 1988. (PMID: 2841608)
16. Bost KL, Hahn BH, **Saag** MS, Shaw GM, Weigent DA, Blalock JE. Individuals infected with HIV possess antibodies against IL-2. *Immunology* 65(4):611-615, 1988. (PMID: 2464543 PMCID: PMC1385572)
17. Gibbons J, **Saag** MS, Parks W, Parks E, Hahn BH, Shaw GM. Genomic diversity of HIV *in vivo* and *in vitro*. *Human Retroviruses, Cancer, and AIDS*, UCLA Symposia on Molecular and Cellular Biology, 71:75-114, 1988.
18. **Saag** MS, Decker D, Campbell S, Leuther M, Brown M, Crain M, Whitley R, Hahn BH, Shaw GM. Replication of HIV-1 *in vivo*: plasma viremia. *Retroviruses of Human AIDS and Related Animal Diseases*, 4e Colloque des Cent Gardes. Pasteur Vaccines, Marnes-La-Coquette, Paris, France, 37-42, 1989.

19. **Saag MS.** The Newer Antifungal Agents. *Inf In Med* 7(8):4-8, 32, 1990.
20. Panel Member. State-of-the-art conference on azidothymidine therapy for early HIV infection. *Amer J Med* 89:335-344, 1990. (PMID: 2203263)
21. **Saag MS.** Unusual, bizarre symptoms can point to HIV infection. *Family Practice News* 20(16):31-32, 1990.
22. Bonner JR, **Saag MS.** Practical reviews: AIDS-1990. *Educational Reviews* 1-3, 1990.
23. Murphy RL, Lavelle JP, Allan JD, Gordin FM, Dupliss R, Boswell SL, Waskin HA, Davies SF, Graziano FM, **Saag MS**, Walter JB, Crane LR, MacDonell KB, Hodges TL, Pierce PF. Aerosolized pentamidine prophylaxis following *Pneumocystis carinii* pneumonia in AIDS patients: Results of a blinded dose-comparison study using an ultrasonic nebulizer. *Amer J Med* 90(4):418-426, 1991. (PMID: 2012082)
24. Clark SJ, **Saag MS**, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med* 324(14):954-960, 1991. (PMID: 1900576)
25. **Saag MS**, Crain MJ, Decker WD, Campbell-Hill S, Robinson S, Brown WJ, Leuther M, Whitley RJ, Hahn BH, Shaw GM. High-level viremia in adults and children infected with human immunodeficiency virus: Relation to disease stage and CD4+ lymphocyte levels. *J Infect Dis* 164:72-80, 1991. (PMID: 1676046)
26. Clark SJ, **Saag MS**, Hahn BH, Shaw GM, Daar ES, Ho D. Letter to the Editor, *N Engl J Med* 325(10):734-735, 1991.
27. **Saag MS**, Weaver BW. HIV infection in primary care: Guidelines for the '90s. *Med Aspects Hum Sexuality* 25(11):42-51, 1991.
28. Shaw GM, Pan G, Clark SJ, Hahn BH, **Saag MS.** Molecular and biologic transitions from acute to chronic HIV-1 infection. *Retroviruses of Human AIDS and Related Animal Diseases*, 6th Colloque des Cent Gardes. Paris, France, p 73-77, 1991.
29. **Saag MS**, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group, and the AIDS Clinical Trials Group. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. *N Engl J Med* 326(2):83-89, 1992. (PMID: 1727236)
30. Powderly WG, **Saag MS**, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE, and the NIAID AIDS Clinical Trials Group, and NIAID Mycoses Study Group. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 326(12):793-798, 1992. (PMID: 1538722)
31. **Saag MS.** Nucleoside analogs: Adverse effects. *Hospital Practice* 27(S2):26-36, 1992. (PMID: 1324255)
32. Dismukes WE, Bradsher Jr RW, Cloud GC, Kauffman CA, Chapman SW, George RB, Stevens DA, Girard WM, **Saag MS**, Bowles-Patton C, and the NIAID Mycoses Study Group. Itraconazole therapy for blastomycosis and histoplasmosis. *Am J Med* 93:489-497, 1992. (PMID: 1332471)
33. **Saag MS.** Cryptococcal meningitis. *PAACNOTES* 5(1):34-37, 1993.
34. Piatak Jr M, **Saag MS**, Yang LC, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 plasma during all stages of infection determined by competitive PCR. *Science* 259:1749-1754, 1993. (PMID: 8096089)
35. Wheat J, Hafner R, Wulfsohn M, Spencer P, Squires K, Powderly W, Wong B, Rinaldi M, **Saag M**, Hamill R, Murphy R, Connolly-Stringfield P, Briggs N, Owens S, and the National Institute of Allergy and Infectious Diseases Clinical Trials Group and Mycoses Study Group collaborators. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. *Annals Internal Med* 118:610-616, 1993. (PMID: 8383934)

36. Ghosh SK, Fultz PN, Keddie E, **Saag** MS, Sharp PM, Hahn BH, Shaw GM. A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. *Virology* 194:858-864, 1993. (PMID: 8503191)
37. Lifson JD, Piatak Jr M, **Saag** MS, Shaw GM. Letter to the Editor, *Science* 260:1705-1706, 1993.
38. Piatak Jr M, Yang LC, Luk K-C, Lifson JD, **Saag** MS, Clark SJ, Kappes JC, Hahn BH, Shaw GM. Viral dynamics in primary HIV-1 infection. *Lancet* 341:1099, 1993. (PMID: 8097000)
39. **Saag** MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, Anderson KW, Massari FE, Shaw GM, and the L-697,661 Working Group. A short term clinical evaluation of L-697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase. *N Engl J Med* 329:1065-1072, 1993. (PMID: 7690462)
40. **Saag** MS. Improved HIV detection. *NCRR Reporter* Jul/Aug No. 4:p 3, 1993.
41. Graziosi C, Pantaleo G, Butini L, Demarest JF, **Saag** MS, Shaw GM, Fauci AS. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. *Proc Natl Acad Sci, USA* 90:6405-6409, 1993. (PMID: 8341646)
42. Piatak Jr M, **Saag** MS, Yang LC, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Lifson JD. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. *AIDS* 7(suppl 2):S65-S71, 1993. (PMID: 7909227)
43. Ennis DM, **Saag** MS. Cryptococcal meningitis in AIDS. *Hospital Practice* 28:99-102, 105-107, 111-112, 1993. (PMID: 7691857)
44. Smith KR, Pate MS, Cobbs CG, **Saag** MS. *In vitro* effect of ofloxacin alone and in combination with ceftazidime or gentamicin against *P. aeruginosa*. *Drugs* 45(suppl 3):234-235, 1993.
45. Piatak Jr M, Shaw GM, Yang LC, Kappes JC, **Saag** MS, Lifson JD. Response. Effect of platelet-associated virus on assays of HIV-1 in plasma. *Science* 262:1585-1586, 1993. (PMID: 8248811)
46. Powderly WG, Cloud GA, Dismukes WE, **Saag** MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of AIDS-associated cryptococcal meningitis. *Clin Infect Dis* 18:789-792, 1994. (PMID: 8075272)
47. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian MS, Cone L, Brennan PJ, Weitzman SA, and the AIDS-related Cachexia Study Group (Dickmeyer MS, Gordin F, Smith JA, **Saag** MS, Grace WR, Gabin SJ, Browder H, Pike IM, Tierney A. Megestrol acetate in patients with AIDS-related cachexia. *Ann Int Med* 121(6):393-399, 1994. (PMID: 7794302)
48. Haddock CC, Fawal H, **Saag** MS. Knowledge and self-reported use of universal precautions in a university teaching hospital. *Hosp Health Serv Adm* 39(3):295-307, 1994. (PMID: 10137051)
49. **Saag** MS. What to do when zidovudine fails. Editorial. *N Engl J Med* 330:706-707, 1994. (PMID: 8107721)
50. **Saag** MS. Managing progressive HIV disease in hemophiliacs. *AIDS Patient Care* 8, S1:S14-S16, 1994.
51. **Saag** MS. Evolving understanding of the immunopathogenesis of HIV. *AIDS Res Hum Retroviruses* 10(8):887-892, 1994. (PMID: 7811538)
52. Pantaleo G, Demarest JF, Soudeyans H, Graziosi C, Denis F, Adelsberger JW, Borrow P, **Saag** MS, Shaw GM, Sekaly RP, Fauci AS. Major expansion of CD8 T-lymphocytes with a predominant V β usage during primary immune response to HIV. *Nature* 370:463-467, 1994. (PMID: 8047166)
53. Gao F, Yue L, Hill SC, Robertson DL, Graves AH, **Saag** MS, Shaw GM, Sharp PM, Hahn B. HIV-1 sequence subtype D in the United States. *AIDS Res Hum Retroviruses* 10:625-627, 1994. (PMID: 7917525)

54. Kilby JM, **Saag** MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? *Infect Agents Dis* 3:313-323, 1994. (PMID: 7534192)
55. **Saag** MS, Hammer SM, Lange JMA. Pathogenicity and diversity of HIV and implications for clinical management: A review. *J Acq Imm Def Synd* 7(Suppl 2):S2-S10, 1994. (PMID: 7965648)
56. Hammer SM, Kessler HA, **Saag** MS. Issues in combination antiretroviral therapy: A review. *J Acq Imm Def Synd* 7(Suppl 2):S24-S37, 1994. (PMID: 7965649)
57. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini E, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, **Saag** MS, Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 373:117-122, 1995. (PMID: 7529365 DOI:10.1038/373117a0)
58. Cao Y, Ho DD, Todd J, Kokka R, Urdea M, Lifson JD, Piatak Jr M, Chen S, Hahn BH, **Saag** MS, Shaw GM. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. *AIDS Res Hum Retroviruses* 11(3):353-361, 1995. (PMID: 7786581)
59. **Saag** MS. Editorial Response: Clinical and host differences between infections with the two varieties of *Cryptococcus neoformans*. *Clin Infect Dis* 21(1):35-36, 1995.
60. **Saag** MS. Sharing HIV patient management experience. *Practice to Practice* 3(1):4-7, 1995.
61. **Saag** MS. An approach to antiretroviral treatment of HIV disease- The Situation: An Overview. *Hosp Pract* 30(Suppl 1):3-4, 1995. (PMID: 7635915)
62. **Saag** MS. Pathogenesis of HIV disease. *Rr-Ricerca* 9:13-15, September 1995.
63. Markowitz M, **Saag** M, Powderly W, Hurley A, Hsu A, Valdes JM, Henry D, Sattler F, LaMarca A, Leonard JM, Ho DD. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. *N Engl J Med* 333:1534-1539, 1995. (PMID: 7477168)
64. Kappes JC, **Saag** MS, Shaw GM, Hahn BH, Chopra P, Chen S, Emini EA, McFarland R, Yang LC, Piatak Jr M, Lifson JD. Assessment of antiretroviral therapy by plasma viral load testing: Standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared. *J Acquir Immune Defic Syndr Hum Retrovirol* 10:139-149, 1995. (PMID: 7552477)
65. **Saag** MS. Effect of antiretroviral therapy on plasma HIV RNA. *J Biol Regul Homeost Agents* 9(3):105-106, 1995. (PMID: 8782017)
66. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, **Saag** MS, Jiang Z, Temsamani J, Martin RR, et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. *Clin Pharmacol Ther* 58:44-53, 1995. (PMID: 7628182)
67. **Saag** MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw G, Richman DD, Volberding PA, for the International AIDS Society-USA. HIV viral load markers in clinical practice. *Nat Med* 2:625-629, 1996. (PMID: 8640545)
68. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner J, Richman DD, **Saag** MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA, for the International AIDS Society-USA. Antiretroviral therapy for HIV infection in 1996: Recommendations of an International Panel. *JAMA* 276:146-154, 1996. (PMID: 8656507)
69. Connick E, Marr DG, Zhang X-Q, Clark SJ, **Saag** MS, Schooley RT, Curiel TJ. HIV-specific cellular and humoral responses in primary HIV infection. *AIDS Res Hum Retroviruses* 12(12):1129-1140, 1996. (PMID: 8844017)
70. Kilby JM, **Saag** MS. Treatment of HIV-1 infection. *Infect Med* 13:903-911, 1996.

71. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi J-P, Liou S-h, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS, and the National Institute of Allergy and Infectious Diseases Clinical Trials Group Protocol 241 Investigators including **Saag MS**. A comparison of combination therapy with nevirapine, zidovudine, and didanosine versus zidovudine and didanosine for human immunodeficiency virus type 1 infection: A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 124:1019-1030, 1996. (PMID: 8633815)
72. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, **Saag MS**, Shaw GM, Quinn TC, Cohen OJ, Welbon CC, Pantaleo G, Fauci AS. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. *Proc Natl Acad Sci, USA* 93:4386-4391, 1996. (PMID: 8633076 PMID: PMC39547)
73. Coombs R, Cotton D, Hammer S, **Saag M**, van der Horst C. To treat or not to treat—approaches to antiretroviral therapy. *AIDS Clin Care* 8(1):1-4, 1996. (PMID: 11363056)
74. Kilby JM, **Saag MS**. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. *Adv Exp Med Biol* 394:291-298, 1996. (PMID: 8815693)
75. Craig CB, Darnell BE, Weinsier RL, **Saag MS**, Epps L, Mullins L, Ennis DM, Akrabawi SS Cornwell PE, Sauberlich HE. Decreased fat and nitrogen losses in patients with AIDS receiving medium-chain-triglyceride-enriched formula vs those receiving long-chain-triglyceride-containing formula. *J Am Dietetic Assoc* 97(6):605-611, 1997. (PMID: 9183320)
76. Wu AW, Jacobson D, Berzon RA, Revicki D, van der Horst C, Fichtenbaum C, **Saag MS**, Lynn L, Hardy D, Feinberg J. The effect of mode of administration on Medical Outcomes Study health ratings and EuroQol scores in AIDS. *Quality of Life Research* 6:3-10, 1997. (PMID: 9062436)
77. **Saag MS**. Itraconazole oral solution: pharmacokinetics and absorption. *AIDS Patient Care & STDs* 11(Suppl 1):S16-S17, 1997. (PMID: 11361746)
78. **Saag MS**. The use of HIV viral load in clinical practice: back to the future. *Ann Intern Med* (editorial) 126:983-985, 1997. (PMID: 9182477)
79. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, **Saag MS**, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA, for the International AIDS Society-USA. Antiretroviral therapy for HIV infection in 1997: Updated recommendations of an International AIDS Society-USA Panel. *JAMA* 277:1962-1969, 1997. (PMID: 9200638)
80. van der Horst CM, **Saag MS**, Cloud GA, Hamill, RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE, and the NIAID Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. *N Engl J Med* 337:15-21, 1997. (PMID: 9203426)
81. **Saag MS**. Candidate antiretroviral agents for use in post-exposure prophylaxis. *Am J Med* 102:25-31, 1997. (PMID: 9845493)
82. **Saag MS**. Use of virologic markers in clinical practice. *J Acquir Immune Defic Syndr Hum Retrovirol* 16(Suppl. 1): S3-S13, 1997. (PMID: 9389310)
83. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, Skahan KJ, Johnson P, Hamill R, Bamberger D, Pappas P, Stansell J, Koletar S, Squires K, Larsen RA, Cheung T, Hyslop N, Lai KK, Schneider D, Kauffman C, **Saag M**, Dismukes W, Powderly W for the NIAID Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Treatment of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. *Am J Med* 103; 223-232, 1997. (PMID: 9316555)
84. Fischl MA, Richman DD, **Saag M**, Meng TC, Squires KE, Holden-Wiltse J, Meehan P. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine and two doses of interferon α -2a in patients with HIV: ACTG Study 197. *J Acquir Immune Defic Syndr Hum Retrovirol* 16:247-253; 1997. (PMID: 9402071)

85. Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, **Saag** MS. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. *AIDS Res Hum Retroviruses* 13:1533-1537, 1997. (PMID: 9390753)
86. **Saag** M, Gersten M, Chang Y, Greenberg SL, Yu G, Clendeninn Nj. Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC). *Clin Infect Dis* 25(2), 396, 1997.
87. Harris S, **Saag** MS. Dermatologic manifestations of HIV infection. *Current Problems in Dermatology* 9(6):212-242, 1997.
88. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, **Saag** MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. *J Infect Dis* 177:40-47, 1998. (PMID: 9419168)
89. **Saag** MS. The changing face of *AIDS Research and Human Retroviruses*: A new forum to display your ART-work. (Editorial) *ARHR* 14:721, 1998.
90. Carpenter C, Feinberg M, Aubry W, Averitt D, Coffin J, Cooper D, Follansbee S, Hamburg P, Harrington, Mhidalgo J, Jaffe H, Landers D, Masur H, Pizzo P, Richman D, **Saag** M, Schooley R, Stone V, Thompson M, Trono D, Vella S, Walker B, Yeni P. Report of the NIH Panel to define principles of therapy of HIV infection. *Ann Intern Med* 128:1057-1078, 1998. (PMID: 9652992)
91. Carpenter CJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, **Saag** MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. *JAMA* 280:78-86, 1998. (PMID: 9660368)
92. Ioannidis JPA, Collier, AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, **Saag** MS, Spruance S, Youle MS. Clinical efficacy of high dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. *J Inf Dis* 178:349-359, 1998. (PMID: 9697714)
93. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Carder L, Johnson R, Nowak MA, Shaw GM, **Saag** MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. *Nat Med* 4:1302-1307, 1998. (PMID: 9809555)
94. **Saag** M. What is the role of partially suppressive therapy? *Antiviral Therapy* 3(suppl 2):4-5, 1998.
95. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin DS, **Saag** M, Vaughn A. Controversies in AIDS treatment. Proceedings from CME coferece sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Faculty rountable discussion. *AIDS Patient Care STDS* 12(7):543, 555, 1998. (PMID: 15462007)
96. Pan G, Zhou T, Radding W. **Saag** MS, Mountz JD, McDonald JM. Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS. *Immunopharmacology* 40:91-103, 1998. (PMID: 9826024)
97. **Saag** M, Sonnerborg A, Torres R, Lancaster D, Gazzard B, Schooley R, Romero C, Kelleher D, Spreen W, LaFon S, and the Abacavir Phase 2 Clinical Team. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. *AIDS* 12/16:F203-F209, 1998. (PMID: 9833848)
98. Hoesley, CJ, **Saag** MS. The role of nucleoside analogues in salvage regimens. *J HIV Therapy* 3:90-94, 1998
99. **Saag** MS, Schooley RT. Antiretroviral chemotherapy (review). *Current Clin topics in Inf Dis* 18:154-179, 1998. (PMID: 9779354)
100. **Saag** MS. Strategies for long-term patient management. *AIDS Patient Care and STDs* 12(7):531-536, 1998. (PMID: 15462004)

101. **Saag** MA, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel WJ, Moskovitz BL, Wiesinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group. A Comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis (MSG #25). *Clin Infect Dis* 28:291-296, 1999. (PMID: 10064246)
102. Bucy RP, Hockett RD, Derdeyn CA, **Saag** MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. *J Clin Invest* 103:1391-1398, 1999. (PMID: 10330421 PMCID: PMC408455)
103. **Saag** MS, Kilby JM. HIV-1 and HAART: A time to cure, a time to kill. *Nature Med* 5:609-611, 1999. (PMID: 10371490)
104. **Saag** MS. A review of the FIAU tragedy and its effect on clinical research. *J Clin Res Practice* 1:21-32, Spring 1999.
105. **Saag** MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarneri JA, Lee J, Brenner-Gati L, Klausner M. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients (MSG #30). *AIDS Res Hum Retroviruses* 15(16):1413-1417, 1999. (PMID: 10555103)
106. Hockett RD, Kilby JM, Derdeyn CA, **Saag** MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. *J Exp Med* 189:1545-1554, 1999. (PMID: 10330433 PMCID: PMC2193638)
107. Derdeyn CA, Costello C, Sfakianos G, Allen S, Chatham A, Kilby JM, **Saag** MS, Kaslow R, Bucy RP. Correlation between circulating SDF-1 levels and CD4 cell count in human immunodeficiency virus type-1 infected individuals. *AIDS Res Hum Retroviruses* 15:1063-1071, 1999. (PMID: 10461826)
108. Derdeyn CA, Kilby JM, Miralles GD, Li-Fang L, Sfakianos G, **Saag** MS, Hockett RD, Bucy RP. Evaluation of distinct blood lymphocyte populations in HIV type 1 infected subjects in the absence or presence of effective therapy. *J Infect Dis* 180:1851-1862, 1999. (PMID: 10558941)
109. Powderly WG, **Saag** MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virologic response to potent antiretroviral therapy. *AIDS* 13:1873-1880, 1999. (PMID: 10513645)
110. O'Sullivan CE, Drew WL, McMullen DJ, Miner R, Lee JY, Kaslow RA, Lazar JG, **Saag** MS. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. *J Infect Dis* 180(3):847-849, 1999. (PMID: 10438377)
111. Lacey L, Mauskopf J, Lindrooth R, Pham S, **Saag** M, Sawyer W. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US. *Pharmacoeconomics* 15(Supplement 1):23-37, 1999. (PMID: 10537440)
112. **Saag** M, Hecht F. Antiretrovirals for HIV nephropathy? *AIDS Clinical Care* 11(6):50, 1999. (PMID: 11366883)
113. Fichtenbaum CJ, Koletar SL, Yiannoutsos C, Holland F, Pottage Jr JC, Cohn SE, Walawander A, Frame P, Feinberg J, **Saag** M, Van der Horst C, Powderly WG, and the ACTG Study 816 Team. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. *Clin Infect Dis* 30(5):749-756, 2000. (PMID: 10816143)
114. Carpenter CCJ, Cooper DA, Fischl MA, Gatell J, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, **Saag** MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. *JAMA* 283:381-390, 2000. (PMID: 10647802)
115. **Saag** MS, Graybill JR, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE for the Mycoses Study Group Cryptococcal Subproject. Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis* 30:710-718, 2000. (PMID: 10770733)

116. Hockett RD, **Saag** MS, Kilby JM, Sfakianos G, Wakefield TB, Bucy RP. Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR. *J Virol Methods* 87(1-2):1-12, 2000. (PMID: 10856747)
117. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, **Saag** MS. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. *Antimicrob Agents & Chemother* 44:2672-2678, 2000. (PMID: 10991842 PMID: PMC90133)
118. Kilby JM, Goepfert PA, Miller AP, Gnann JW, Sillers M, **Saag** MS, Bucy RP. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. *Ann Intern Med* 133:435-438, 2000. (PMID: 10975961)
119. **Saag** MS, Advisory Committee Member of the HIV Surrogate Marker Collaborative Group. Human Immunodeficiency Virus Type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis. *AIDS Res Hum Retroviruses* 16:1123-1133, 2000. (PMID: 19054887)
120. Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, Centor R, **Saag** MS. Health-related quality of life and virologic outcomes in an HIV clinic. *Quality of Life Research* 9:977-985, 2000. (PMID: 11332226)
121. Call SA, Heudebert G, **Saag** M, Wilcox CM. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm³. *Am J Gastroenterol* 95(11):3142-3146, 2000. (PMID: 11095332)
122. Hoesley CJ, **Saag** MS, Chatham A, Kilby JM. Prolonged HIV-1 RNA suppression on dual nucleoside reverse transcriptase inhibitor therapy in clinical practice. *Clin Infect Dis* 31:1095-1097, 2000. (PMID: 11049795)
123. Graybill JR, Sobel J, **Saag** M, van der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W and the NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. *Clin Infect Dis* 30(1):47-54, 2000. (PMID: 10619732)
124. Marlink R, Kao H, Hsieh E and Co-chairs of the "Giving Voice to a Silent Epidemic" Working Group including **Saag** MS. Clinical care issues for women living with HIV and AIDS in the United States. *ARHR* 17:1-33, 2001. (PMID: 11177380 DOI: 10.1089/088922201750056753)
125. Call SA, **Saag** MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. *J Infect Dis* 183:401-408, 2001. (PMID: 11133371)
126. **Saag** MS. Antiretroviral rounds (Response #1). *AIDS Clin Care* 13:26, 2001.
127. **Saag** MS. The role of immunotherapy in the treatment of HIV (editorial). *AIDS* 15(suppl 2):S1-3, 2001. (PMID: 11424970)
128. **Saag** MS. The impact of highly active antiretroviral therapy on HIV-specific immune function. *AIDS* 15 (suppl 2):S4-10, 2001. (PMID: 11424976)
129. **Saag** MS. HIV resistance testing in clinical practice: A QALY-fied success (editorial). *Ann Intern Med* 134:475-477, 2001. (PMID: 11255523)
130. **Saag** MS, Tebas P, Sension M, Conant M, Myers R, Chapman, SK, Anderson R, Clendeninn N, for the Viracept Collaborative Study Group. Randomized, double-blind, comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). *AIDS* 15:1971-1978, 2001. (PMID: 11600825)
131. Gerbert B, Moe JC, **Saag** MS, Benson CA, Jacobsen DM, Feraios A, Hill ME, Bronstone A, Caspers N, Volberding PA. Toward a definition of HIV expertise: A survey of experienced HIV physicians. *AIDS Patient Care & STDs* 15(6):321-330, 2001. (PMID: 11445014)

132. Ross L, Liao Q, Gao H, Pham S, Tolson J, Hertogs K, Larder B, **Saag MS**. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. *AIDS Res Human Retrovir* 17:1379-1385, 2001. (PMID: 11679150)
133. Coghlan ME, Sommadossi J-P, Jhala NC, Many WJ, **Saag MS**, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A Report of 12 cases. *Clin Infect Dis* 33:1914-21, 2001. (PMID: 11692304)
134. Sabin CA, Olmscheid B, Moyle G, Carr A, Boyle B, Cohen C, Cooper D, Deeks S, Gulick T, **Saag M**. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois. *HIV Clinical Trials* 2(4):366-386, 2001. (PMID: 11590541 DOI: 10.1310/FPDY-DK6J-GLTV-HC50)
135. **Saag MS**, Powderly WG, Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: Summary of selected trials. *Topics in HIV Medicine* 10:47-51, 2002.
136. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, **Saag MS**, Wu X, Shaw GM, Kappes JC. Emergence of resistant Human Immunodeficiency Virus Type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents & Chemotherapy* 46(6):1896-1905, 2002. (PMID: 12019106 PMCID: PMC127242)
137. Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, **Saag MS**. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. *AIDS Res Human Retrovir* 18(13):909-916, 2002. (PMID: 12230934)
138. Yeni PG, Hammer SM, Carpenter CCJ, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, **Saag MS**, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV-1 infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. *JAMA* 288:222-235, 2002. (PMID: 12095387)
139. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, **Saag MS**. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. *J Acquir Immune Defic Syndr* 31:257-275, 2002. (PMID: 12439201)
140. Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, **Saag MS**. Patient-perceived barriers to antiretroviral adherence: associations with race and gender. *AIDS Care* 14:607-617, 2002. (PMID: 12419110)
141. Chen RY, Kilby JM, **Saag MS**. Enfuvirtide. *Expert Opin Investig Drugs* 11(12):1837-1843, 2002. (PMID: 12457443)
142. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, **Saag MS**, Nelson EL, Sista PR, Dusek A. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. *ARHR* 18(10):685-693, 2002. (PMID: 12167274)
143. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, **Saag MS**, Komarova N, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. *Nature* 422:307-312, 2003. (PMID: 12646921)
144. **Saag MS**. Is it time to proactively switch successful antiretroviral therapy? Carefully check your swatch. *Ann Int Med* (editorial) 139(2):148-149, 2003. (PMID: 12859164)
145. **Saag M**. Introduction; The next wave: Blocking fusion on HIV. *The AIDS Reader* 13(6):S4, 2003.
146. Fischl MA, Ribaldo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, **Saag MS**, Hammer SM, Vella S, Morse GD, Feinberg JE, for the Adult AIDS Clinical Trials Group 388 Study Team. A randomized trial of 2 different 4-drug antiretroviral regimens with a 3-drug regimen, in advanced human immunodeficiency virus disease. *J Infect Dis* 188:625-634, 2003. (PMID: 12934177)

147. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Call S, **Saag MS**. Duration of Highly Active Antiretroviral therapy Regimens. *Clin Infect Dis* 37:714-722, 2003. (PMID: 12942406)
148. Hass DW, Wilkinson GR, Kuritzkes DR, Richmann DD, Nicotera J, Mahon LF, Sutcliffe C, Siminski S, Andersen J, Coughlin K, Clayton EW, Haines J, Marshak A, **Saag MS**, Lawrence J, Gustavson J, Bennett JA, Christensen R, Matula MA, Wood AJJ, and the Adult AIDS Clinical Trials Group. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. *HIV Clin Trials* 4(5):287-300, 2003. (PMID: 14583845)
149. Saag, MS. Antiretroviral therapy: select lessons from recent studies. *Top HIV Med* 11(5):164-168, 2003. (PMID: 14555804)
150. Goetzman ES, Tian L, Nagy TR, Gower BA, Schoeb TR, Elgavish A, Acosta EP, **Saag MS**, Wood PA. HIV protease inhibitor ritonavir induces lipotrophy in male mice. *ARHR* 19(12):1141-1150, 2003. (PMID: 14709251)
151. Lalezari J and the TORO team (including MS **Saag**). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals in North America and Brazil. *N Engl J Med* 348:2175-2185, 2003 (PMID: 12637625 DOI: 10.1056/NEJMoa035026)
152. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, **Saag M**, Bock D, Simons G, Gertner JM. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. *JAIDS* 35(3):239-252, 2004. (PMID: 15076238)
153. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, **Saag MS**, for the Anemia in HIV Working Group. Anemia in HIV infection: Clinical impact and evidence-based management strategies. *Clin Infect Dis* 38: 1454-63, 2004. (PMID: 15156485)
154. Yeni PG, Hammer, SM, Hirsch MS, **Saag MS**, Schechter, M, Carpenter CCJ, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 Recommendations of the International AIDS Society-USA Panel. *JAMA* 292:251-265, 2004. (PMID: 15249575)
155. **Saag MS**, Cahn P, Raffi F, Wolff M, Pearce D, Molina J-M, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F, for the FTC-301 Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients – A randomized trial. *JAMA* 292(2):180-190, 2004. (PMID: 15249567)
156. **Saag MS**, Bowers P, Leitz GJ, Levine AM, for the Community HIV Anemia Management Protocol Sites (CHAMPS) Study Group. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV+ patients. *AIDS Res Hum Retroviruses* 20(10):1037-1045, 2004. (PMID: 15587490)
157. Phillips A, Ledergerber B, Lundgren J, Hogg B, Monforte A d'A, Castelli F, Walker S, Staszewski S, Dabis F, Gazzard B, **Saag M**, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. *J Infect Dis* 190:675-87, 2004. (PMID: 15272393 DOI: 10.1086/421707)
158. Jones NA, Wei, X, Flower DR, Wong M, Michor F, **Saag MS**, Hahn BH, Nowak MA, Shaw GM, Borrow P. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. *J Exp Med* 200:1243-1256, 2004. (PMID: 15545352 PMCID: PMC2211924)
159. Saag MS. Initiation of antiretroviral therapy: implications of recent findings. *Top HIV Med* 12(3):83-8, 2004. (PMID: 15310939)
160. Wingood GM, DiClemente RJ, Mikhail I, Lang DL, McCree DH, Davies SL, Hardin JW, Hook III ED, **Saag MS**. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV *The Willow Program*. *J Acquir Immune Defic Syndr* 37 (suppl 2): S58-S67, 2004. (PMID: 15385901)

161. Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, Dubay J, **Saag** MS, Hoesley CJ. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989 to 2002. *Clin Infect Dis* 39(9):1380-1384, 2004. (PMID: 15494916)
162. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, **Saag** M, Bock D, Simons G, Gertner JM. Effects of Growth Hormone on Visceral Adipose Tissue and Dyslipidemia in HIV, an Erratum. *J Acquir Immune Defi Syndr*. Nov 1;43(3):378-380, 2006. (PMID: 17079997)
163. Bachmann LH, Grimley DM, Waithaka Y, Desmond R, **Saag** MS, Hook III EW. Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care. *Sexually Transmitted Diseases* 32(1):20-26, 2005. (PMID: 15614117)
164. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang, W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, **Saag** MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. Antigenic conservation and immunogenicity of the HIV co-receptor binding site. *J Exp Med* 201(9):1407-1419, 2005. (PMID: 15867093 PMCID: PMC2213183)
165. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AIM, **Saag** MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. *Nature Medicine* 11(11):1170-1172, 2005. (PMID: 16205738)
166. Dillmon MS, **Saag** MS, Hamza SH, Adler BK, Marques MB. Unusual thromboses associated with protein S deficiency in patients with the acquired immunodeficiency syndrome: case reports and review of the literature. *ARHR* 21(9):753-756, 2005. (PMID: 16218798)
167. Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, **Saag** MS, Scherzer R, Shlipak M, Tien P; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. *J Acquir Immune Defi Syndr* 40(2):121-131, 2005.
168. **Saag** MS. Emtricitabine, a new antiretroviral agent with activity against HIV and Hepatitis B virus. *Clin Infect Dis* 42(1):126-131, 2006. (PMID: 16323102)
169. Raffi F, Katlama C, **Saag** M, Wilkinson M, Chung J, Smiley L, Salgo M. Week 12 response to therapy as a predictor of week 24, 48 and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus optimized regimen only (TORO) trials. *Clin Infect Dis* 42:870-877, 2006. (PMID: 16477567)
170. **Saag** MS. Introduction: A retrospective look at the AIDS epidemic. *AIDS Reader* 16(no. 3 Suppl): S3-S4, March 2006.
171. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, Stone BK, Carter J, Call S, Pisu M, Allison J, **Saag** MS. Distribution of health care expenditures for HIV-infected patients. *Clin Infect Dis* 42:1003-1010, 2006. (PMID: 16511767)
172. Leth FV, Kappelhoff BS, Johnson D, Losso MH, Boron-Kaczmarek A, **Saag** MS, Livrozet J-M, Hall DB, Huitema ADR, Wit FW, Beijnen JH, Lange JMA. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. *AIDS Res Human Retroviruses* 22(3):232-239, 2006. (PMID: 1655009)
173. Curtis, JR, Smith B, Weaver M, Landers K, Lopez-Ben R, Raper JL, **Saag** M, Venkataraman R, Saag KG. Ethnic variations in the prevalence of metabolic bone disease among HIV positive patients with lipodystrophy. *ARHR* 22(2):125-131, 2006. (PMID: 16478393)
174. Montaner JSG, Schutz M, Schwartz R, Jayaweera DT, Burnside AF, Walmsley S, **Saag** MS. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naïve, HIV-infected patients. *Medscape General Medicine* 8(2):36, 2006. (PMID: 16926775 PMCID: PMC1785231)

175. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, **Saag MS**, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia - Feasibility and Early Outcomes. *JAMA* 296(7):782-793, 2006. (PMID: 16905784)
176. Hammer SM, **Saag MS**, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV Infection: 2006 recommendations of the International AIDS Society-USA Panel. *JAMA* 296(7):827-843, 2006. (PMID: 16905788)
177. **Saag MS**. The experts speak. Burn-out among HIV care providers. *AIDS Patient Care and STDs* 20(6):385-390, 2006. (PMID: 16789851)
178. Bedimo R, Chen RY, Westfall AO, Raper JL, Allison JJ, **Saag MS**. Sustained HIV viral suppression following treatment interruption: an observational study. *AIDS Res Human Retroviruses* 22(1):40-44, 2006. (PMID: 16438644)
179. Appelbaum JS, Elion R, Henry K, Newman MD, **Saag MS**, Sax PE. Roundtable. Who should be providing HIV care? *AIDS Clin Care* 18(3):21-24, 2006. (PMID: 16596731)
180. Jacobson JM, Bucy PR, Spritzler J, **Saag MS**, Eron JJ Jr, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I: National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. *J Infect Dis* 194(5):623-632, 2006. (PMID: 16897661)
181. **Saag MS**. Which policy to ADAP-T: Waiting lists or waiting lines? *Clin Infect Dis* 43:1365-1367, 2006. (PMID: 17051506)
182. Hammer SM, **Saag MS**, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA Panel. Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel. *Top HIV Med* 14(3):827-43, 2006. (PMID: 17016878)
183. Saag MS. Ryan White CARE Act reauthorization: we need help. *AIDS Read* 16(11):594-596, 2006. (PMID: 17152647)
184. Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, DOms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, **Saag MS**, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA. A Plea for Justice For Jailed Medical Workers. *Science* 314(5801):924-925, 2006. (PMID: 17062652)
185. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, **Saag M**, Shatin D, Saag KG. Risk of Serious Bacterial Infections Among Rheumatoid Arthritis Patients Exposed to Tumor Necrosis Factor Alpha Antagonists. *Athritis Rheum.* 56(4):1125-1133, 2007. (PMID: 17393394)
186. Mugavero MJ, **Saag MS**. HIV Care at A Crossroads: The Emerging Crisis in the US HIV Epidemic. *MedGenMed* 9(1):58, 2007. (PMID: 17435658 PMID: PMC1924992)
187. Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, **Saag MS**. Can routine markers be used longitudinally to monitor antiretroviral therapy success in resource limited settings? *Clin Infect Dis* 44:135-138, 2007. (PMID: 17143829)
188. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, Wilkin T, Nadler J, Pierone G, **Saag M**, van Baelen B, Lefebvre E, on behalf of the POWER 2 study group. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: POWER 2. *AIDS* 21(6):F11-F18, 2007. (PMID: 17413685)

189. Gange SJ, Kitahata MM, **Saag** M, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). *Int J Epidemiol* 36(2):294-301, 2007. (PMID: 17213214 PMID: PMC2820873)
190. Mugavero MJ, Lin HY, Allison JJ, Willig JH, Chang PW, Marler M, Raper JL, Schumacher JE, Pisu M, **Saag** MS. Failure to establish HIV care: Characterizing the "No Show" phenomenon. *Clin Infect Dis* 45:127-130, 2007. (PMID: 17554713)
191. Willig JH, Westfall AO, Allison J, Van Wagoner N, Chang P-W, Raper J, **Saag** MS, Mugavero MJ. Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era. *Clin Infect Dis* 45(5):658-661, 2007. (PMID: 17683005)
192. Chen RY, Westfall AO, Hardin JM, Miller-Hardwick C, Stringer JSA, Raper JL, Vermund SH, Gotuzzo E, Allison J, **Saag** MS. Complete blood count as a surrogate CD4 marker for HIV monitoring in resource-limited settings. *J Acquir Immune Defic Syndr* 44(5):525-530, 2007. PMID: 17259910)
193. **Saag** MS. Opt-Out Testing: Who can afford to take care of patients with newly diagnosed HIV infection? *Clin Infect Dis* 45(Suppl 4):S261-265, 2007. (PMID: 18190297)
194. Wingood GM, DiClemente RJ, Mikhail I, McCree DH, Davies SL, Hardin JW, Peterson SH, Hook EW, Vermund S, **Saag** M. HIV discrimination and the health of women living with HIV. *Women & Health* 46(2-3):99-112, 2007. (PMID: 18160372)
195. Davey R, Pertel P, Benson A, Cassell D, Gazzard B, Holodniy M, Lalezari J, Levy Y, Mitsuyasu R, Palella F, Pollard R, Rajagopalan P, **Saag** M, Salata R, Sha B, Choudhri S. Safety, tolerability, pharmacokinetics, and efficacy of an Interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. *J Interferon & Cytokine Res* 28:89-100, 2008. (PMID: 18279104)
196. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, Lober WB, Van Rompaey SE, Crane HM, Moore RD, Bertram M, Kahn JO, **Saag** MS. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. *Internat J of Epidemiology* 37:948-955, 2008. (PMID: 18263650 PMID: PMC2597168)
197. **Saag** MS, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M, for the Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation (SHAPE) Study Team. High sensitivity of Human Leukocyte Antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. *Clin Infect Dis* 46:1111-1118, 2008. (PMID: 18444831)
198. Keele B, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping Li-Hua, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, **Saag** MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci USA* 105(21):7552-7557, 2008. (PMID: 18490657 PMID: PMC2387184)
199. Wilcox CM, **Saag** MS. Gastrointestinal complications of HIV infection: changing priorities in the HAART era. *Gut* 57:861-870, 2008. (PMID: 18203808)
200. Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, **Saag** MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA, for the UAB Acute Infection and Early Disease Research Program (AIEDRP) Group. Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline. *AIDS* 22(8):957-962, 2008. (PMID: 18453855 PMID: PMC3899827)
201. Effros RB, Austad S, Blau H, Chesselet M-F, Ingram D, Johnson TE, Kaeberlein M, Lundblad V, McCarter R, McElhaney J, **Saag** M. The biological sciences section program at the 60th annual meeting of The Gerontological Society of America. *J of Gerontol A Biol Sci Med Sci* 63(4):331-337, 2008. (PMID: 18426956)

202. Willig JH, Jackson DA, Westfall AO, Allison J, Chang Pei-Wen, Raper J, **Saag** MS, Mugavero MJ. Clinical inertia in the management of low density lipoprotein abnormalities in an HIV clinic. *Clin Infect Dis* 46(8):1315-1318, 2008. (PMID: 18444873)
203. Lalezari JP, **Saag** M, Walworth C, Larson P. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). *AIDS Res Human Retroviruses* 24(6):805-813, 2008. (PMID: 18507525)
204. Goldman JD, Cantrell RA, Mulenga LB, Tambatamba BC, Reid SE, Levy JW, Limbada M, Taylor A, **Saag** MS, Vermund SH, Stringer JSA, Chi BH. Simple adherence assessments to predict virologic suppression among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. *AIDS Res Hum Retroviruses* 24(8):1031-1035, 2008. (PMID: 18724803 PMCID: PMC2747786)
205. Willig JH, Abrams S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, **Saag** MS, Mugavero MJ. Increased regimen durability in the era of once daily fixed-dose combination antiretroviral therapy. *AIDS* 22:1951-1960, 2008. (PMID: 18784459)
206. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, Allison JJ, Willig JH, Raper JL, Wilcox CM, **Saag** MS. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. *AIDS Res Hum Retroviruses* 24(11):1347-1355, 2008. (PMID: 19032064 PMCID: PMC2928492)
207. Harris RJ, Abgrall S, Dabis F, Reiss P, **Saag** MS, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M (The Writing Committee members). Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. *Antiviral Therapy* 13(8):959-967, 2008. (PMID: 19195321 PMCID: PMC4507810)
208. Tan R, Westfall AO, Willig JH, Mugavero MJ, **Saag** MS, Kaslow RA, Kempf MC. Clinical outcome of HIV-Infected antiretroviral-naïve patients with discordant immunologic and virologic responses to Highly Active Antiretroviral Therapy. *J Acquir Immune Defic Syndr* 47:553-558, 2008. (PMID: 18285713)
209. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, Stringer EM, Krishnasami Z, Mwinga A, **Saag** MS, Stringer JS, Chi BH. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. *AIDS* 22(14):1821-1827, 2008. (PMID: 18753939 PMCID: PMC2649719)
210. Jacobson JM, **Saag** MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. *J Infect Dis* 198(9):1345-1352, 2008. (PMID: 18771406)
211. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, **Saag** MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Kitahata M, Sterne JAC, and The Antiretroviral Cohort Collaboration (ART-CC). Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? *AIDS* 22(18):2481-2492, 2008. (PMID: 19005271)
212. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman IM, Lampiris HW, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, **Saag** MS, Cooper D, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead SM, Mayer H, Van Der Ryst E for the MOTIVATE 1 and MOTIVATE 2 study groups. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med* 359(14):1442-1455, 2008. (PMID: 18832245)
213. Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JW, Raper JL, Wray NP, Cole SR, Schumacher JE, Davies S, **Saag** MS. Racial disparities in HIV virologic failure: do missed visits matter? *J Acquir Immune Defic Syndr* 50(1):100-108, 2009. (PMID: 19295340 PMCID: PMC2766510)
214. Mugavero MJ, Lin H-Y, Willig JH, Westfall AO, Ulett KB, Routman JS, Abrams S, Raper JL, **Saag** MS, Allison JJ. Missed visits and mortality among patients establishing initial outpatient HIV treatment. *Clin Infect Dis* 48:248-256, 2009. (PMID 19072715 PMCID: PMC2737584)

215. Ulett K, Willig J, Lin H-Y, Routtman J, Abroms S, Allison J, Chatham A, Raper J, **Saag** M, Mugavero M. The therapeutic implications of timely linkage and early retention in HIV care. *AIDS Pat Care & STDs* 23(1):41-49, 2009. (PMID: 19055408 PMID: PMC2733237)
216. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, Reid S, Mwango A (Albert), Mwinga A (Alwyn), Bulterys M, **Saag** MS, Stringer JSA. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. *Int J Epidemiol* 38(3):746-756 2009. (PMID: 19223334 PMID: PMC2689395)
217. Kitahata MM, Gange SJ, Abraham A, Merriman B, **Saag** MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein GDB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD, for The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med* 360(18):1815-1826, 2009. (PMID: 19339714 PMID: PMC2854555)
218. Antiretroviral Therapy (ART) Cohort Collaboration Steering Committee, the Multicenter AIDS Cohort Study, Amsterdam Homosexual Cohort and the CASCADE Collaboration 1917 Clinic Cohort University of Alabama, Birmingham US; Steering Committee: 1917 Clinic Cohort: Steering Committee: **Saag** MS, Mugavero MJ, Willig JH, Raper JL, Allison JJ, Kempf M-C, Schumacher JE, Westfall AO. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *The Lancet* 373(9672):1352-1363, 2009.
219. Antiretroviral Therapy Cohort Collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, **Saag** M, Khaykin P, de Wolf F, Sterne JA, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 23(16):2199-2208, 2009.
220. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig JH, Mugavero MJ, **Saag** MS, Martin JN, Deeks SG. Incomplete peripheral CD4 cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. *Clin Infect Dis* 48:787-794, 2009. (PMID: 19193107 PMID: PMC2720023)
221. Lubinski C, Aberg J, Bardequez AD, Elion R, Emmanuel P, Kuritzkes D, **Saag** MS, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JR, Fleming DA, Bronson D, Croke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia B. HIV Policy: The path forward- A joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. *Clin Infect Dis* 48:1335-1344, 2009.
222. McKinnell J, **Saag** M. Novel drug classes: entry inhibitors [enfuvirtide, chemokine(C-C motif) receptor 5 antagonists]. *Curr Opin HIV AIDS* 2009, 4:513-517, 2009.
223. **Saag** MS. Ryan White: an unintentional home builder. *AIDS Read* 19(5):166-168, 2009. (PMID: 19554735)
224. Deeks SG, Gange SJ, Kitahata MM, **Saag** MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. *Clin Infect Dis* 49:1582-1590, 2009. (PMID: 19845473 PMID: PMC2871149)
225. Patkar NM, Curtis JR, Teng GG, Allison JJ, **Saag** M, Martin C, Saag KG. Administrative Codes Combined with Medical Records Based Criteria Accurately Identified Bacterial Infections Among Rheumatoid Arthritis Patients. *J Clinical Epidemiol* 62(3):321-327, 2009. (PMID: 18834713 PMID: PMC2736855)
226. Lee HY, Giorgi EE, Keele BF, Gaschen B, Arthreya GS, Salazar-Gonzalez JF, Pham KT, Goepfert PA, Kilby JK, **Saag** MS, Delwart EL, Busch MP, Hahn BH, Shaw GM, Korber BT, Bhattacharya T, Perelson AS. Modeling Sequence Evolution in Acute HIV-1 Infection. *Journal Theor Biol* 261(2):341-360, 2009. (PMID: 19660475 PMID: PMC2760689)

227. McKinnell JA, Lin HY, Nevin CN, Willig JH, McFarland G, Genz M, Raper JL, DeLaitch LL, Mrus JM, Klaskala W, Mugavero MJ, **Saag** MS. Early virologic suppression with three-class experienced patients: 24-week effectiveness in the Darunavir Outcomes Study. *AIDS* 23(12):1539-1546, 2009. (PMID: 19487910 doi: 10.1097/QAD.0b013e32832c7b5c)
228. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Md JM, **Saag** MS. Gender Differences in Discontinuation of Antiretroviral Treatment Regimens. *J Acquir Immune Defic Syndr* 52(3):336-341, 2009. (PMID: 19654551 PMCID: PMC2783854)
229. **Saag** MS, Goodrich J, Fätkenheuer G, Koeln U, Clumeck N, Sullivan J, Westby M, Mayer H, van der Ryst E. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-CCR5-tropic HIV-1: 24 week results. *J Infect Dis* 199 (11):1638-1647, 2009. (PMID: 19432546)
230. Lubinski C, Aberg J, Bardeguet AD, Elion R, Emmanuel P, Kurtizkes D, **Saag** M, Squires KE, Weddle A, Rainey J (HIVMA authors), Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia B (ACP authors). HIV policy: The path forward. (a joint position paper of the HIV Medicine Association of IDSA and the American College of Physicians). *Clin Infect Dis* 48(10):1335-1344, 2009. (PMID: 19385087)
231. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, **Saag** MS, Cohen MS, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med* 206(6):1273-1289, 2009. (PMID: 19487424 PMCID: PMC2715054)
232. Antiretroviral Therapy Cohort Collaboration (ART-CC), A Mocroft, Sterne J, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, **Saag** M. Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: Not all AIDS Defining Conditions are Created Equal. *Clin Infect Dis* 48(8):1138-1151, 2009. (PMID: 19275498 PMCID: PMC3032444)
233. Antiretroviral Therapy Cohort Collaboratoion (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, **Saag** M, Khaykin P, de Wolf F, Sterne JA, and Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS* 23(16):2199-2208, 2009.
234. Paredes R, Lalama CM, Ribaud HJ, Schackman BR, Shikuma C, Giguel F, Meyer 3rd WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, and Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. *J Infect Dis* 201(5):662-71, 2009.
235. When to Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, **Saag** MS, Smith C, Staszewski S, Egger M, and Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 373(9672):1352-63, 2009. (PMID: 19361855)
236. Willig JH, **Saag** MS. HIV/AIDS: The only thing constant. *J Nat Med Assoc* 101(12):1299-1300, 2009. (PMID: 20070022)
237. Antiretroviral Therapy Cohort Collaboration, Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, G Fatkenheuer, Lewden C, **Saag** M, Staszewski S, D'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol* 38(6):1624-1633, 2009. (PMID: 19820106)
238. Willig JH, J Echevarria, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz 3rd J, Hernandez F, Tomatis C, **Saag** MS, and Gotuzzo E. Durability of Initial Antiretroviral Therapy in a Resource Constrained Setting and the Potential Need for Zidovudine Weight-Based Dosing. *J Acquir Immune Defic Syndr* 53(2):215-221, 2010. (PMID: 20104120 DOI: 10.1097/QA1.0b013e3181bc0f10)

239. McKinnell JA, Willig JH, Westfall AO, Nevin C, Allison JJ, Raper JL, Mugavero MJ, Saag MS. Antiretroviral prescribing patterns in treatment-naïve patients in the United States. *AIDS Patient Care STDS* 24(2):79-85, 2010. (PMID: 20059309 PMCID: PMC3826470)
240. Routman JS, Willig JH, Westfall AO, Abroms SR, Koethe JR, Westfall AO, Luhanga DK, Clark GM, Goldman JD, Mulenga PL, Cantrell RA, Chi BH, Zulu I, **Saag MS**, Stringer JSA. A Cluster Randomized Trial of HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. *Plos One* 5(3):1-8, 2010.
241. McKinnell JA, **Saag MS**. Novel drug classes: entry inhibitors (enfuvirtide, chemokine (C-C motif) receptor 5 antagonists). *Curr Opin HIV AIDS* 4(6):518-517, 2010. (PMID: 20048719)
242. Cooper DA, Heera J, Goodrich J, Tawadrous M, **Saag MS**, Dejesus E, Clumeck N, Walmsley S, Ting N, E Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus Efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. *J Infect Dis* 201(6):803-813, 2010. (PMID: 20151839 DOI: 1086/650697)
243. Routman JS, Willig JH, Westfall AO, Abroms SR, Varshney M, Adusumilli S, JAllison JJ, Savage KG, **Saag MS**, Mugavero JM. Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. *Clin Infect Dis* 50(4):574-584, 2010. (PMID: 20067423 PMCID: PMC2848720)
244. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, **Saag M**. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med* 11(7):462-468, 2010.
245. Koethe JR, Westfall AO, Luhanga DK, Clark GM, Goldman JD, Mulenga PL, Cantrell RA, Chi BH, Zulu I, **Saag MS**, Stringer JS. A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics. *PLos One* 5(3):e9680, 2010. (PMID: 20300631 PMCID: PMC2837376)
246. Cole SR, Napravnik S, Mugavero MJ, Lau B, Jr Eron JJ, **Saag MS**. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. *Am J Epidemiol* 171(2):198-205, 2010. (PMID: 20007202 PMCID: PMC2878100)
247. Jacobson JM, Thompson MA, Lalezari JP, **Saag MS**, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. *J Infect Dis* 201(10):1481-1487, 2010. (PMID: 20377413 PMCID: PMC2856743)
248. Lawrence ST, Willig JH, Crane HM, Ye J, Aban I, Lober W, Nevin CR, Batey DS, Mugavero MJ, McCullumsith C, Wright C, Kitahata M, Raper JL, **Saag MS**, and Schumacher JE. Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting. *Clin Infect Dis* 50:1165-1173, 2010. (PMID: 20210646 PMCID: PMC2841210)
249. Gill J, Lewden C, **Saag MS**, Egger M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, May M, Sterne JAC. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 50(10):1387-1396, 2010.
250. Sierra-Madero J, Di Perri G, Wood R, **Saag M**, Frank I, Craig C, Burside R, McCracken J, Pontani D, Goodrich J, Heera J, Mayer H. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. *HIV Clin Trials* 11(3):125-132, 2010. (PMID: 20736149 DOI: 10.1310/hct1103-125)
251. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horbert MA, **Saag MS**, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, B Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus care in the United States and Canada. *Clin Infect Dis* 50(11):1512-1520, 2010. (PMID: 20415573 PMCID: PMC2862849)

252. Grunfeld C, **Saag** MS, Cofrancesco Jr. J, Lewis CE, Kronmal R, Heymsfield S, Tien PC, Bacchetti P, Shlipak M, Scherzer R, for the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipotrophy. *AIDS* 24:1717-1726, 2010. (PMID: 20502316 PMID: PMC3309711)
253. Smith K, Zheng L, Bosch R, Tenorio A, Napolitano L, **Saag** MS, Connic E, Gross B, Francis I, Valdez H, Muurahainen M, Stocker V, and Pollard R. Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. *AIDS Res Hum Retroviruses* 26(4):425-432, 2010. (PMID: 20415638 PMID: PMC2864047)
254. Crane PK, Gibbons LE, Willig JH, Mugavero MJ, Lawrence ST, Schumacher JE, **Saag** MS, Kitahata MM, and Crane HM. Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9). *AIDS Care*, 22(7):874-885, 2010. (PMID: 20635252 PMID: PMC3410748)
255. **Saag** MS, Squires KE, Aberg JA, Bardeguex A, and HIVMA. Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. *Infect Control Hosp Epidemiol* 31(10):1092-1093, 2010. (PMID: 20812818 DOI: 10.1086/656559)
256. Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, **Saag** MS, Niederweis M, and Kutsch O. Hit-and-Run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. *J Virology* 84(17):8712-8720, 2010. (PMID: 20538859 PMID: PMC2919022)
257. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J, Hernandez F, Tomatis C, **Saag** MS, and Gotuzzo E. Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. *J Acquir Immune Defic Syndr* 53(2):215-221, 2010.
258. Raper JL, Willig JH, Lin H-Y, Allison JJ, Bennet Broner M, Mugavero MJ and **Saag** MS. Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. *Clin Infect Dis* 51(6):718-724, 2010. (PMID: 20695800 PMID: PMC4892366)
259. Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ, and **Saag** MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. *Am J Epidemiol* 171:198-205, 2010.
260. Willig JH, Nevin CR, Willig AL, Burkhardt JH, Raper JL, Schmacher JE, Johnson VA, **Saag** MS, Mugavero MJ. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. *J Acquir Immune Defic Syndr* 54(4):442-444, 2010. PMID: 20611035 PMID: PMC2901889)
261. **Saag** M, Deeks SG. How do HIV elite controllers do what they do? *Clin Infect Dis* 51(2):239-241, 2010. (PMID: 20550453 doi: 10.1086/653678)
262. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, **Saag** MS. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. *HIV Med* 11(7):462-468, 2010. (PMID: 20163481 DOI: 10.1111/j.1468-1293.2009.00815/x)
263. Gill J, May M, Lewden C, **Saag** M, Mugavero M, Reiss P, Ledergerber B, Mocroft A, Harris R, Fux C, Justice A, Costagliola D, Casbona J, Hogg R, Khaykin P, Lampe F, Vehreschild J, Sterne J. Causes of Death in ART treated Patients: Causes of death in HIV-1-infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 50(10):1387-1396, 2010.
264. Choi A, R Scherzer, P Bacchetti, PC Tien, MS **Saag**, CL Gilbert, LA Szczech, C Grunfeld, MG Shlipak. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. *Am J Kidney Dis* 56(5):872-882, 2010. (PMID: 20709438 PMID: PMC3164880)
265. Willig JH, I Aban, CR Nevin, J Ye, JL Raper, JA McKinnel, LL Delaitich, JM Mrus, GR De La Rosa, MJ Mugavero, MS **Saag**. Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. *AIDS Res Hum Retroviruses* 26(12):1279-1285, 2010. (PMID: 20961276 PMID: PMC3011996)

266. Jacobson JM, JP Lalezari, MA Thompson, CJ Fichtenbaum, MS **Saag**, BS Zingman, P D;Ambrosio, N Stambler, Y Rotshteyn, AJ Marozsan, PJ Maddon, SA Morris, WC Olson. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. *Antimicrob Agents Chemother* 54(10):4137-4142, 2010. (PMID: 20660677 PMID: PMC2944554)
267. Althoff KN, KA Gebo, SJ Gange, MB Klein, JT Brooks, RS Hogg, RJ Bosch, MA Horberg, MS **Saag**, MM Kitahata, JJ Eron, S Napravnik, SB Rourke, MJ Gill, B Rodriguez, TR Sterling, SG Deeks, JN Martin, LP Jacobson, GD Kirk, AC Collier, CA Benson, MJ Silverberg, JJ Goedert, RG McKAig, J Thorne, A Rachlis, RD Moore, AC Justice; North American AIDS Cohort Collaboration on Research and Design. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? *AIDS Res Ther* 7:45, 2010. (PMID: 21159161 PMID: PMC3022663)
268. Althoff KN, AC Justin, SJ Gange, SG Deeks, MS **Saag**, MJ Silverberg, MJ Gill, B Lau, S Napravnik, E Tedaldi, MB Klein, KA Gebo; North American AIDS Cohorts Collaboration on Research, Design (NA-ACCORD). Virologic and Immunologic response to HAART, by age and regimen class. *AIDS* 24(16):2469-2479, 2010. (PMID: 20829678 PMID: PMC3136814)
269. Zhang R, J Yan, H Shahinian, G Amin, Z Lu, T Liu, MS Saag, Z Jian, J Temsamani, R Martin, PJ Schechter, S Agrawal, and RB Diasio. (2011) CORRIGENDUM: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. *Clin Pharm Thera* 89(2), 320, 2011. (doi: 10.1016/0009-9236(95)90071-3).
270. Crane HM, C Grunfeld, JH Willig, MJ Mugavero, S Van Rompaey, R Moore, B Rodriguez, BJ Feldman, MM Lederman, MS **Saag** and MM Kitahata. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. *AIDS* 25(2):185-195, 2011. (PMID: 21150555 PMID: PMC6027746)
271. Vance DE, M Mugavero, J Willig, JL Raper, MS **Saag**. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. *J Assoc Nurses in AIDS Care* 22:17-25, 2011. (PMID: 20471864 DOI: 10.1016/j.jana.2010.04.002)
272. Hauschild BC, A Weddle, C Lubinski, JT Tegelvik, V Miller and MS **Saag**. HIV clinic capacity and medical workforce challenges: results of a survey of Ryan White part C-funded programs. *Ann Forum Collab HIV Res* 12:1-9, 2011.
273. Singh S., JH Willig, MJ Mugavero, PK Crane, RD Harrington, RH Knopp, BW Kosel, MS **Saag**, MM Kitahata, and HM Crane. Comparative effectiveness and toxicity of statins among HIV-infected patients. *Clin Infect Dis* 53(3):387-395, 2011. (PMID: 21189273 PMID: PMC3106249)
274. **Saag** MS. The ghosts of Christmas past. How would those we've lost guide us today? *Posit Aware* 23(4):10-12, 2011. (PMID: 21710875)
275. Achenbach CJ, SR Cole, MM Kitahata, C Casper, JH Willig, MJ Mugavero and MS **Saag**. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. *AIDS* 25(5):691-700, 2011. (PMID: 21160411 PMID: PMC4379707)
276. Irvin MR, S Shrestha, Y-D I Chen, HW Wiener, T Haritunians, LK Vaughan, HK Tiwari, KD Taylor, R Scherzer, MS **Saag**, C Grunfeld, JI Rotter and DK Arnett. Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. *Pharmacogenet Genomics* 21:798-807, 2011. (PMID: 21897333 PMID: PMC3210910)
277. Mugavero MJ, WE Norton, MS **Saag**. Health care system and policy factors influencing engagement in HIV care: Piecing together the fragments of a fractured health care delivery system. *Clin Infect Dis* 15 Supp2:S238-246, 2011. (PMID: 21342913 PMID: PMC3106258)
278. Kitahata MM, CJ Achenbach, MS **Saag**. Age at cancer diagnosis among persons with AIDS. *Ann Intern Med* 154(9):642-643, 2011. (PMID: 21536942 DOI: 10.7326/0003-4819-154-9-201105030-00013)
279. Seal PS, DA Jackson, E Chamot, JH Willig, CR Nevin, JJ Allison, JL Raper, MC Kempf, JE Schumacher, MS **Saag**, MJ Mugavero. Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. *J Gen Intern Med* 26(7):745-750, 2011. (PMID: 21465301 PMID: PMC3138583)

280. Molina JM, P Cahn, B Grinsztejn, A Lazzarin, A Mills, MS **Saag**, K Supparatpinyo, S Walmsley, H Crauwels, LT Rimsky, S Vanveggel, K Boven; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. *Lancet* 378(9787):238-246, 2011. (PMID: 21763936 DOI: 10.1016/S0140-6736(11)60936-7)
281. Poon AF, JL Aldous, WE Mathews, M Kitahata, JS Kahn, MS **Saag**, B Rodriguez, SL Boswell, SD Frost, RH Haubrich. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load. *PLoS One* 6(6):e21189, 2011. (PMID: 21701595 PMCID: PMC3118815)
282. Godwin N, JH Willig, C Nevin, H Lin, J Allison, K Gaddis, JN Peterson, MS **Saag**, MJ Mugavero, JL Raper. Underutilization of the AIDS drug assistance program: associated factors and policy implications. *Health Serv Res* 46(3):982-995, 2011. (PMID: 21210795 PMCID: PMC2907412)
283. Feinberg J, MS **Saag**, K Squires, J Currier, R Ryan, B Coate, J Mrus. Health-related quality of life in the gender, race, and clinical experience trial. *AIDS Res Treat* 2011:349165, 2011. (PMID: 21904672 PMCID: PMC3166720)
284. Nevin CR, J Ye, I Aban, MJ Mugavero, D Jackson, HY Lin, J Allison, JL Raper, MS **Saag**, JH Willig. The role of toxicity-related regimen changes in the development of antiretroviral resistance. *AIDS Res Hum Retroviruses* 27(9):957-963, 2011. (PMID: 21342052 PMCID: PMC3192056)
285. Gnanakaran S, T Bhattacharya, M Daniels, BF Keele, PT Hraber, AS Lapedes, T Shen, B Gaschen, M Krishnamoorthy, H Li, JM Decker, JF Salazar-Gonzalez, S Wang, C Jiang, F Gao, R Swanstrom, JA Anderson, LH Ping, MS Cohen, M Markowitz, PA Goepfert, MS **Saag**, JJ Eron, CB Hicks, WA Blattner, GD Tomaras, M Asmal, NL Letvin, PB Gilbert, AC Decamp, CA Magaret, WR Schief, YE Ban, M Zhang, KA Soderberg, JG Sodroski, BF Haynes, GM Shaw, BH Hahn, B Korber. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. *PLoS Pathog* 7(9):e1002209, 2011. (PMID: 21980282 PMCID: PMC3182927)
286. Rockstroh JK, JL Lennox, E Dejesus, MS **Saag**, A Lazzarin, H Wan, ML Walker, X Xu, J Zhao, H Teppler, MJ Dinubile, AJ Rodgers, BY Nguyen, R Leavitt, P Sklar; STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. *Clin Infect Dis* 53(8):807-816, 2011. (PMID: 21921224 DOI: 10.1093/cid/cir510)
287. Mugavero MJ, M May, HJ Ribaldo, RM Gulick, SA Riddler, R Haubrich, S Napravnik, S Abgrall, A Phillips, R Harris, MJ Gill, F de Wolf, R Hogg, HF Gunthard, G Chene, A D'Arminio Monforte, JL Guest, C Smith, J Murillas, J Berenguer, C Wyen, P Domingo, MM Kitahata, JA Sterne, MS **Saag**; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 Team; Antiretroviral Cohort Collaboration. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. *J Acquir Immune Defic Syndr* 58(3):253-260, 2011. (PMID: 21857357 PMCID: PMC3196673)
288. Mugavero MJ, S Napravnik, SR Cole, JJ Eron, B Lau, HM Crane, MM Kitahata, JH Willig, RD Moore, SG Deeks, MS **Saag**; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study. Viremia copy-years predicts mortality among treatment-naïve HIV-infected patients initiating antiretroviral therapy. *Clin Infect Dis* 53(9):927-935, 2011. (PMID: 21890751 PMCID: PMC3189165)
289. Gibbons LE, BJ Feldman, HM Crane, M Mugavero, JH Willig, D Patrick, J Schumacher, MS **Saag**, MM Kitahata, PK Crane. Migrating from a legacy fixed-format measure to CAT Administration: calibrating the PHQ-9 to the PROMIS depression measures. *Qual Life Res* 20(9):1349-1357, 2011. (PMID: 21409516 PMCID: PMC3175024)
290. Irvin MR, S Shrestha, YD Chen HW Wiener, T haritunians, LK Vaughan, HK Tiwari, KD Taylor, R Scherzer, MS **Saag**, C Grunfield, JL Rotter, DK Arnett. Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. *Pharmacogenet Genomics* 21(12):798-807, 2011. (PMID: 21897333)
291. **Saag** MS. HIV now firmly established in the Middle Ages. *Clin Infect Dis* 53(11):1140-1142, 2011. (PMID: 21998283 DOI: 10.1093/cid/cir629)

292. Mugavero MJ, KR Amico, AO Westfall, HM Crane, Z Zinski, JH Willig, JC Dombrowski, WE Norton, JL Raper, MM Kitahata, MS **Saag**. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. *J Acquir Immune Defic Syndr* 59(1):86-93, 2012. (PMID: 21937921 PMID: PMC3237801)
293. Kozak MS, MJ Mugavero, J Ye, I Aban, ST Lawrence, CR Nevin, JL Raper, C McCullumsmith, JE Schumacher, HM Crane, MM Kitahata, MS **Saag**, JH Willig. Patient reported outcomes in routine care: Advancing data capture for HIV cohort research. *Clin Infect Dis* 54(1):141-147, 2012. (PMID: 22042879 PMID: PMC3243652)
294. Murray M, R Hogg, V Lima, M May, D Moore, S Abgrall, M Druyand, A D'Arminio Monforte, C Tural, M Gill, R Harris, P Reiss, A Justice, O Kirk, MS **Saag**, C Smith, R Weber, J Rockstroh, P Khaykin, J Sterne: for the Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. *HIV Med* 13(2):89-97, 2012. (PMID: 21819529 PMID: PMC4539012)
295. Azzoni L., AS Foulkes, Y Liu, X Li, M Johnson, C Smith, AB Kamarulzaman, J Montaner, K Mounzer, M **Saag**, P Cahn, C Cesar, A Krolewiecki, I Sanne, LJ Montaner. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. *PLoS Med* 9(4):e1001207, 2012. (PMID: 22529752 PMID: PMC3328436)
296. Stringer JS, AJ Mwangi, MJ Giganti, L Mulenga, JW Levy, EM Stringer, P Mulenga, MS **Saag**, P Musonda, FB Williams, SE Reid, BH Chi. Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study. *Int J Epidemiol* 41(2):448-459, 2012. (PMID: 22493326 PMID: PMC3324461)
297. Silverberg MJ, B Lau, AC Justice, E Engels, MJ Gill, JJ Goedert, GD Kirk, G D'Souza, RJ Bosch, JT Brooks, S Napravnik, NA Hessol, LP Jacobson, MM Kitahata, MB Klein, RD Moore, B Rodriguez, SB Rourke, MS **Saag**, TR Sterling, KA Gebo, N Press, JN Martin, R Dubrow, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. *Clin Infect Dis* 54(7):1026-1034, 2012. (PMID: 22291097)
298. Cohen CJ, JM Molin, P Cahn, B Clotet, J Fourie, B Grinsztejn, H Wu, MA Johnson, M **Saag**, K Supparatpinyo, H Crauwels, E Lefebvre, LT Rimsky, S Vanveggel, P Williams, K Boven, ECHO Study Group, THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. *J Acquire Immune Defic Syndr* 60(1):33-42, 2012. (PMID: 22343174 DOI: 10.1097/QAI.9b913e31824d006e)
299. DeJesus E, JK Rockstroh, JL Lennox, MS **Saag**, A Lazzarin, J Zhao, H Wan, AJ Rodgers, ML Walker, M Miller, MJ DiNubile, BY Nguyen, H Teppler, R Leavitt, P Sklar, STARTMRK Investigators. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1 infected patients: week-192 overall and subgroup analyses from STARTMRK. *HIV Clin Trials* 13(4):228-232, 2012. (PMID: 22849964 DOI: 10.1310/hct11304-228)
300. Li H, MB Stoddard, S Wang, LM Blair, EE Giorgi, EH Parrish, GH Learn, P Hrabec, PA Goepfert, MS **Saag**, TN Denny, BF Haynes, BH Hahn, RM Ribeiro, AS Perelson, BT Korber, T Bhattacharya, GM Shaw. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. *PLoS Pathog* 8(8):e1002880, 2012. (PMID: 22927816 PMID: PMC3426529)
301. **Saag** MS. Editorial commentary: viva no difference! *Clin Infect Dis* 55(9):1252-1254, 2012. (PMID: 23019272 DOI: 10.1093/cid/cis656)
302. Tate T, AL Willig, JH Willig, JL Raper, L Moneyham, MC Kempf, MS **Saag**, MJ Mugavero. HIV infection and obesity: where did all the wasting go? *Antivir Ther* 17(7):1281-1289, 2012. (PMID: 22951353 PMID: PMC3779137)
303. Burkholder GA, AR Tamhane, JL Salinas, MJ Mugavero, JL Raper, AO Westfall, MS **Saag**, JH Willig. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. *Clin Infect Dis* 55(11):1550-1557, 2012. (PMID: 22942209 PMID: PMC3491860)

304. Merlin JS, AP Westfall, JL Raper, A Zinski, WE Norton, JH Willig, R Gross, CS Ritchie, MS **Saag**, MJ Mugavero. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. *J Acquir Immune Defic Syndr* 61(2):164-170, 2012. (PMID: 22766967 PMID: PMC3459261)
305. May MT, RS Hogg, AC Justice, BE Shepherd, D Costagliola, B Ledergerber, R Thiebaut, MJ Gill, O Kirk, A van Sighem, MS **Saag**, G Navarro, P Sobrino-Vegas, F Lampe, S Ingle, JL Guest, HM Crane, A D'Arminio Monforte, JJ Vehreschild, JA Sterne, Antiretroviral Therapy Cohort Collaboration (ART-CC). Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. *Int J Epidemiol* 41(6):1807-1820, 2012. (PMID: 23148105)
306. **Saag** MS. New and investigational antiretroviral drugs for HIV infection: Mechanisms for action and early research findings. *Top Antivir Med* 20(5):162-167, 2012. (PMID: 23363694)
307. Kim DJ, AO Westfall, E Chamot, AL Willig, MJ Mugavero, C Ritchie, GA Burkholder, HM Crane, JL Raper, MS **Saag**, JH Willig. Multimorbidity patterns in HIV-infected patients: The role of obesity in chronic disease clustering. *J Acquir Immune Defic Syndr* 61(5):600-605, 2012. (PMID: 23023101 PMID: PMC3508375)
308. Willig JH, SA Wilkins, A Tamhane, CR Nevin, MJ Mugavero, JL Raper, LA Napolitano, MS **Saag**. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients. *AIDS Res Hum Retroviruses* 29(1):105-111, 2013. (PMID: 22881368 PMID: PMC3608020)
309. Feldman BJ, RJ Fredericksen, PK Crane, SA Safren, MJ Mugavero, JH Willig, JM Simoni, IB Wilson, MS **Saag**, MM Kitahata, HM Crane. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. *AIDS Behav* 17(1):307-318, 2013. (PMID: 23108721 PMID: PMC3549002)
310. Willig JH, AO Westfall, M Mugavero, CR Nevin, T Correll, A Duggal, W Guyer, MS **Saag**, T Juday. Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes. *AIDS Res Hum Retroviruses* 29(4):698-703, 2013. (PMID: 23151191 PMID: PMC3607971)
311. Abraham AG, HD Strickler, Y Jing, SJ Gange, TR Sterling, M Silverberg, M **Saag**, S Rourke, A Rachlis, S Napravnik, RD Moore, M Klein, M Kitahata, G Kirk, R Hogg, NA Hessol, JJ Goedert, MJ Gill, K Gebo, JJ Eron, EA Engels, R Dubrow, HM Crane, JT Brooks, R Bosch, G D'Souza, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Invasive cervical cancer risk among HIV-infected women: A North American multi-cohort collaboration prospective study. *J Acquir Immune Defic Syndr* 62(4):405-413, 2013. (PMID: 23524153 PMID: PMC3633634)
312. Bachmann LH, DM Grimley, H Gao, I Aban, H Chen, JL Raper, MS **Saag**, SD Rhodes, EW Hook III. Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting. *AIDS Educ Prev* 25(2):87-101, 2013. (PMID: 23514077 DOI: 10.1521/aeap.2013.25.2.87)
313. Rockstroh JK, E Dejesus, JL Lennox, Y Yazdanpanah, MS **Saag**, H Wan, AJ Rodgers, ML Walker, M Miller, MJ Dinubile, BY Nguyen, H Teppler, R Leavitt, P Sklar, STARTMRK Investigators. Durable efficacy and safety of Raltegravir versus Efavirenz when combined with Tenofovir/Emtricitabine in treatment-naïve HIV-1-infected patients: Final 5-year results from STARTMRK. *J Acquir Immune Defic Syndr* 63(1):77-85, 2013. (PMID: 23412015 DOI: 10.1097/QAI.0b013e31828ace69)
314. Shrestha S. DC Johnson, E Reid, J Palchinsky, S Napravnik, WC Mathews, JJ Eron, MS **Saag**. Short communication: Lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. *AIDS Res Hum Retroviruses* 29(6):887-891, 2013. (PMID: 23351216 PMID: PMC3653389)
315. Perry BA, AO Westfall, E Molony, R Tucker, C Ritchie, MS **Saag**, MJ Mugavero, JS Merlin. Characteristics of an ambulatory palliative care clinic for HIV-infected patients. *J Palliat Med* 16(8):934-937, 2013. (PMID: 23477304 PMID: PMC3727562)

316. Schumacher JE, C McCullumsmith, MJ Mugavero, PE Ingle-Pang, JL Raper, JH Willig, Z You, DS Batey, H Crane, ST Lawrence, C Wright, G Treisman, MS **Saag**. Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment. *AIDS Behav* 17(8):2781-2791, 2013. (PMID: 23086427 PMCID: PMC4559144)
317. Blashill AJ, KH Mayer, H Crane, JF Magidson, C Grasso, WC Mathews, MS **Saag**, SA Safren. Physical activity and health outcomes among HIV-infected men who have sex with men: A longitudinal mediational analysis. *Ann Behav Med* 46(2):149-156, 2013. (PMID: 23483379 PMCID: PMC3714319)
318. Abgrall S, SM Ingle, MT May, D Costagliola, P Mercie, M Cavassini, J Reekie, H Samji, MJ Gill, HM Crane, J Tate, TR Sterling, A Antinori, P Reiss, MS **Saag**, MJ Mugavero, A Phillips, C Manzardo, JC Wasmuth, C Stephan, JL Guest, JL Gomez Sirvent, JA Sterne, Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. *AIDS* 27(5):803-813, 2013. (PMID: 23419350 DOI: 10.1097/QAD.9b913e32835cb997)
319. Merlin JS, RO Tucker, MS **Saag**, PA Selwyn. The role of palliative care in the current HIV treatment era in developed countries. *Top Antivir Med* 21(1):20-26, 2013. (PMID: 23596275)
320. Yanik EL, S Napravnik, SR Cole, Achenbach CJ, S Gopal, A Olshan, DP Dittmer, MM Kitahata, MJ Mugavero, MS **Saag**, RD Moore, K Mayer, WC Mathews, PW Hunt, B Rodriguez, JJ Eron. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. *Clin Infect Dis* 57(5):756-764, 2013. (PMID: 23735330 PMCID: PMC3739467)
321. Franco RA, MS **Saag**. When to start antiretroviral therapy: as soon as possible. *BMC Med* 11:147, 2013. (PMID: 23767762 PMCID: PMC3682940)
322. Cropsey KL, PS Hendricks, B Jardin, CB Clark, N Katiyar, J Willig, M Mugavero, JL Raper, MS **Saag**, MJ Carpenter. A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in non-treatment seeking smokers with HIV. *Addic Behav* 38(20):2541-2546, 2013. (PMID: 23787030 PMCID: PMC3725186)
323. Munoz MA, W Liu, JA Delaney, E Brown, MJ Mugavero, WC Mathews, S napravnik, JH Willig, JJ Eron, PW Hunt, JO Kahn, MS **Saag**, MM Kitahata, HM Crane. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. *J Acquir Immune Defic Syndr* 64(3):254-260, 2013. (PMID: 23892238 PMCID: PMC4112457)
324. Flexner C, MS **Saag**. The antiretroviral drug pipeline: prospects and implications for future treatment research. *Curr Opin HIV AIDS* 8(6):572-578, 2013. (PMID: 24100879 DOI: 10.1097/COH.0000000000000011)
325. Merlin JS, AO Westfall, E Chamot, ET Overton, JH Willig, C Ritchie, MS **Saag**, MJ Mugavero. Pain is independently associated with impaired physical function in HIV-infected patients. *Pain Med* 14(12):1985-1993, 2013. (PMID: 24119077 PMCID: PMC3886835)
326. Kim HN, CV Rodriguez, S Van Rompaey, JJ Eron, CL Thio, HM Crane, ET Overton, MS **Saag**, J Martin, E Geng, M Mugavero, B Rodriguez, WC Mathews, S Boswell, R Moore, MM Kitahata; Centers for AIDS Research Network of Integrated Clinical Systems. *J Acquir Immune Defic Syndr* 66(1):96-101, 2014. (PMID: 24500175 PMCID: PMC2981874)
327. Molony E, AO Westfall, BA Perry, R Tucker, C Ritchie, M **Saag**, M Mugavero, JC Sullivan III, JS Merlin. Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic. *Pain Med* 15(3):418-424, 2014. (PMID: 24033875 PMCID: PMC2949151)
328. Abgrall S, SM Ingle, MT May, D Costagliola, P Mercie, M Cavassini, J Reekie, H Samji, MJ Gill, HM Crane, J Tate, TR Sterling, A Antinori, P Reiss, MS **Saag**, MJ Mugavero, A Phillips, C Manzardo, JC Wasmuth, C Stephan, JL Guest, JL Gomez Sirvent, JA Sterne; Antiretroviral Therapy Cohort Collaboratoin (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Eurpoe and North America 2002-2009. *AIDS* 27(5):803-813, 2014.

329. Achenbach CJ, AL Buchanan, SR Cole, L Hou, MJ Mugavero, HM Crane, RD Moore, RH Haubrich, S Gopal, JJ Eron, PW Hunt, B Rodriguez, K Mayer, MS **Saag**, MM Kitahata; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. *Clin Infect Dis* 58(11):1599-1606, 2014. (PMID: 24523217 PMID: PMC4017888)
330. Crane HM, SR Heckbert, DR Drozd, MJ Budoff, JAC Delaney, C Rodriguez, P Paramsothy, WB Lober, G Burkholder, JH Willig, MJ Mugavero, WC Mathews, PK Crane, RD Moore, S Napravnik, JJ Eron, P Hunt, E Geng, P Hsue, GS Barnes, J McReynolds, I Peter, C Grunfeld, MS **Saag**, MM Kitahata for the Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. *Am J Epidemiol* 179(8):996-1005, 2014. (PMID: 24618065 PMID: PMC2966717)
331. May MT, SM Ingle, D Costagliola, AC Justice, F de Wolf, M Cavassini, A D'Arminio Monforte, J Casabona, RS Hogg, A Mocroft, FC Lampe, F Dabis, G Fatkenheuer, TR Sterling, J Del Amo, MJ Gill, HM Crane, MS **Saag**, J Guest, HR Brodt, JA Sterne, the Antiretroviral Cohort Collaboration. Cohort profile: Antiretroviral therapy cohort collaboration (ART-CC). *Int J Epidemiol* 43(3):691-702, 2014. (PMID: 23599235 PMID: PMC4052127)
332. Merlin JS, A Zinski, WE Norton, CS Ritchie, MS **Saag**, MJ Mugavero, G Treisman, WM Hooten. A conceptual framework for understanding chronic pain in patients with HIV. *Pain Pract* 14(3):207-216, 2014. (PMID: 23551857 DOI: 10.1111/papr.12052)
333. Cooper DA, J Heera, P Ive, M Botes, E DeJesus, R Burnside, N Clumeck, S Walmsley, A Lazzarin, G Mukwaya, MS **Saag**, E Van Der Ryst. Efficacy and safety of maraviroc vs. efavirenz in treatment-naïve patients with HIV-1: MERIT 5-year findings. *AIDS* 28(5):717-725, 2014. (PMID: 24983542 PMID: PMC2940293)
334. Merlin JS, M Walcott, I Herbey, E Chamot, CS Ritchie, MS **Saag**, S Kertesz. Qualitative investigation of a brief chronic pain screening tool in HIV-infected patients. *AIDS Pt Care STDs*, 28(4):176-182, 2014. (PMID: 24621145 PMID: PMC2985507)
335. Yanik EL, S Napravnik, SR Cole, CJ Achenbach, S Gopal, DP Dittmer, AF Olshan, MM Kitahata, MJ Mugavero, M **Saag**, RD Moore, WC Matthews, P Hunt, JJ Eron. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. *AIDS* 28(7):979-987, 2014. (PMID: 24681415 PMID: PMC4040952)
336. Clotet B, J Feinberg, J van Lunzen, MA Khuong-Josses, A Antinori, I Dumitru, V Pokrovskiy, J Fehr, R Ortiz, M **Saag**, J Harris, C Brennan, T Fukiwarara, S Min, ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. *Lancet* 383(9936):2222-2231, 2014. (PMID: 24698485 DOI: 10.1016/S0140-6736(14)60084-2)
337. Ingle SM, MT May, MJ Gill, MJ Mugavero, C Lewden, S Abgrall, G Fatkenheuer, P Reiss, MS **Saag**, C Manzardo, S Grabar, M Bruyand, D Moore, A Mocroft, TR Sterling, A D'Arminio Monforte, V Hernando, R Teira, J Guest, M Cavassini, HM Crane, JA Sterne, Antiretroviral Therapy cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. *Clin Infect Dis* 59(2):287-297, 2014. (PMID: 24771333 PMID: PMC4073781)
338. Gardner LI, TP Giordano, G Marks, TE Wilson, JA Craw, ML Drainoni, JC Keruly, AE Rodriguez, F Malitz, RD Moore, LA Bradley-Springer, S Holman, CE Rose, S Girde, M Sullivan LR Metsch, M **Saag**, MJ Mugavero; Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. *Clin Infect Dis* 59(5):725-734, 2014. (PMID: 24837481 PMID: PMC4366591)
339. Dorfman D, MS **Saag**. Decline in locomotor functions over time in HIV-infected patients. *AIDS* 28(10):1531-1532, 2014. (PMID: 24896802 DOI: 10.1097/QAD.0000000000000302)
340. **Saag** MS. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection. *JAMA* 312(4):347-348, 2014. (PMID: 25038351 DOI: 10.1001/jama.2014.7735)
341. Gunthard HF, JA Aberg, JJ Eron, JF Hoy, A Telenti, CA Benson, DM Burger, P Cahn, JE Gallant, MJ Glesby, P Reiss, MS **Saag**, DL Thomas, DM Jacobsen, PA Volberding; International Antiviral Society-USA Panel. Antiretroviral

- treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA* 312(4):410-425, 2014. (PMID: 25038359 doi: 10.1001/jama.2014.8722)
342. Merlin JS, JM Turan, I Herbey, AO Westfall, JL Starrels, SG Kertesz, MS **Saag**, CS Ritchie. Aberrant drug-related behaviors: a qualitative analysis of medical record documentation in patients referred to an HIV-chronic pain clinic. *Pain Med* 15(10):1724-1733, 2014. (PMID: 25138608 PMID: PMC4208944)
 343. Eaton EF, MS **Saag**, M Mugavero. Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence. *Infect Dis Clin North Am* 28(3):355-369, 2014. (PMID: 25151561 DOI: 10.1016/j.idc.2014.06.004)
 344. Burkholder GA, AR Tamhane, LE Appell, JH Willig, MS **Saag**, JL Raper, AO Westfall, MJ Mugavero. Short communication: viral suppression is associated with increased likelihood of colorectal cancer screening among persons living with HIV/AIDS. *AIDS Res Hum Retroviruses* 31(5):519-524, 2015. (PMID: 25435340 PMID: PMC4426328)
 345. **Saag** MS, H Masur. HIV/AIDS. *Infect Dis Clin North Am* 28(3):xv-xvi, 2014. (PMID: 25151570 DOI: 10.1016/j.idc.2014.07.001)
 346. **Saag** MS, H Masur. HIV/AIDS. *Infect Dis Clin North Am* 28(4):xv-xvi, 2014. (PMID: 25455316 DOI: 10.1016/j.idc.2014.09.001)
 347. Galbraith JS, RA Franco, JP Donnelly, JB Rodgers, JM Morgan, AF Viles, ET Overton, MS **Saag**, HE Wang. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. *Hepatology* 61(3):776-782, 2014. (PMID: 25179527 DOI: 10.1002/hep.27410)
 348. Boulle A, M Schomaker, MT May, RS Hogg, BE Shepherd, S Monge, O Keiser, FC Lampe, J Giddy, J Ndirangu, D Garone, M Fox, SM Ingle, P Reiss, F Dabis, D Costagliola, A Castagna, K Ehren, C Campbell, MJ Gill, M **Saag**, AC Justice, J Guest, HM Crane, M Egger, JA Sterne. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. *PLoS Med* 11(9):e1001718, 2014. (PMID: 25203931 PMID: PMC4159124)
 349. Merlin JS, M Walcott, C Ritchie, I Herbey, SG Kertesz, E Chamot, M **Saag**, JM Turan. 'Two pains together': patient perspectives on psychological aspects of chronic pain while living with HIV. *PLoS One* 9(11):e111765, 2014. (PMID: 25365306 PMID: PMC4218809)
 350. **Saag** MS. Editorial commentary: Fixing a hole in the HIV safety net. *Clin Infect Dis* 60(1):126-127, 2015. (PMID: 25225232 DOI: 10.1093/cid/ciu729)
 351. Burkholder GA, AR Tamhane, LE Appell, JH Willig, MS **Saag**, JL Raper, AO Westfall, MJ Mugavero. Short communication: viral suppression is associated with increased likelihood of colorectal cancer screening among persons living with HIV/AIDS. *AIDS Res Hum Retroviruses* 31(5):519-524, 2015.
 352. Ho CP, A Zinski, SA Fogger, JD Peters, AO Westfall, MJ Mugavero, ST Lawrence, CR Nevin, JL Raper, MS **Saag**, JH Willig. Factors associated with missed psychiatry visits in an urban HIV clinic. *AIDS Behav* 19(8):1423-1429, 2015. (PMID: 25491027 DOI: 10.1007/s10461-014-0967-9)
 353. Merlin JS, AO Westfall, E Chamot, M **Saag**, M Walcott, C Ritchie, S Kertesz. Quantitative evaluation of an instrument to identify chronic pain in HIV-infected individuals. *AIDS Res Hum Retroviruses* 31(6):623-627, 2015. (PMID: 25693683 PMID: PMC4458733)
 354. **Saag** MS. Preventing HIV in women—still trying to find their VOICE. *N Engl J Med* 372(6):564-566, 2015. (PMID: 25651251 DOI: 10.1056/NEJMe1415750)
 355. **Saag** MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. *Clin Infect Dis* 61(2):169-170, 2015. (PMID: 25778748 DOI: 10.1093/cid/civ221)

356. Edwards JK, SR Cole, JN Martin, R Moore, WC Mathews, M Kitahata, JJ Eron, M **Saag**, MJ Mugavero, CNICS Investigators. Dynamic visual display of treatment response in HIV-infected adults. *Clin Infect Dis* 61(1):e1-4, 2015. (PMID: 25838289)
357. May MT, AC Justice, K Birnie, SM Ingle, C Smit, C Smith, D Neau, M Guiguet, C Schwarze-Zander, S Moreno, JL Guest, AD Monforte, C Tural, MJ Gill, A Gregenzer, O Kirk, M **Saag**, TR Sterling, HM Crane, JA Sterne. Injection drug use and Hepatitis C as risk factors for mortality in HIV-infected individuals: the antiretroviral therapy cohort collaboration. *J Acquir Immune Defic Syndr* 69(3):348-354, 2015. (PMID: 25848927 PMID: PMC4506784)
358. Mills A, G Crofoot Jr, C McDonald, P Shalit, JA Flamm, J Gathe Jr, A Scribner, D Shambraw, M **Saag**, H Cao, H Martin, M Das, A Thomas, HC Liu, M Yan, C Callebaut, J Custodio, A Cheng, S McCallister. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. *J Acquir Immune Defic Syndr* 69(4):439-445, 2015. (PMID: 25867913 DOI: 10.1097/QAI.0000000000000618)
359. Seu L, S Sabbaj, A Duverger, F Wagner, JC Anderson, E Davies, F Wolschendorf, CD Willey, MS **Saag**, P Goepfert, O Kutsch. Stable phenotypic changes of the host T cells are essential to the long-term stability of latent HIV-1 infection. *J Virol* 89(13):6656-6672, 2015. (PMID: 25878110 PMID: PMC4468477)
360. Naggie S, C Cooper, M **Saag**, K Workowski, P Ruane, WJ Towner, K Marks, A Luetkemeyer, RP Baden, PE Sax, E Gane, J Santana-Bagur, LM Stamm, JC Yang, P German, H Dvory-Sobol, L Ni, PS Pang, JG McHutchison, CA Stedman, JO Morales-Ramirez, N Brau, D Jayaweera, AE Colson, P Tebas, DK Wong, D Dieterich, M Sulkowski, ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfecting with HIV-1. *N Engl J Med* 373(8):705-713, 2015. (PMID: 26196665 PMID: PMC4892372)
361. Sax PE, D Wohl, MT Yin, F Post, E DeJesus, M **Saag**, A Pozniak, M Thompson, D Podzamczar, JM Molina, S Oka, E Koenig, B Trottier, J Andrade-Villanueva, G Crofoot, JM Custodio, A Plummer, L Zhong, H Cao, H Martin, C Callebaut, AK Cheng, MW Fordyce, S McCallister, GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. *Lancet* 385(9987):2606-2615, 2015. (PMID: 25890673 DOI: 10.1016/S0140-6736(15)60616-X)
362. Cropsey KL, BF Jardin, GA Burkholder, CB Clark, JL Raper, **Saag** MS. An algorithm approach to determining smoking cessation treatment for persons living with HIV/AIDS: results of a pilot trial. *J Acquir Immune Defic Syndr* 69(3):291-298, 2015. (PMID: 26181705 PMID: PMC4505746)
363. Willig AL, AO Westfall, ET Overton, MJ Mugavero, GA Burkholder, D Kim, E Chamot, JL Raper, HM Crane, MS **Saag**, JH Willig. Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. *AIDS Res Hum Retroviruses* 31(9):898-904, 2015. (PMID 26114374 PMID: PMC4553382)
364. Eaton EF, A Kulczycki, M **Saag**, M Mugavero, JL Raper. Immunization costs and programmatic barriers at an urban HIV clinic. *Clin Infect Dis* 61(11):1726-1731, 2015. (PMID: 26224001 DOI: 10.1093/cid/civ637)
365. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology* 62(3):932-954, 2015. (PMID: 26111063 DOI: 10:1002/hep.27950)
366. Rockstroh JK, M Nelson, C Katlama, J Lalezari, J Mallolas, M Bloch, GV Matthews, MS **Saag**, PJ Zamor, C Orkin, J Gress, S Klopfer, M Shaughnessy, J Wahl, BY Nguyen, E Barr, HL Platt, MN Robertson, M Sulkowski. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *Lancet HIV* 2(8):e319-327, 2015. (PMID: 26423374 doi: 10.1016/S2352-3018(15)00114-9)
367. Willig AL, AO Westfall, ET Overton, MJ Mugavero, GA Burkholder, D Kim, E Chamot, JL Raper, HM Crane, MS **Saag**, JH Willig. Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults. *AIDS Res Hum Retroviruses* 31(9):898-904, 2015. (PMID: 26111063 doi: 10.1089/AID.2015.0062)

368. Duran L, C Rodriguez, D Drozd, RM Nance, JA Delaney, G Burkholder, MJ Mugavero, JH Willig, AH Warriner, PK Crane, BE Atkinson, RD Harrington, S Dhanireddy, MS **Saag**, MM Kitahata, HM Crane. Fructosamine and hemoglobin A1c correlations in HIV-infected adults in routine clinical care: impact of anemia and albumin levels. *AIDS Res Treat* 47850, 2015. (PMID: 26273478 PMID: PMC4529884)
369. Merlin JS, A Tamhane, JL Starrels, S Kertesz, M **Saag**, K Cropsey. Factors associated with prescription of opioids and co-prescription of sedating medications in individuals with HIV. *AIDS Behav* 20(3):687-698, 2016. (PMID: 26487298 PMID: PMC4777647)
370. Winthrop KL, SA Novosad, JW Baddley, L Calabrese, T Chiller, P Polgreen, F Bartalesi, M Lipman, X Mariette, O Lortholary, ME Weinblatt, M **Saag**, J Smolen. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. *Ann Rheum Dis* 74(12):2107-2116, 2015. (PMID: 26395500 DOI: 10.1136/annrheumdis-2015-207841)
371. Thompson M, M **Saag**, E DeJesus, J Gathe, J Lalezari, AL Landay, J Cade, J Enejosa, E Lefebvre, J Feinberg. A 48-week randomized phase 2b study evaluating cenicriviroc vs. efavirenz in treatment-naïve HIV-infected adults with CCR5-tropic virus. *AIDS* 30(6):869-878, 2016. (PMID: 26636929 PMID: PMC4794136)
372. Cropsey KL, JH Willig, MJ Mugavero, HM Crane, C McCullumsmith, S Lawrence, JL Raper, WC Mathews, S Boswell, MM Kitahata, JE Schumacher, MS **Saag**; CFAR Network of Integrated Clinical Systems. Cigarette smokers are less likely to have undetectable viral loads: Results from four HIV clinics. *J Addict Med* 10(1):13-19, 2015. (PMID: 26656939 PMID: PMC4733609)
373. Cain LE, MS **Saag**, M Peterson, MT May, SM Ingle, R Logan, JM Robins, S Abgrall, BE Shepherd, SG Deeks, MJ Gill, G Touloumi, G Vourli, F Dabis, MA Vandenhende, P Reiss, A van Sighem, H Samji, RS Hogg, J Rybniker, CA Sabin, S Jose, J Del Amo, S Moreno, I Jarrin, JL Guest, AD Monforte, A Antinori, R Moore, CN Campbell, J Casabona, L Meyer, R Seng, AN Phillips, HC Bucher, M Egger, MJ Mugavero, R Haubrich, EH Geng, A Olson, JJ Eron, S Napravnik, MM Kitahata, SE Van Rompaey, R Teira, AC Justice, JP Tate, D Costagliola, JA Sterne, MA Hernan; Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. *Int J Epidemiol* 45(6):2038-2049, 2015. (PMID: 26721599 PMID: PMC5841611)
374. Willig AL, ET Overton, MS **Saag**. The silent epidemic – frailty and aging with HIV. *Total Patient Care HIV HCV* 1(1):6-17, 2016. (PMID: 28386608 PMID: PMC5380370).
375. Stellbrink HJ, EL Fevre, A Carr, MS **Saag**, G Mukawaya, S Nozza, SR Valluri, M Vourvahis, AR Rinehart, L Mcfadyen, C Fichtenbaum, A Clark, C Craig, AF Fang, J Heera. Once Daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. *AIDS* 30(8):1229-1238, 2016. (PMID: 26854810 PMID: PMC4856180)
376. Chander G, AK Monroe, HM Crane, HE Hutton, MS **Saag**, K Cropsey, JJ Eron, EB Quinlivan, E geng, WC Matthews S Boswell, B Rodriguz, M Ellison, MM Kitahata, RD Moore, ME McCaul. HIV primary care providers—screening, knowledge, attitudes and behaviors related to alcohol interventions. *Drug Alcohol Depend* 161:59-66, 2016. (PMID: 26857898 PMID: PMC4841449)
377. Caniglia EC, C Sabin, JM Robins, R Logan, LE Cain, S Abgrall, MJ Mugavero, S Hernandez-Diaz, L Meyer, R Seng, DR Drozd, GR Seage 3rd, F Bonnet, F Dabis, RR Moore, P Reiss, A van Sighem, WC Mathews, J Del Amo, S Moreno, SG Deeks, R Muga, SL Boswell, E Ferrer, JJ Eron, S Napravnik, S Jose, A Phillips, A Olson, AC Justice, JP Tate, HC Bucher, M Egger, G Touloumi, JA Sterne, D Costagliola, M **Saag**, MA Hernan; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. When to monitor CD4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: a prospective observational study. *J Acquir Immune Defic Syndr* 72(2):214-221, 2016. (PMID: 26895294 PMID: PMC4866894)
378. Kim HN, R Nance, S Van Rompaey, JC Delaney, HM Crane, ER Cachay, E Geng, SL Boswell, B Rodriguez, JJ Eron, M **Saag**, RD Moore, MM Kitahata. Poorly controlled HIV infection: an independent risk factor for liver fibrosis. *J Acquir Immune Defic Syndr* 72(4):437-443, 2016. (PMID: 26990826 PMID: PMC4925189)

379. May MT, JJ Vehreschild, A Trickey, N Obel, P Reiss, F Bonnet, M Mary-Krause, H Samji, M Cavassini, MJ Gill, LC Shepherd, HM Crane, A D'Arminio Monforte, GA Burkholder, MM Johnson, P Sobrino-Vegas, P Domingo, R Zangerle, AC Justice, TR Sterling, JM Miro, JAC Sterne; Antiretroviral Therapy Cohort Collaboration (ART-CC), A Boule, C Stephan, JM Miro, M Cavassini, G Chene, D Costagliola, F Dabis, AD Monforte, J Del Amo, A Van Sighem, G Fatkenheuer, J Gill, J Guest, DH Haerry, R Hogg, A Justice, L Shepherd, N Obel, H Crane, C Smith, P Reiss, M **Saag**, T Sterling, R Teira, M Williams, J Sterne, M May, S Ingle, A Trickey. Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients followed for up to 15 years after start of treatment: collaborative cohort study. *Clin Infect Dis* 62(12):1571-1577, 2016. (PMID: 27025828 PMID: PMD4885653)
380. Eaton EF, A Tamhane, M **Saag**, MJ Mugavero, ML Kilgore. Cost considerations in the current antiretroviral era. *AIDS* 30(14):2115-2119, 2016. (PMID: 27088319 PMID: PMC5963514)
381. Gibbons LE, R Fredericksen, JO Merrill, ME McCaul, G Chander, H Hutton, WB Lober, WC Mathews, K Mayer, G Burkholder, JH Willig, MJ Mugavero, MS **Saag**, MM Kitahata, TC Edwards, DL Patrick, HM Crane, PK Crane. Suitability of the PROMIS alcohol use short form for screening in a HIV clinical in a care setting. *Drug Alcohol Depend* 164:113-119, 2016. (PMID: 27209223 PMID: PMC4896136)
382. Eaton EF, AR Tamhane, GA Burkholder, JH Willig, MS **Saag**, MJ Mugavero. Unanticipated effects of new drug availability on antiretroviral durability: implications for comparative effectiveness research. *Open Forum Infect Dis* 3(2):ofw109, 2016. (PMID: 27419181 PMID: PMC4943538)
383. Cooper C, S Naggie, M **Saag**, JC Yang, LM Stamm, H Dvory-Sobol, L Han, PS Pang, JG McHutchison, D Dieterich, M Sulkowski. Successful re-treatment of Hepatitis C Virus in patients coinfecting with HIV who relapsed after 12 weeks of ledipasvir/sofosbuvir. *Clin Infect Dis* 63(4):528-531, 2016. (PMID: 27225242 PMID: PMC4967607)
384. Yang C, HM Crane, K Cropsey, H Hutton, G Chander, M **Saag**, ME McCaul. Implementation of computer-delivered brief alcohol intervention in HIV clinical settings: who agrees to participate? *J Addict Res Ther* 7(2).pii:276, 2016. (PMID: 27274904 PMID: PMC4890715)
385. Shepherd BE, Q Liu, N Mercaldo, CA Jenkins, B Lau, SR Cole, MS **Saag**, TR Sterling. Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy. *Stat Med* 35(24):4335-4351, 2016. (PMID: 27264354 PMID: PMC5048599)
386. Trickey A, MT May, J Vehreschild, N Obel, MJ Gill, H Crane, C Boesecke, H Samji, S Grabar, C Cazamave, M Cavassini, L shepherd, A d'Arminio Monforte, C smit, M **Saag**, F Lampe, V Hernando, M Montero, R Zangerle, AC Justice, T Sterling, J Miro, S Ingle, JA Sterne; Antiretroviral Therapy Cohort Collaboration (ART-CC). Cause-specific mortality in HIV-positive patients who survived ten years after starting antiretroviral therapy. *PLoS One* 11(8):e0160460, 2016. (PMID: 27525413 PMID: PMC4985160)
387. Gunthard HF, MS **Saag**, CA Benson, C del Rio, JJ Eron, JE Gallant, JF Hoy, MJ Mugavero, PE Sax, MA Thompson, RT Gandhi, RJ Landovitz, DM Smith, DM Jacobsen, PA Volberding. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. *JAMA* 316(2):191-210, 2016. (PMID: 27404187 PMID: PMC5012643)
388. Moylan DC, PA Goepfert, MC Kempf, MS **Saag**, HE Richter, J Mestecky, S Sabbaj. Diminished CD103 (α E β 7) expression on resident Tcells from the female genital tract of HIV-positive women. *Pathog Immun* 1(2):371-387, 2016. (PMID: 28164171 PMID: PMC5288734)
389. Crane HM, RJ Fredericksen, A Church, A Harrington, P Ciechanowski, J Magnani, K Nasby, T Brown, S Dhanireddy, RD Harrington, WB Lober, J Simoni, SA Safren, TC Edwards, DL Patrick, MS **Saag**, PK Crane, MM Kitahata. A randomized controlled trial protocol to evaluate the effectiveness of an integrated care management approach to improve adherence among HIV-infected patients in routine clinical care: rationale and design. *JMIR Res Protoc* 5(4):e156, 2016. (PMID: 27707688 PMID: PMC5071617)
390. Crane HM, RM Nance, JO Merrill, H Hutton, G Chander, ME McCaul, WC Mathews, R Fredericksen, JM Simoni, K Mayer, MJ Mugavero, JH Willig, G Burkholder, DR Drozd, M Mimiaga, B Lau, HN Kim, K Cropsey, RD Moore, K Christopoulos, E Geng, JJ Eron, S Napravnik, MM Kitahata, MS **Saag**, JA Delaney. Not all non-drinkers with HIV

- are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders. *AIDS Care* 29(2):177-184, 2017. (PMID: 27482893 PMID: PMC5628736)
391. **Saag** MS, AO Westfall, SR Cole, WC Mathews, DR Drozd, KH Mayer, GA Burkholder, M Kitahata, EM Maiese, CFAR Network of Integrated Clinical Systems (CNICS). Brief report: factors associated with the selection of initial antiretroviral therapy from 2009 to 2012. *J Acquire Immune Defic Syndr* 74(1):60-64, 2017. (PMIC: 27552153 PMID: PMC5140679)
 392. Feinstein MJ, RM Nance, DR Drozd, H Ning, JA Delaney, SR Heckbert, MJ Budoff, WC Mathews, MM Kitahata, MS **Saag**, JJ Eron, RD Moore, CJ Achenbach, DM Lloyd-Jones, HM Crane. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the Centers for AIDS Research Network of Integrated Clinical Systems. *JAMA Cardiol* 2(2):155-162, 2017. (PMID: 28002550 PMID: PMC5310962)
 393. Merlin JS, SR Young, MO Johnson, M **Saag**, W Demonte, R Modi, S Shurbaji, WA Anderson, R Kerns, MJ Bair, S Kertesz, S Davies, JM Turan. Using patient perspectives to inform the development of a behavioral intervention for chronic pain in patients with HIV: a qualitative study. *Pain Med* 18(5):879-888, 2017. (PMID: 27425186 doi: 10.1093/pm/pnw150)
 394. Kim HN HM Crane, CV Rodriguez, S Van Rompaey, KH Mayer, K Christopoulos, S Napravnik, G Chander, H Hutton, ME McCaul, ER Cachay, MJ Mugavero, R Moore, E Geng, JJ Eron, MS **Saag**, JO Merrill, MM Kitahata, The role of current and historical alcohol use in hepatic fibrosis among HIV-infected individuals. *AIDS Behav* 21(7):1878-1884, 2017. (PMID: 28035496 PMID: PMC6029880)
 395. Crane HM, P Paramsothy, DR Drozd, RM Nance, JA Delaney, SR Heckbert, MJ Budoff, GA Burkholder, JH Willig, MJ Mugavero, WC Mathews, PK Crane, RD Moore, JJ Eron, S Napravnik, PW Hunt, E Geng, P Hsue, C Rodriguez, I Peter, GS Barnes, J McReynolds, WB Lober, K Crothers, MJ Feinstein, C Grunfeld, MS **Saag**, MM Kitahata; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. Types of myocardial infarction among human immunodeficiency virus-infected individuals in the United States. *JAMA Cardiol* 2(3):260-267, 2017. (PMID: 28052152 PMID: PMC5538733)
 396. Franco RA, ET Overton, AR Tamhane, JM Forsythe, JB Rodgers, JK Schexnayder, D Guthrie, S Thogaripally, A Zinsky, MS **Saag**, MJ Mugavero, HE Wang, JW Galbraith. Characterizing failure to establish Hepatitis C care of baby boomers diagnosed in the emergency department. *Open Forum Infect Dis* 3(4):ofw211 (PMID: 28066793 PMID: PMC5198583)
 397. Noorhasan M, DR Drozd, C Grunfeld, JO Merrill, GA Burkholder, MJ Mugavero, JH Willig, AL Willig, KL Cropsey, KH Mayer, A Blashill, M Mimiaga, ME McCaul, H Hutton, G Chander, WC Mathews, S Napravnik, JJ Eron, K Christopoulos, RJ Fredericksen, RM Nance, JC Delaney, PK Crane, MS **Saag**, MM Kitahata, HM Crane. Associations between at-risk alcohol use, substance use, and smoking with lipohypertrophy and lipoatrophy among patients living with HIV. *AIDS Res Hum Retroviruses* [Epub ahead of print] Feb 16, 2017. (PMID: 28092168 PMID: PMC5467136)
 398. Vinikoor MJ, E Sinkala, R Chilengi, LB Mulenga, BH Chi, Z Zyambo, CJ Hoffmann, MS **Saag**, MA Davies, M Egger, G Wandeler; leDEA-Southern Africa. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia. *Clin Infect Dis* 64(10): 1343-1349, 2017. (PMID: 28158504 PMID: PMC5411400)
 399. Benson CA, JS Currier, C Del Rio, JE Gallant, RM Gulick, JM Marrazzo, DD Richman, MS **Saag**, RT Schooley, PA Volberding. A conversation among the IAS-USA board of directors: hot topics and emerging data in HIV research and care. *Top Antivir Med* 24(4):142-151, 2017. (PMID: 28208122)
 400. Locke JE, S Mehta, D Sawinski, S Gustafson, BA Shelton, RD Reed, P MacLennan, C Bolch, C Durand, A Massie, RB Mannon, R Gaston, M **Saag**, T Overton, DL Segev. Access to kidney transplantation among HIV-infected waitlist candidates. *Clin J Am Soc Nephrol* 12(3):467-475, 2017. (PMID: 28232406 PMID: PMC5338712)
 401. Crane HM, ME McCaul, G Chander, H Hutton, RM Nance, JAC Delaney, JO Merrill, B Lau, KH Mayer, MJ Mugavero, M Mimiaga, JH Willig, GA Burkholder, DR Drozd, RJ Fredericksen, K Cropsey, RD Moore, JM Simoni, WC Matthews, JJ Eron, S Napravnik, K Christopoulos, E Geng, MS **Saag**, MM Kitahata. Prevalence and factors

- associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. *AIDS Behav* 21(7):1914-1925, 2017. (PMID: 28285434 PMID: PMC5628735)
402. Wyles D, M **Saag**, RM Viani, J Lalezari, O Adeyemi, L Bhatti, A Khatrri, JR King, YB Hu, R Trinh, NS Shulman, P Ruane. TURQUOISE-1 Part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for Hepatitis C Virus Infection in HIV-1 coinfecting patients on darunavir. *J Infect Dis* 215(4):599-605, 2017. (PMID: 28329334 DOI: 10.1093/infdis/jiw597)
403. Vinikoor MJ, E Sinkala, R Chilengi, LB Mulenga, BH Chi, Z Zyambo, CJ Hoffmann, MS Saag, MA Davies, M Egger, G Wandeler, leDEA-Southern Africa. Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia. *Clin Infect Dis* 64(10):1343-1349, 2017. (PMID: 28158504 PMID: PMC5411400)
404. Drozd DR, MS **Saag**, AO Westfall, WC Mathews, R Haubrich, SL Boswell, SR Cole, D Porter, MM Kitahata, T Juday, L Rosenblatt; CFAR Network of Integrated Clinical Systems (CNICS). Comparative effectiveness of single versus multiple table antiretroviral therapy regimens in clinical HIV practice. *Medicine (Baltimore)* 96(14):e6275, 2017 (PMID: 28283402 PMID: PMC5411186)
405. Caniglia EC, LE Cain, CA Sabin, JM Robins, R Logan, S Abgrall, MJ Mugavero, S Hernandez-Diaz, L Meyer, R Seng, DR Drozd, GR Seage 3rd, F Bonnet, F Dabis, RD Moore, P Reiss, A van Sighem, WC Matthews, J Del Amo, S Moreno, SG Deeks, R Muga, SL Boswell, E Ferrer, JJ Eron, S Napravnik, S Jose, A Phillips, AC Justice, JP Tate, J Gill, A Pacheco, VG Velosa, HC Bucher, M Egger, H Furrer, K Porter, G Touloumi, H Crane, JM Miro, JA Sterne, D Costagliola, M **Saag**, MA Hernan; HIV-CAUSAL Collaboration; Centers for AIDS Research Network of Integrated Clinical Systems. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. *Lancet* 4(6):e251-e259, 2017. (PMID: 28411091 PMID: PMC5492888)
406. Cole SR, JK Edwards, HI Hall, MA Brookhart, WC Matthews, RD Moore, HM Crane, MM Kitahata, MJ Mugavero, MS **Saag**, JJ Eron; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) investigators. Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including Raltegravir or Efavirenz among adults in the United States. *Clin Infect Dis* 64(11):1591-1596, 2017. (PMID: 2848892 PMID: PMC6059161)
407. Drozd Dr, MM Kitahata, KN Althoff, J Zhang, SJ Gange, S Napravnik, GA Burkholder, WC Mathews, MJ Silverberg, TR Sterling, SR Heckbert, MJ Budoff, S Van Rompaey, JAC Delaney, C Wong, W Tong, FJ Palella, RA Elion, JN Martin, JT Brooks, LP Jacobson, JJ Eron, AC Justice, MS Freiberg, DB Klein, WS Post, MS **Saag**, RD Moore, HM Crane. Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. *J Acquir Immune Defic Syndr* 75(5):568-576, 2017. (PMCID: PMC5522001 PMID: PMC5522001).
408. Barbian HJ, R Jackson-Jewett, CS Brown, F Bibollet-Ruche, GH Learn, T Decker, EF Kreider, Y Li, TN Denny, PM Sharp, GM Shaw, J Lifson, EP Acosta, MS **Saag**, JK Bar, BH Hahn. Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. *Retrovirology* 14(1):35, 2017. (PMID: 28576126 PMID: PMC5457593)
409. Trickey A, MT May, JJ Vehreschild, N Obel, MJ Gill, HM Crane, C Boesecke, S Patterson, S Grabar, C Cazanave, M Cavassini, L Shepherd, AD Monforte, A van Sighem, M **Saag**, F Lampe, V Hernado, M Montero, R Zangerle, AC Justice, T Sterling, SM Ingle, JAC Sterne. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV* 4(8):e349-e356, 2017. (PMID: 28501495 PMID: PMC5555438)
410. Trickey A, MT May, P Schommers, J Tate, SM Ingle, JL Guest, MJ Gill, R Zangerle, M **Saag**, P Reiss, AD Monforte, M Johnson, VD Lima, TR Sterling, M Cavassini, L Wittkop, D Costagliola, JAC Sterne, Antiretroviral Therapy Cohort Collaboration (ART-CC). CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC). *Clin Infect Dis* 65(6):959-966, 2017. (PMID: 28903507 PMID: PMC5850630)
411. Moore T, LM Dembry, MS **Saag**. Sunday in the park with infectious disease: workforce mismatch in a colorful universe of possibilities. *J Infect Dis* 216(Supp5):S581-S587, 2017. (PMID: 28938044 PMID: PMC5853217)

412. Pappas PG, MS **Saag**. In Memorium: William Ernest Dismukes 1939-2017. *J Infect Dis* 216(10):1185-1186, 2017. (PMID: 28968670)
413. Young J, C Smith, R Teira, P Reiss, I Jarrin Vera, H Crane, JM Miro, A D'Arminio Monforte, M **Saag**, R Zangerle, HC Bucher, Antiretroviral Therapy Cohort Collaboration (ART-CC). Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. *HIV Med* 19(2), 132-142, 2018 (PMID: 29110395 DOI: 10.1111/hiv.12562)
414. Bilal U, ME McCaul, HM Crane, WC Mathews, KH Mayer, E Geng, S Napravnik, KL Cropsey, MJ Mugavero, MS **Saag**, H Hutton, B Lau, G Chander. Predictors of longitudinal trajectories of alcohol consumption in people with HIV. *Alcohol Clin Exp Res* 42(3):561-570, 2018. (PMID: 29265385 PMCID: PMC5832592)
415. Vinikoor MJ, Z Zyambo, M Muyoyeta, G Chander, MS **Saag**, K Cropsey. Point-of-care urine ethyl glucuronide testing to detect alcohol use among HIV-Hepatitis B Virus coinfecting adults in Zambia. *AIDS Behav* 22(7): 2334-2339, 2018. (PMID: 29336004 PMCID: PMC6021200)
416. Merlin JS, AO Westfall, D Long, S Davies, M **Saag**, W Demonte, S Young, RD Kerns, MJ Bair, S Kertesz, JM Turan, M Kilgore, OJ Clay, J Starrels, D Pekmezi, MO Johnson. A randomized pilot trial of a novel behavioral intervention for chronic pain tailored to individuals with HIV. *AIDS Behav* 22(8):2633-2742, 2018. (PMID: 29340913 PMCID: PMC6047927)
417. Merlin JS, SR Young, MO Johnson, MS **Saag**, W Demonte, R Kerns, MJ Blair, S Kertesz, JM Turan, M Kilgore, OJ Clay, D Pekmezi, S Davies. Intervention mapping to develop a social cognitive theory-based intervention for chronic pain tailored to individuals with HIV. *Contemp Clin Trials Commun* 10:9-16, 2018.(PMID: 29696153 PMCID: PMC5898474)
418. Pettit AC, MJ Giganti, SM Ingle, MT May, BE Shepherd, MJ Gill, G Fatkenheuer, S Abgrall, MS **Saag**, J Del Amo, AC Justice, JM Miro, M Cavasinni, F Dabis, AD Monforte, P Reiss, J Guest, D Moore, L Shepherd, N Obel, HM Crane, C Smith, R Teira, R Zangerle, JA Sterne, TR Sterling; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. *J Int AIDS Soc* 21(1), 2018. (PMID: 29334197 PMCID: PMC5810321)
419. Eaton EF, A Tamhane, T Davy-Mendez, WC Mathews, RD Moore, MS **Saag**, MJ Mugavero. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. *AIDS* 32(3):347-355, 2018. (PMID: 29194118 DOI:10.1097/QAD.0000000000001708)
420. Burkholder GA, AR Tamhane, MM Safford, PM Muntner, AL Willig, JH Willig, JL Raper, MS **Saag**, MJ Mugavero. Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States. *PLoS One* 13(3):e0194940. (PMID: 29596462 PMCID: PMC5875791)
421. Modi R, KR Amico, A Knudson, AO Westfall, J Keruly, HM Crane, EB Quinlivan, C Golin, J Willig, Zinski, R Moore, S Napravnik, L Bryan, MS **Saag**, MJ Mugavero. Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: rationale and design of iENGAGE intervention trial. *Contemp Clin Trials* 2018 Jun 69:48-54. (PMID: 29526609 DOI: 10.1016/j.cct.2018.03.003)
422. Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, Monforte AD, Smith C, Cavassini M, **Saag M**, Sterling TR, Sterne JAC. Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. *AIDS*. 2018. [Epub ahead of print] (PMID: 29734221 doi: 10.1097/QAD.0000000000001848)
423. Hughes RA, May MT, Tilling K, Taylor N, Wittkop L, Reiss P, Gill J, Schommers P, Costagliola D, Guest JL, Lima VD, d'Arminio Monforte A, Smith C, Cavassini M, **Saag M**, Castilho JL, Sterne JAC. Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+: CD8+ ratio. *AIDS*. 2018 32(10):1361-1367, 2018. (PMID: 29851663 doi: 10.1097/QAD.0000000000001848)
424. Saag MS, CA Benson, RT Gandhi, JF Hoy, RJ Landovitz, MJ Mugavero, PE Sax, DM Smith, MA Thompson, SP Buchbinder, C del Rio, JJ Eron, G Fatkenheuer, HF Gunthard, J-M Molina, DM Jacobsen, PA Volberding. Antiretroviral drugs for treatment and prevention of HIV infection in adults – 2018 recommendations of the

- international antiviral society-USA panel. *JAMA* 320(4):379-396, 2018. (PMID: 30043070 doi: 10.1001/jama.2018.8431)
425. Eaton EF, Mathews RE, Lane PS, Paddock CS, Rodriguez JM, Taylor BB, **Saag** MS, Kilgore ML, Lee RA. A 9-point risk assessment for patients who inject drugs requiring intravenous antibiotics may allow health systems to focus inpatient resources on those at greatest risk of ongoing drug use. *Clin Infect Dis*. 2018 Aug 25. [Epub ahead of print] (PMID: 30165395 doi: 10.1093/cid/ciy722)
426. Merlin JS, Long D, Becker WC, Cachay ER, Christopoulos KA, Claborn K, Crane HM, Edelman EJ, Harding R, Kertesz SG, Liebschutz JM, Mathews WC, Mugavero MJ, Napravnik S, O' Cleirigh C, **Saag** MS, Starrels JL, Gross R. Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. *J Acquir Immune Defic Syndr* 79(1):77-82, 2018. (PMID: 29771793 doi: 10.1097/QAI.0000000000001741)
427. Nance RM, JAC Delaney, JM Simoni, IB Wilson, KH Mayer, BM Whitney, FM Aunon, SA Safren, MJ Mugavero, WC Matthews, KA Christopoulos, JJ Eron, S Napravnik, RD Moore, B Rodriguez, B Lau, RJ Frederickesen, MS Saag, MM Kitahata, HM Crane. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: A cohort study. *Ann Intern Med* 169(6):376-384, 2018.
428. Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, Chilengi R, Wandeler G, Mulenga J, Chisenga T, Bhattacharya D, **Saag** MS, Foster G, Fried MW, Kelly P. Chronic hepatitis B virus mono-infection at a university hospital in Zambia. *World J Hepatol*. 10(9):622-628, 2018. (PMID: 30310540 doi: 10.4254/wjh.v10.i9.622)
429. Weibel AR, Willig AL, Liu W, Sattar A, Boswell S, Crane HM, Hunt P, Kitahata M, Matthews WC, Saag MS, Lederman MM, Rodriguez B. Physical activity intensity is associated with symptom distress in the CNICS cohort. *AIDS Behav*. 2018 [Epub ahead of print] (PMID: 30368620 doi: 10.1007/s10461-018-2319-7)
430. Delaney JA, Nance RM, Whitney BM, Altice FL, Dong X, Trejo MEP, Matsuzaki M, Taxman FS, Chander G, Kuo I, Frederickesen R, Strand LN, Eron JJ, Geng E, Kitahata MM, Mathews WC, Mayer K, Moore RD, Saag MS, Springer S, Chandler R, Kahana S, Crane HM. Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV. *J Acquir Immune Defic Syndr* 79(3):283-287, 2018. (PMID: 30036277 doi: 10.1097/QAI.0000000000001803)
431. Nance RM, Crane HM, Ritchings C, Rosenblatt L, Budoff M, Heckbert SR, Drozd DR, Mathews WC, Geng E, Hunt PW, Feinstein MJ, Moore RD, Hsue P, Eron JJ, Burkholder GA, Rodriguez B, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC. Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. *AIDS Res Hum Retroviruses* 34(11):916-921, 2018. Epub 2018 Aug 21. (PMID: 29984593 doi: 10.1089/AID.2018.0053)
432. Hutton HE, Lesko CR, Li X, Thompson CB, Lau B, Napravnik S, Mayer KH, Mathews WC, McCaul ME, Crane HM, Frederickesen RJ, Cropsey KL, **Saag** M, Christopoulos K, Chander G. Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States. *AIDS Behav*. 2018 [Epub ahead of print] (PMID:30443807 doi: 10.1007/s10461-018-2337-5)
433. **Saag** MS, Günthard HF, Smith DM. Baseline genotype testing to assess drug resistance before beginning HIV treatment-reply. *JAMA*. 2018 320(20):2154. (PMID:30480722 doi: 10.1001/jama.2018.15946)
434. Gras L, May M, Ryder LP, Trickey A, Helleberg M, Obel N, Thiebaut R, Guest J, Gill J, Crane H, Lima VD, Monforte AD, Sterling TR, Miro J, Moreno S, Stephan C, Smith C, Tate J, Shepherd L, **Saag** M, Rieger A, Gillor D, Cavassini M, Montero M, Ingle SM, Reiss P, Costagliola D, Wit FWNM, Sterne J, de Wolf F, Gekus R; Antiretroviral Therapy Cohort Collaboration (ART-CC). Determinants of restoration of CD4 and CD8 cell counts and their ratio in HIV-1 positive individuals with sustained virological suppression on antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2018 [Epub ahead of print] (PMID: 30531492 doi: 10.1097/QAI.0000000000001913)
435. Muhammad JN, JR Fernandez, OJ Clay, MS **Saag**, ET Overton, AL Willig. Associations of food insecurity and psychosocial measures with diet quality in adults gaining with HIV. *AIDS Care* 17:1-9, 2018. (PMID: 30558446)

436. Delaney JA, Nance RM, Whitney BM, Crane HM, Williams-Nguyen J, Feinstein MJ, Kaplan RC, Hanna DB, Budoff MJ, Drozd DR, Burkholder G, Mugavero MJ, Mathews WC, Moore RD, Eron JJ, Hunt PW, Geng E, **Saag MS**, Kitahata MM, Heckbert SR. Cumulative human immunodeficiency viremia, antiretroviral therapy, and incident myocardial infarction. *Epidemiology*. 30(1):69-74, 2019. (PMID: 30273188 doi: 10.1097/EDE.0000000000000930)
437. Chan A, Collins LF, Cooper C, **Saag M**, Dieterich D, Sulkowski M, Naggie S, Correlation between tenofovir drug levels and the renal biomarkers RBP-4 and B2M in the ION-4 study cohort. *Open Forum Infect Dis* 6(1):ofy273, 2019. (PMID: 30697570 doi: 10.1093/ofid/ofy273)
438. Simoni JM, Nance RM, Whitney BM, **Saag MS**, Crane HM. HIV viral suppression trends. *Ann Intern Med* 170(8):582-583, 2019. (PMID: 30986840)
439. Eaton EF, Tamhane A, Davy-Mendez T, Moore RD, Mathews WC, Saag MS, Mugavero MJ, Wyatt CM, Gutierrez OM. Brief report: Kidney dysfunction does not contribute significantly to antiretroviral therapy modification in treatment-naïve PLWH receiving initial ART. *J Acquir Immune Defic Syndr* 81(1):e6-39, 2019. (PMID: 30865173 doi: 10.1097/QAI.0000000000001999.)
440. Merlin JS, Long D, Becker WC, Cachay ER, Christopolous KA, Claborn KR, Crane HM, Edelman EJ, Lovejoy TI, Mathews WC, Morasco BJ, Napravnik S, O'Clerigh C, **Saag MS**, Starrels JL, Gross R, Liebschutz JM. Marijuana use is not associated with changes in opioid prescriptions or pain severity among people living with HIV and chronic pain. *J Acquir Immune Defic Syndr* 81(2):231-247, 2019. (PMID: 30865181 doi: 10.1097/QAI.0000000000001998)
441. Crane HM, Miller ME, Pierce J, Willig AL, Case ML, Wilkin AM, Brown S, Asirof MG, Fredericksen RJ, **Saag MS**, Landay AL, High KP. Physical functioning among patients aging with human immunodeficiency virus (HIV) versus HIV uninfected: Feasibility of using the short physical performance battery in clinical care of people living with HIV aged 50 or older. *Open Forum Infect Dis* 6(3):ofz038, 2019 (PMID: 30882010 doi: 10.1093/ofid/ofz038)
442. Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrail S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage Lii GR, Gonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrin I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justic A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, **Saag M**, Herman MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. *Stat Med* 38(13):2428-2446, 2019. (PMID: 30883859 doi: 10.1002/sim.8120)
443. Kim HN, Nance RM, Williams-Nguyen JS, Chris Delaney JA, Crane HM, Cachay ER, Martin J, Mathews WC, Chander G, Franco R, Hurt CB, Geng EH, Rodriguez B, Moore RD, **Saag MS**, Kitahata MM: Centers for AIDS Research Network of Integrated Clinical Systems. Effectiveness of direct-acting antiviral therapy in patients with human immunodeficiency virus-Hepatitis C virus coinfection in routine clinical care: a multicenter study. *Open Forum Infect Dis* 6(4):ofz100, 2019 (PMID: 30949539 doi: 10.1093/ofid/ofz100)
444. Hudson FP, Mulenga L, Westfall AP, Warriar R, Mweemba A, **Saag MS**, Stringer JS, Eron JJ, Chi BH. Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia. *Antivir Ther* 24(4):291-300, 2019. (PMID 30977467 doi: 10.3851/IMP3299)
445. Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopolous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Oullet LJ, Quan VM, **Saag MS**, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load. *Clin Infect Dis* Apr 17, 2019 [Epub ahead of print] (PMID: 30994900 doi: 10.1093/cid/ciz299)
446. Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, Kallungal B, Coakley E, Acosta EP, Calandra G, **Saag M**. Antiretroviral activity of AMD11070 (An orally administered CXCR4 entry inhibitor): results of NIH/NIAID AIDS Clinical Trials Group (ACTG) Protocol A5210. *AIDS Res Hum Retroviruses* May 17, 2019 [Epub ahead of print] (PMID: 31099252 doi: 10.1089/AID.2018.0256.)

447. Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, **Saag** MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. *J Acquir Immune Defic Syndr* 81(5):572-577, 2019. (PMID: 31107299 doi: 10.1097/QAI.0000000000002075)
448. Crane HM, Nance RM, Heckbert SR, Ritchings C, Rosenblatt L, Budoff M, Wood BR, Tirschwell DL, Kim HN, Mathews WC, Geng E, Moore RD, Hunt PW, Eron JJ, Burkholder GA, Drozd Dr, Chow FC, Becker KJ, Zunt JR, Ho EL, Kalani R, Huffer A, Whitney BM, **Saag** MS, Kitahata MM, Delaney JAC. Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the United States. *J Acquir Immune Defic Syndr* 81(5):e141-e147, 2019. (PMID: 31135582 doi: 10.1097/QAI.0000000000002075)
449. Feinstein MJ, Nance RM, Delaney JAC, Heckbert SR, Budoff MJ, Drozd Dr, Burkholder GA, Willig JH, Mugavero MJ, Mathews WC, Moore RD, Eron JJ, Napravnik S, Hunt PW, Geng E, Hsue P, Peter I, Lober Wb, Crothers K, Grunfeld C, **Saag** MS, Kitahata MM, Lloyd-Jones DM, Crane Hm. Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network of Integrated Clinical Systems (CNICS). *BMC Med* 17(1):149, 2019 (PMID: 31362721 doi: 10.1186/s12916-019-1385-7)
450. **Saag** MS. What's all this fuss I hear about viral "blips"? *Clin Infect Dis* Sep 24, 2019 [Epub ahead of print] (PMID: 31550000 doi: 10.1093/cid/ciz937)
451. **Saag** MS, Dumond JB. Déjà vu all over again. *AIDS* 33(13):2097-2098, 2019.
452. **Saag** MS. HIV 101: fundamentals of antiretroviral therapy. *Top Antivir Med* 27(3):123-127, 2019.
453. Williams-Nguyen J, Hawes SE, Nance RM, Lindstrom S, Heckbert SR, Kim HN, Mathews WC, Cachay ER, Budoff M, Hurt CB, Hunt PW, Geng E, Moore RD, Mugavero MJ, Peter I, Kitahata MM, **Saag** MS, Crane HM, Delaney JA. Association of infection with chronic Hepatitis C virus and myocardial infarction in people living with HIV in the United States. *Am J Epidemiol* Nov 12, 2019 [Epub ahead of print] (PMID: 31712804 doi: 10.1093/aje/kwz236)
454. **Saag** MS, Mendoza DP, Sherman MS, Cote GM, Shih AR. Case 36-2019: A 34-year old man with dyspnea, odynophagia, and abdominal pain. *N Engl J Med* 381(21):2052-2061, 2019 (PMID: 31747731 doi: 10.1056/NEJMcpc1909625)
455. Simoni JM, Nance RM, Whitney BM, **Saag** MS, Crane HM. HIV Viral Suppression Trends. *Ann Intern Med* 170(8):582-583, 2019 (PMID: 39086840)

BOOKS:

1. Saag, Michael. *Positive: One doctor's personal encounters with death, life, and the US healthcare system.* Austin: Greenleaf Book Group Press, 2014.

Chapters:

1. **Saag** MS, Bennett JC. Immunoglobulins: structure, function, and molecular genetics. *In: Rheumatology and Immunology*, 2nd ed., eds. A.S. Cohen and J.C. Bennett, Grune and Stratton, p389-395, 1986.
2. **Saag** MS, Dismukes WE. Cryptococcosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 2nd ed., Butterworths, Stoneham, MA, p368-370, 1988.
3. **Saag** MS, Dismukes WE. Blastomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 2nd ed., Butterworths, Stoneham, MA, p373-375, 1988.
4. **Saag** MS, Dismukes WE. Histoplasmosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 2nd ed., Butterworths, Stoneham, MA, p370-373, 1988.
5. **Saag** MS, Dismukes WE. Coccidioidomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 2nd ed.,

- Butterworths, Stoneham, MA, p375-377, 1988.
6. **Saag MS, Dismukes WE.** Chronic pneumonia syndrome. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 2nd ed., Butterworths, Stoneham, MA, p335-338, 1988.
 7. Gibbons J, **Saag MS**, Parks ES, Parks WP, Hahn BH, Shaw GM. Genetic variation of Human Immunodeficiency Virus Type 1 (HIV-1) *in vitro* and *in vivo*. *In: Human Retroviruses, Cancer, and AIDS: Approaches to Prevention and Therapy*, p101-114, Aland Liss, Inc., 1988.
 8. **Saag MS, Dismukes WE.** Chronic pneumonia syndrome, Cryptococcosis, Histoplasmosis, Blastomycosis, Coccidioidomycosis. *In: Criteria for Diagnosis*, J.W. Hurst, ed., Butterworths, Stoneham, MA, pages 105, 123 - 125, 1989.
 9. Lapidus W, **Saag M.** Cryptococcal meningitis. *In: The Anti-fungal Agents: Fluconazole*, S. Johnson and F.N. Johnson, Series Editors, W. B. Powderly and J. W. Van't Wout, Consultant Editors, Marius Press, Lancashire, England, p133-151, 1992.
 10. **Saag MS.** Mycetoma. *In: Cecil's Textbook of Medicine*, J.B. Wyngaarden, L.H. Smith, J.C. Bennett, eds., 19th ed., W.B. Saunders Co., Philadelphia, PA, p1905-1906, 1992.
 11. **Saag MS.** Dematiaceous Fungal Infections. *In: Cecil's Textbook of Medicine*, J.B. Wyngaarden, L.H. Smith, J.C. Bennett, eds., 19th ed., W.B. Saunders Co., Philadelphia, PA, p1906-1907, 1992.
 12. **Saag MS.** Introduction to HIV and Associated Disorders. *In: Cecil's Textbook of Medicine*, J.B. Wyngaarden, L.H. Smith, J.C. Bennett, eds., 19th ed., W.B. Saunders Co., Philadelphia, PA, p1908,1992.
 13. **Saag MS.** Prevention of HIV infection. *In: Cecil's Textbook of Medicine*, J.B. Wyngaarden, L.H. Smith, J.C. Bennett, eds.,19th ed., W.B. Saunders Co., Philadelphia, PA, p1925-1928,1992.
 14. **Saag MS.** Renal, cardiac, endocrine, and rheumatologic manifestations of HIV infection. *In: Cecil's Textbook of Medicine*, J.B. Wyngaarden, L.H. Smith, J.C. Bennett, eds., 19th ed., W.B. Saunders Co., Philadelphia, PA, p1952-1957,1992.
 15. **Saag MS.** AIDS testing: Now and in the future. *In: The Medical Management of AIDS*, M.A. Sande and P.A. Volberding, eds., 3rd ed., W.B. Saunders Company, Philadelphia, PA, p33-53,1992.
 16. **Saag MS, Dismukes WE.** Chronic pneumonia syndrome. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 3rd ed., Butterworth-Heinemann, Stoneham, MA, p 314-316,1992.
 17. **Saag MS, Dismukes WE.** Cryptococcosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 3rd ed., Butterworth-Heinemann, Stoneham, MA, p 415-418,1992.
 18. **Saag MS, Dismukes WE.** Histoplasmosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 3rd ed., Butterworth-Heinemann, Stoneham, MA, p 418-420,1992.
 19. **Saag MS, Dismukes WE.** Blastomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 3rd ed., Butterworth-Heinemann, Stoneham, MA, p 420-422,1992.
 20. **Saag MS, Dismukes WE.** Coccidioidomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 3rd ed., Butterworth-Heinemann, Stoneham, MA, p 423-425,1992.
 21. Shaw GM, Pan G, Clark SJ, Hahn BH, **Saag MS.** Molecular and biologic transitions from acute to chronic HIV-1 infection. *In: Retroviruses of Human AIDS and Related Animal Diseases*, M. Girard, L. Valette, ed., 6th Colloque des Cent Gardes, Paris, France, p 73-77, 1992.
 22. **Saag MS.** Non-nucleoside reverse transcriptase inhibitor: L-697,661. *In: Antiviral Chemotherapy: New Directions for Clinical Application and Research*, J. Mills, L. Corey, eds., Vol. 3, PTR Prentice Hall, Englewood Cliffs, NJ, p349-354,1993.

23. **Saag MS.** Cryptococcosis infections. *In: Internal Medicine*, J. Stein, ed., 4th ed., Mosby Publishing, St. Louis, MO, p2235-2240,1994.
24. **Saag MS.** Natural history of HIV-1 disease. *In: Textbook of AIDS Medicine*, S. Broder, T.C. Merigan, Jr., D. Bolognesi, eds., Williams & Wilkins, Baltimore, MD, p 45-53,1994.
25. **Saag MS.** Cryptococcus and other fungal infections (histoplasmosis, coccidioidomycosis). *In: The Medical Management of AIDS*, M.A. Sande and P.A. Volberding, eds., 4th ed., W. B. Saunders Company, Philadelphia, PA, p437-459,1995.
26. **Saag MS.** AIDS testing: Now and in the future. *In: The Medical Management of AIDS*, M.A. Sande and P.A. Volberding, eds., 4th ed., W. B. Saunders Company, Philadelphia, PA, p65-88,1995.
27. **Saag MS.** Human immunodeficiency virus. *In: Atlas of Infectious Diseases*, G.L. Mandell, D. Mildvan, eds., second ed., Current Medicine, Philadelphia, PA, p 2.2-2.18,1995.
28. **Saag MS.** Mycetoma. *In: Cecil's Textbook of Medicine*, J.C. Bennett, F. Plum eds., 20th ed. Vol. 2, W.B. Saunders Co., Philadelphia, PA, p1834-1835, 1996.
29. **Saag MS.** Dematiaceous fungal infections. *In: Cecil's Textbook of Medicine*, J.C. Bennett, F. Plum eds., 20th ed. Vol. 2, W.B. Saunders Co., Philadelphia, PA, 1836, 1996 .
30. **Saag MS.** Prevention of HIV infection. *In: Cecil's Textbook of Medicine*, J.C. Bennett, F. Plum, eds., 20th ed. Vol. 2, W. B. Saunders Co., Philadelphia, PA, 1851-1855, 1996.
31. **Saag MS.** Renal, cardiac, endocrine, and rheumatologic manifestations of HIV infection. *In: Cecil's Textbook of Medicine*, J.C. Bennett, F. Plum eds., 20th ed. Vol 2, W.B. Saunders Co., Philadelphia, PA, 1875-1879, 1996.
32. Kilby JM, **Saag MS.** Clinical Experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. *In: Antiviral Chemotherapy: New Directions for Clinical Application and Research*, J. Mills, P.A. Volberding, L. Corey, eds., Vol. 4, Plenum Press, New York, NY, 291-298, 1996.
33. Pinner RW, **Saag MS**, Hajjeh R, Dismukes WE. Cryptococcosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 4th ed., Appleton & Lange, Stamford, CT, Chapter 8-54:446-449,1996.
34. Hajjeh RA, **Saag MS**, Pinner RW, Dismukes WE. Histoplasmosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 4th ed., Appleton & Lange, Stamford, CT, Chapter 8-55:449-452,1996.
35. **Saag MS**, Dismukes, WE. Blastomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 4th ed., Appleton & Lange, Stamford, CT, Chapter 8-56:452-454,1996.
36. Hajjeh RA, **Saag MS**, Pinner RW, Dismukes WE. Coccidioidomycosis. *In: Medicine for the Practicing Physician*, J.W. Hurst, ed., 4th ed., Appleton & Lange, Stamford, CT, Chapter 8-57:454-457,1996.
37. **Saag MS.** Clinical spectrum of human immunodeficiency virus diseases. *In: AIDS: Etiology, Diagnosis, Treatment and Prevention*, V.T. DeVita, Jr, S. Hellman, S.A. Rosenberg, eds., 4th ed., Lippincott-Raven Publishers, Philadelphia, PA, Chapter 13:203-213,1997.
38. **Saag MS.** Quantitation of HIV viral load: A tool for clinical practice? *In: Medical Management of AIDS*, M.A. Sande, P.A. Volberding, eds., 5th ed., W. B. Saunders Company, Philadelphia, PA, Chapter 4:57-74,1997.
39. **Saag MS.** Cryptococcosis and other fungal infections (histoplasmosis, coccidioidomycosis). *In: Medical Management of AIDS*, M.A. Sande, P.A. Volberding, eds., 5th ed., W. B. Saunders Company, Philadelphia, PA, Chapter 23:327-342,1997.
40. Mulanovich VE, **Saag MS.** Cryptococcal meningitis. *In: AIDS and the Nervous System*, J.R. Berger, R.M. Levy, eds., 2nd ed., Lippincott-Raven Publishers, Philadelphia, PA, 661-675,1997.
41. **Saag MS.** Human immunodeficiency virus. *In: Atlas of Infectious Diseases*, G. L. Mandell, D. Mildvan, eds., Vol. 1, second edition, Current Medicine, Inc., Philadelphia, PA, p2.3-2.14,1997.

42. Kilby JM, **Saag** MS. The pathogenesis of HIV-1 infection. *In: Manual of HIV Therapeutics*, W.G. Powderly, ed., Lippincott-Raven Publishers, Philadelphia, PA, 1-6, 1997.
43. Kilby JM, **Saag** MS. Natural history of HIV-1 disease. *In: Textbook of AIDS Medicine*, T.C. Merigan, Jr., J. Bartlett, D. Bolognesi, eds., 2nd ed., Williams & Wilkins, Baltimore, MD, 49-58, 1998.
44. **Saag** MS, Schooley RT. Antiretroviral chemotherapy. *In: Current Clinical Topics in Infectious Diseases - Volume 18*, J.S. Remington, M.N. Swartz, eds., Blackwell Scientific Publications, 154-179, 1998.
45. Hoesley CJ, **Saag** MS. Adefovir dipivoxil. *In: AIDS Therapy*, R. Dolin, H. Masur, **M. Saag**, eds., Churchill Livingstone, Philadelphia, PA, Chapter 16, 198-204, 1999.
46. **Saag** MS. Management of antiretroviral therapy failure. *In: AIDS Therapy*, R. Dolin, H. Masur, **M. Saag**, eds., Churchill Livingstone, Philadelphia, PA, Chapter 22, 263-278, 1999.
47. Grant RM, **Saag** MS. Laboratory testing for HIV-1. *In: The Medical Management of AIDS*, M.A. Sande, P.A. Volberding, eds., 6th ed., W. B. Saunders Company, Philadelphia, PA, Chapter 3, 43-65, 1999.
48. **Saag** MS. Cryptococcosis and other fungal infections (histoplasmosis, coccidioidomycosis). *In: The Medical Management of AIDS*, M.A. Sande, P.A. Volberding, eds., 6th ed., W. B. Saunders Company, Philadelphia, PA, Chapter 24, 361-377, 1999.
49. **Saag** MS. Approach to the management of patients who are failing antiretroviral therapy. *In: Principles and Practice of Infectious Diseases: Update*. G.L. Mandell, J. E. Bennett, R. Dolin, eds., 4th ed., W. B. Saunders Co., Philadelphia, PA Vol 1, No. 1 (suppl):1-18, 1999.
50. **Saag** MS. Mycetoma. *In: Cecil's Textbook of Medicine*, L. Goldman, J.C. Bennett, eds., 21st ed., W.B. Saunders Co., Philadelphia, PA, Part XXIII;404:1885-1887, 2000.
51. **Saag** MS. Dematiaceous fungal infections. *In: Cecil's Textbook of Medicine*, L. Goldman, J.C. Bennett, eds., 21st ed., W.B. Saunders Co., Philadelphia, PA, Part XXIII;405:1887-1888, 2000.
52. **Saag** MS. Prevention of HIV infection. *In: Cecil's Textbook of Medicine*, L. Goldman, J.C. Bennett, eds., 21st ed., W. B. Saunders Co., Philadelphia, PA, Part XXIII;410:1904-1907, 2000.
53. **Saag** MS. Renal, cardiac, endocrine, and rheumatologic manifestations of HIV infection. *In: Cecil's Textbook of Medicine*, L. Goldman, J.C. Bennett, eds., 21st ed., W.B. Saunders Co., Philadelphia, PA, Part XXIII;417:1928-1933, 2000.
54. Ehrensing ER, **Saag** MS. Cryptococcosis. *In: Fungal Diseases of the Lungs*. G.A. Sarosi, S. F. Davies, eds., 3rd ed., Lippincott Williams & Wilkins, Philadelphia, PA Chapter 7:91-103, 2000.
55. **Saag** MS. Strategic use of antiretroviral therapy. *In: AIDS Therapy*, R. Dolin, H. Masur, **M. S. Saag**, eds., 2nd ed., Churchill Livingstone, Philadelphia, PA, Chapter 27, 359-380, 2002.
56. Smith B, Raper J, **Saag** M. Human immunodeficiency virus. *In: Clinical Exercise Physiology*, JK Ehrman, PM Gordon, PS Visich, SJ Keteyian, eds., Human Kinetics Publishers, Inc., Champaign, IL. Chapter 23, 423-441, 2003.
57. **Saag** MS. Prevention of HIV infection. *In: Cecil's Textbook of Medicine*, L. Goldman, D. Ausiello, eds., 22nd ed., W. B. Saunders Co., Orlando, FL. Part XXIV, Chapter 413, 2149-2153, 2004.
58. **Saag** MS. Renal, cardiac, endocrine, and rheumatologic manifestations of HIV infection. *In: Cecil's Textbook of Medicine*, L. Goldman, D. Ausiello, eds., 22nd ed., W. B. Saunders Co., Orlando, FL. Part XXIV, Chapter 420, 2177-2183, 2004.
59. **Saag** MS. Strategic use of antiretroviral therapy. *In: AIDS Therapy*, R. Dolin, H. Masur, **M. S. Saag**, eds., 3rd ed., Churchill Livingstone Elsevier Inc, Philadelphia, PA, Chapter 4, 71-97, 2008.

60. Smith BA, Raper JL, **Saag** MS. Human immunodeficiency virus. In: *Clinical Exercise Physiology*, J.K. Erhman, P.M. Gordon, P.S. Visich & S.J. Keteyian, eds., 2nd ed., Champaigne, IL: Human Kinetics Publishers, pp. 443-458, 2009.
61. Saag MS. HIV as a chronic disease: the changing clinical profile. In: *HIV: Emerging Challenges in an Ongoing Epidemic*. Chapter 2, 8-16, 2012.

Published Abstracts

1. **Saag** MS, Reid KH. Site of Crossing of Jaw Opening Reflex in the Cat (Poster) Student Research Day, Louisville, KY, 1978.
2. **Saag** MS, Reid KH. Site of Crossing of Jaw Opening Reflex in the Cat (Slide) 63rd Annual Meeting FASEB, American Psychological Society, Dallas, TX, 1979.
3. **Saag** MS, Bonner JR, Gray BM. Group B streptococcal infections in adults. *Clin Res* 32(5):894A, 1984.
4. **Saag** MS, Shaw GM, Hahn BH, et al. Genetic analysis of sequential HTLV-III isolates over time. Department of Medicine Research Symposia, Birmingham, AL, 1986.
5. **Saag** MS, Shaw GM, Hahn BH, Redfield RR, Markham PD, Salahuddin SZ, Wong-Staal F, Gallo RC. Genetic analysis of sequential HTLV-III/LAV isolates before and after treatment with suramin. *Proceedings of the Second International Conference on AIDS*, Paris, France, 1986.
6. Dismukes WE, Bradsher R, Girard W, **Saag** M, Chapman S, Karam G, Stevens D, Kauffmann C, Gregg C, Shadomy S, and the NIAID Mycosis Study Group. Itraconazole therapy for blastomycosis and histoplasmosis - 26th ICAAC, 1986.
7. **Saag** MS, Cobbs CG. Treatment of chronic osteomyelitis in adults with ciprofloxacin. Southern Medical Association Meeting, Atlanta, GA, 1986.
8. Lyon MD, Smith KR, **Saag** MS, Cobbs CG. *Neisseria gonorrhoeae in vitro*. Symposium "Ciprofloxacin: A major advance in quinolone chemotherapy". Fort Lauderdale, FL, 1986.
9. **Saag** MS, Gibbons J, Parks W, Parks E, Wong-Staal F, Gallo RC, Shaw G, Hahn B. Extensive heterogeneity HTLV-III/LAV genomes in chronically infected patients with AIDS and related diseases. American Society of Hematology Meeting, *Blood* 65(5):132a, 1986.
10. **Saag** MS, Graves AH, Cobbs CG. The treatment of selected infections with ciprofloxacin, a new oral quinolone. A Scientific Exhibit. American College of Physicians 68th Annual Session, New Orleans, LA, 1987.
11. **Saag** MS, Gibbons J, Parks W, Parks E, Wong-Staal F, Gallo RC, Shaw G, Hahn B. Extensive heterogeneity of HIV genomes *in vivo*. *Proceedings of the Third International Conference on AIDS*, Washington, D.C., 1987.
12. Gibbons J, Kong L, **Saag** MS, Parks W, Parks E, Hahn B, Shaw GM. Molecular characterization of human immunodeficiency virus Type I isolate from plasma and peripheral blood mononuclear cells. American society of Hematology, 29th Annual Meeting, *Blood* 70:121a, 1987.
13. **Saag** MS, Bradsher R, Chapman S, Kauffman C, Girard W, Stevens D, Bowles-Patton C, Dismukes W, and the NIAID Mycoses Study Group. Itraconazole Therapy for Blastomycosis, Histoplasmosis, and Sporotrichosis. ICAAC, 28th Annual Meeting, Los Angeles, CA, 1988.
14. **Saag** MS, Decker D, Campbell S, Crain M, Leuther M, Shaw G. Quantification of plasma viremia in HIV infected children and adults. VI International Conference on AIDS, San Francisco, CA, 1990.
15. Emanuel PD, Robinson S, **Saag** M, Zuckerman KS. Hematopoietic growth factor and cytokine production by monocytes isolated from HIV-infected patients. VI International Conference on AIDS, San Francisco, CA, 1990.

16. Buchalter SE, Rainey D, **Saag** M. ICU survival of HIV-infected patients with and without respiratory failure. VI International Conference on AIDS, San Francisco, CA, 1990.
17. **Saag** MS. Pharmacologic management of acute cryptococcal meningitis. VI International Conference on AIDS, San Francisco, CA, 1990.
18. Middlebrooks M, Holloway M, Lakeman A, **Saag** M, Tolpin M, Pollard R, Whitley R. Predictive value of positive cytomegalovirus (CMV) cultures in AIDS patients. ICAAC, 30th Annual Meeting, Atlanta, GA, 1990.
19. Powderly W, **Saag** M, Cloud G, Dismukes W, Meyer R, Robinson P. Fluconazole (FLU) versus amphotericin B (AMB) as maintenance therapy for prevention of relapse of AIDS-associated cryptococcal meningitis (CM). ICAAC, 30th Annual Meeting, Atlanta, GA, 1990.
20. **Saag** MS, Clark SJ, Kappes JC, Hahn BH, Shaw GM. High-titer plasma viremia in acute HIV-1 infection. Symposium "HIV Disease: Pathogenesis and Therapy". Grenelle, Florida, 1991.
21. Clark SJ, **Saag** MS, Decker WD, Campbell-Hill S, Roberson JL, Kappes JC, Veldkamp PJ, Hahn BH, Shaw GM. High-level replication and cytopathicity of human immunodeficiency virus type-1 during primary infection. American Federation for Clinical Research, Seattle, WA, 1991.
22. **Saag** MS, Powderly WG, Hamill R, Graybill JR, Waskin HA, Hafner R, Albrecht J, Dismukes WE, and the NIAID Mycoses Study Group and AIDS Clinical Trials Group. Primary (1^o) therapy (RX) of AIDS-associated cryptococcal meningitis (CM) with SCH 39304. 31st ICAAC Meeting, Chicago, IL, 1991.
23. Clark SJ, **Saag** MS, Pan G, Decker WD, Hahn BH, Shaw GM. Biologic and genetic analysis of human immunodeficiency virus type-1 associated with viral transmission and primary infection. 31st ICAAC Meeting, Chicago, IL, 1991, #259.
24. Emini EA, Schleif WA, Byrnes VW, Kappes JC, **Saag** MS, Shaw GM. *In Vitro* and *In Vivo* derivation of HIV-1 variants resistant to inhibition by the nonnucleoside reverse transcriptase inhibitor L-697,661. Second Workshop on Viral Resistance, San Diego, CA, 1992.
25. **Saag** MS, Davis G, Bennett G, Bachus V, and the Zidovudine/Acyclovir Collaborative Group. Acyclovir in the management of early ARC patients. Symposium: Herpes - A Global Challenge, Berlin, Germany, 1992.
26. Lavelle J, Lang W, Lefkowitz L, Peterson E, **Saag** M, Spruance S, Greenberg S, Kessler H, and the ZDV/ACV Collaborative Group, USA. A randomized trial comparing zidovudine alone and in combination with acyclovir for treatment of early symptomatic HIV infection. VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 1992, #PoB 3585.
27. Clark S, Campbell-Hill S, Chopra P, Hahn B, Kappes J, **Saag** M, Shaw G. Quantitative assessment of viral replication in acute and early chronic HIV-1 infection: Implications for natural history and intervention. VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 1992, #PoA 2132.
28. **Saag** MS, Douglas J, Lapidus W, DeLoach LJ, Maples V, Laskin O, Massari F, Whitley R, Kappes J, Shaw G, Emini E. Safety and relative antiretroviral activity of L697,L661 versus zidovudine in HIV-1 infected patients. VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 1992, #WeB 1013.
29. Kappes J, Chopra P, Campbell-Hill S, Conway J, Wang S, Emini E, **Saag** M, Shaw G. Multiple surrogate marker analyses of Merck L-697,661 anti-HIV-1 activity in vivo. VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 1992, #PoB 3021.
30. Connick E, Clark S, **Saag** MS, Schooley RT, Curiel T. HIV-1 envelope and gag specific cellular immunity in primary HIV infection. VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 1992, #PoA 2172.
31. Graziosi C, Pantaleo G, Demarest J, **Saag** M, Shaw G, Fauci AS. Analysis of viral burden and expression during primary HIV infection. VIII International Conference on AIDS/STD World Congress, Amsterdam, the Netherlands, 1992, #MoA 0015.

32. Blanchard A, **Saag** MS, Hahn BH, Cassell GH. PCR detection of *mycoplasma fermentans* in HIV-infected patients and in HIV-seronegative patients. Congress of the International Organization for Mycoplasmatology, Ames, Iowa, 1992.
33. Smith KR, Pate MS, Cobbs CG, **Saag** MS. The *in vitro* effect of ofloxacin alone and in combination with ceftazidime or gentamicin against *Pseudomonas aeruginosa*. 4th International Symposium on New Quinolones, Munich, Germany, 1992, #332.
34. **Saag** MS, Douglas J, Lapidus W, Laskin O, Massari F, Kappes J, Shaw G, Emini E. Relative antiretroviral activity and development of resistance to L-697,661 (L-661). Infectious Diseases Society of America, Anaheim, CA, 1992.
35. Powderly WG, Cloud GA, **Saag** MS, Dismukes WE, NIAID AIDS Clinical Trials Group (ACTG) and Mycoses Study Group (MSG). Predictive value of serum and cerebrospinal fluid (CSF) cryptococcal antigen measurement in management of AIDS-associated cryptococcal meningitis. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992, #1208.
36. **Saag** MS. Fluconazole therapy. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
37. Emini EA, Byrnes VW, Sardana VV, Condra JH, Schleif WA, Kappes JC, Shaw GM **Saag** MS. The genetic and structural basis of resistance to the HIV type 1-specific nonnucleoside reverse transcriptase inhibitors. International Congress on Drug Therapy in HIV Infection, 1992.
38. Graziosi C, Pantaleo G, Demarest JF, **Saag** MS, Shaw GM, Fauci AS. Analysis of HIV proviral burden and viral expression during primary HIV infection. Keystone Symposia on Molecular and Cellular Biology, Albuquerque, NM, 1993, #Q001.
39. **Saag** MS, Piatak M, Kappes JC, Clark SJ, Luk KC, Yang LM, Hahn BH, Emini EA, Lifson JD, Shaw, GM. The use of quantitative competitive PCR (QC-PCR) as a measurement of antiretroviral drug activity. Keystone Symposia on Molecular and Cellular Biology, Albuquerque, NM, 1993, #Q004.
40. Shaw G, **Saag** M, Clark S, Kappes J, Hahn B, Yang L-M, Luk K-C, Piatak M, Lifson J. Implications of persistent plasma viremia in acute and early-chronic infection in HIV-1 natural history and pathogenesis. Keystone Symposia on Molecular and Cellular Biology, Albuquerque, NM, 1993, #Q005.
41. Connick E, Clark S, **Saag** MS, Schooley RT, Curiel TJ. HIV-specific cellular immunity in primary HIV-1 infection. Keystone Symposia on Molecular and Cellular Biology, Albuquerque, NM, 1993, #Q107.
42. Piatak Jr M, **Saag** MS, Yang L-M, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of plasma virus during all stages of HIV-1 infection, including asymptomatic infection: Measurement by quantitative competitive PCR (QC-PCR). Keystone Symposia on Molecular and Cellular Biology, Albuquerque, NM, 1993, #Q143.
43. Ghosh SK, Fultz PN, **Saag** MS, Sharp PM, Hahn BH, Shaw GM. A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Keystone Symposia on Molecular and Cellular biology, Albuquerque, NM, 1993, Q425.
44. Piatak Jr M, Yang L-M, Clark SJ, Kappes JC, Luk K-C, Hahn BH, **Saag** MS, Lifson JD, Shaw G. Direct evidence using QC-PCR methods for persistent, high levels of circulating virus in acute and early-chronic HIV-1 infection. International Society for Antiviral Research, April, 1993.
45. Piatak Jr M, Yang L-M, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Emini EA, Lifson JD, **Saag** MS. Accurate monitoring by QC-PCR of changes in circulating HIV-1 levels in patients in response to antiviral therapy. International Society for Antiviral Research, April, 1993.
46. Piatak Jr M, **Saag** MS, Yang L-M, Clark SJ, Kappes JC, Luk K-C, Hahn BH, Shaw GM, Lifson JD. High levels of plasma virus detected during asymptomatic, as well as during acute and late stages of HIV-1 infection by quantitative competitive PCR (QC-PCR). International Society for Antiviral Research, April, 1993.

47. **Saag** MS, Piatak Jr M, Kappes JC, Clark SJ, Luk KC, Yang LM, Hahn BH, Emini EA, Lifson JD, Shaw GM. The use of quantitative competitive PCR (QC-PCR) as a measurement of antiretroviral drug activity. IXth International Conference on AIDS, Berlin, Germany, June, 1993. PO-B43-2514
48. Mulligan M, Duliege A, Nail C, Petrakis T, Shaw G, **Saag** M, Rainey D, Kappes J, DeLoach L, Campbell-Hill S. HIV-1 therapy with high dose CD4-IgG. IXth International Conference on AIDS, Berlin, Germany, June, 1993. PO-B26-2007
49. Stewart KE, Haley WE, **Saag** MS. Effects of caregiving tasks, social network, and patient functioning on informal caregivers of HIV-infected men. IXth International Conference on AIDS, Berlin, Germany, June, 1993. PO-D22-4105
50. Cheeseman SH, Murphy RL, **Saag** MS, Havlir D, and ACTG 164/168 Study Team. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in. IXth International Conference on AIDS, Berlin, Germany, June, 1993. PO-B26-2109
51. Powderly WG, Cloud GA, **Saag** MS, Dismukes WE. Antigen testing in cryptococcosis. Cryptococcal Conference, Milan, Italy, September, 1993.
52. **Saag** M, Piatak Jr M, Kappes J, Lifson J, Shaw G. The use of quantitative competitive PCR (QC-PCR) as a measurement of antiretroviral drug activity. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October, 1993, #825.
53. **Saag** MS, Robinson S, Myers M, Cort S, Piatak M, Lifson J, Kappes J, Shaw GM. Changes in plasma HIV-1 load in patients adding nevirapine to continuing regimens of AZT/ddC, AZT/ddI, or ddI. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October, 1993.
54. Teppler H, Pomerantz R, Bjornsson T, Pientka J, Woolf E, Yeh K, Deutsch P, Squires K, **Saag** MS, Waldman S. Pharmacokinetics and tolerability of L-735,524, an HIV protease inhibitor, in healthy HIV-1 seronegative and HIV-1 infected subjects. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 1993.
55. Weinsier RL, **Saag** MS, Craig CB, Darnell S, Epps L, Mullins L, Ennis, D, Akrabawi SS. Specialized enteral nutrition with medium chain triglycerides (MCT) in people with AIDS (PWA) and fat malabsorption. American Society of Parenteral Enteral Nutrition, 1993.
56. **Saag** MS, Sommadossi JP, Rainey D, Myers M, Cort S, Hall D, Robinson S, Piatak M, Lifson J, Kappes J, Shaw GM. A pharmacokinetic and antiretroviral activity study of nevirapine in combination with zidovudine plus zalcitabine (ZDV/ddC), zidovudine plus didanosine (ZDV/ddI), or didanosine (ddI) alone. The First National Conference on Human Retroviruses and Related Infections, Washington, DC, December 1993.
57. **Saag** MS, Squires KE, Teppler H, Pomerantz R, Waldman S, Bjornsson T, Shaw GM, Kappes J, Emini E, Deutsch P. Clinical trials of inhibitors of the HIV-1 protease. Keystone Symposia on Molecular & Cellular Biology, Hilton Head, SC, January, 1994.
58. Shaw GM, **Saag** MS, Kappes JC, Hahn BH, Emini EA, Ho DD, Piatak Jr M, Lifson JD. Quantitative analysis of HIV-1 replication in acute and chronic infection and following treatment with novel antiviral regimens. Keystone Symposia on Molecular & Cellular Biology, Hilton Head, SC, January 1994, #J013.
59. Piatak Jr M, **Saag** MS, Yang LC, Kappes JC, Emini EA, Shaw GM, Lifson JD. QC-PCR monitoring of plasma viral load in the evaluation of experimental treatment for HIV infection. Keystone Symposia on Molecular & Cellular Biology, Hilton Head, SC, January 1994, #J523.
60. Lifson JD, Luk KC, Kappes JC, **Saag** MS, Shaw GM, Piatak Jr M. Biophysical, biochemical, and specimen processing considerations in the use of QC-PCR for analysis of HIV-1 viral load in plasma of infected patients. Keystone Symposia on Molecular & Cellular Biology, Hilton Head, SC, January 1994, #J248.
61. Squires KE, **Saag** MS, Teppler H, Pomerantz R, Waldman S, Bjornsson T, Woolf E, Yeh K, Emini E, Deutsch P. Phase I studies of L-735,524, an HIV protease inhibitor: Pharmacokinetics, tolerability and short-term antiviral activity. American Federation for Clinical Research, Baltimore, MD, April 1994. N-AD-0036.

62. Shaw G, Wei X, Johnson V, Taylor M, Decker J, Kilby M, Lifson J, Hahn B, **Saag M**. Nucleotide sequence analysis of HIV-1 RNA and DNA from plasma and PBMCs of patients treated with ZDV, ddI, and nevirapine: Rapid HIV-1 turnover and resistance development *in vivo*. Third International Workshop on HIV Drug Resistance, Kauai, Hawaii, August, 1994.
63. Johnson V, **Saag M**, Decker J, Sommadossi J-P, Myers M, Cort S, Hall D, Griffin J, Lifson J, Shaw G. Viral resistance in adults treated with nevirapine (NVP) added to established nucleoside RT inhibitor regimens of ZDV + ddC, ZDV + ddI, or ddI alone. Third International Workshop on HIV Drug Resistance, Kauai, Hawaii, August, 1994.
64. Shaw G, Wei X, Johnson V, Taylor M, Decker J, Kilby M, Lifson J, Hahn B, **Saag M**. Nucleotide sequence analysis of HIV-1 RNA and DNA from plasma and PBMCs of patients treated with AZT, ddI, and nevirapine: Evidence for rapid HIV-1 turnover *in vivo*. Gallo Lab Meeting, Rockville, MD, September 1994.
65. Olsen SJ, **Saag MS**, Sommadossi JP, Hedden BC, Raymond R, Stewart MB. Safety and pharmacokinetic interaction of sorivudine (BV-araU) and zidovudine. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, Session 40, #A58.
66. Kilby M, Taylor M, Wei X, Johnson V, Lifson J, Hahn B, **Saag M**, Shaw G. *In situ* expression and functional analysis of HIV-1 reverse transcriptase (RT) in patients treated with nevirapine (Nev), AZT, and ddI. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, Session 110, #1216.
67. Wei X, Johnson V, Taylor M, Decker J, Kilby M, Lifson J, Hahn B, **Saag M**, Shaw G. Rapid HIV-1 turnover in patients receiving combination nevirapine (Nev) therapy. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, Session 29, #164.
68. **Saag M**, Johnson V, Wei X, Sommadossi J-P, Myers M, Cort S, Hall D, Piatak M, Lifson J, Shaw G, and the BI1009 Working Group. Clinical, pharmacokinetic, and virologic results in adults treated with nevirapine (Nev) in combination with AZT/ddC, AZT/ddI, or ddI alone: Final report of the BI1009 study. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, Session 105, #M16.
69. Deutsch P, Teppler H, Squires K, **Saag M**, Pomerantz R, Bjornsson T, Waldman S, Osborne B, Justice S, DeLoach L, Pientka J, Hildebrand C, Massari F, Emini E. Antiviral activity of L-735,524, an HIV protease inhibitor, in infected patients. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994, Session 29, #159.
70. Zhang R, Yan J, Shahinlan H, Amin G, Lu Z, **Saag MS**, Jiang Z, Tamsamani J, Schechter PJ, Martin RR, Agrawai S, Diasio RB. Human pharmacokinetics of an anti-HIV antisense oligonucleotide phosphorothioate (GEM 91) in HIV-infected individuals. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 1994.
71. Cloud G, **Saag MS**, van der Horst C, Hafner R, Riser L, MaWhinney S, Thomas C. Design of a phase III trial of cryptococcal meningitis in AIDS patients. Society for Clinical Trials, Washington, D.C., December 1994.
72. Craig CB, Weinsier RL, **Saag MS**, Darrell B, Epps L, Mullins L, Akrabawi SS. Specialized enteral nutrition with medium chain triglycerides (MCT) in people with AIDS (PWA) and fat malabsorption. MeadJohnson Nutritional Group Clinical Study involving Lipisorb, 1994.
73. Murphy R, Havlir D, **Saag MS**, Cheeseman SH, Dransfield K, and the ACTG 168 Study Team. Safety, immunologic and virologic activity of nevirapine in combination with zidovudine therapy in HIV-infected patients. Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 1995.
74. Shaw G, Wei X, Ghosh S, Taylor M, Kilby Jr JM, Johnson V, Emini E, Lifson J, Hahn B, **Saag M**. Viral dynamics in HIV-1 infection. Second National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 1995.

75. MacGregor TR, Lamson MJ, Cort S, Pav JW, **Saag** MS, Elvin AT, Sommadossi J-P, Myers M, Keirns JJ. Steady state pharmacokinetics of nevirapine, didanosine, zalcitabine, and zidovudine combination therapy in HIV-1 positive patients. American Association of Pharmaceutical Scientists, New Brunswick, NJ, June 1995. Published in *Pharmaceutical Research* 12(9):S101,1995.
76. Taylor R, Germany-Decker J, Wei X, Lifson J, Nowak M, **Saag** MS, Hahn B, Shaw G. Quantitative analysis of replication-active, latent, and defective forms of HIV-1 provirus in peripheral blood implications for viral pathogenesis and therapy. 4th International Workshop on HIV Drug Resistance, Sardinia, Italy, July 6-9, 1995.
77. **Saag** MS, Cloud GC, Graybill JR, Sobel J, Tuazon C, Wiesinger B, Riser L, Moskovitz BL, Dismukes WE, and the NIAID Mycoses Study Group (MS). Comparison of fluconazole (FLU) versus itraconazole (ITRA) as maintenance therapy of AIDS-associated cryptococcal meningitis (CM). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995 (#453).
78. Van der Horst C, **Saag** M, Cloud G, Hamil R, Graybill R, Sobel J, Johnson P, Tuazon C, Kerkering T, Fisher J, Henderson H, Stansell J, Mildvan D, Riser L, Schneider D, Hafner R, Thomas C, Wiesinger B, Moskovitz, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group. PART I. Randomized double blind comparison of amphotericin B plus flucytosine (AMB+FC) to AMB alone (STEP 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995.
79. **Saag** M, van der Horst C, Cloud G, Hamill R, Graybill R, Sobel J, Johnson P, Tuazon C, Kerkering T, Fisher J, Henderson H, Stansell J, Mildvan D, Riser L, Schneider D, Hafner R, Thomas C, Wiesinger B, Moskovitz B, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group. PART 2. Randomized double blind comparison of amphotericin B plus flucytosine (AMB+FC) to AMB alone (Step 1) followed by a comparison of fluconazole (FLU) to itraconazole (ITRA) (Step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995 (#1199).
80. **Saag** M, Lancaster D, Sonnerborg A, Mulder J, Torres R, Schooley R, Harrigan R, Kelleher D, Symonds W. A Phase I/II study of a novel nucleoside reverse transcriptase inhibitor, 1592U89 monotherapy vs. 1592U89 + zidovudine (ZDV) or placebo in HIV infected patients with CD4 counts 200-500/mm³. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1996.
81. Cloud G, **Saag** M, van der Horst C, Dixon D, Hafner R and the NIAID Mycoses Study Group (MSG) and AIDS Clinical Trials Group (ACTG). The impact of early closure of a clinical trial on a related study. The Society for Clinical Trials, May 1996.
82. **Saag** M, Lancaster D, Sonnerborg A, Torres R, Thompson M, Mulder J, Schooley R, Gazzard B, D'Aquila R, Santin M, Gurgui M, Harrigan PR, LaFon S. Preliminary data on the safety and antiviral effect of 1592U89, alone and in combination with zidovudine (ZDV) in HIV-infected patients with CD4+ counts 200-500/mm³. XI International Conference on AIDS, Vancouver, Canada, July 1996 (#2675).
83. McDonald JM, Pan G, Zhou T, Mountz J, Radding W, **Saag** M. Calmodulin antagonists inhibit spontaneous apoptosis of CD4+ cells from HIV+ infected patients. XI International Conference on AIDS, Vancouver, Canada, July 1996.
84. Johnson VA, Bassett RL, Stanley KE, **Saag** MS, Fischl MA, and the ACTG 259 Study Team and Virology Laboratories. Predictors of syncytium-inducing viral phenotype in a phase II double-blind trial of SC-49483 plus ZDV vs. ZDV. 5th HIV Drug Resistance Workshop, Whistler, Canada, July 1996.
85. Sonnerborg A, Lancaster D, Torres R, Thompson M, **Saag** M, Schooley R, Mulder J, Gazzard B, D'Aquila R, Gurgui M, Feinberg J, Santin M, Lang W, Harrigan PR, Steel H, Tortell S, Romero C. The safety and antiviral effect of 1592U89, alone and in combination with zidovudine in HIV-1 infected patients with CD4+ counts 200-500 cells/mm³. Third International Congress on Drug Therapy in HIV Infection, Birmingham, UK, November 1996.
86. Marschner I, DeGruttola V, **Saag** M for the ACTG Cross Protocol Study Group. Prognostic value of CD4 counts and plasma HIV RNA: An ACTG cross protocol analysis. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997.

87. Johnson VA, Bassett RL, Stanley KE, **Saag** MS, Fischl MA, and the ACTG 259 Study Team and Virology Laboratories. Predictors of syncytium-inducing viral phenotype in a phase II double-blind trial of SC-49483 plus ZDV vs. ZDV. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
88. Many Jr WJ, **Saag** M. Delayed seroconversion to HIV at eighteen months following percutaneous exposure (PE) with rapid progression to AIDS. 7th Annual Meeting of the Society for Healthcare Epidemiology of America, St. Louis, MO, April 1997.
89. **Saag** M, Gersten M, Chang Y, Greenberg SL, Yu G, Clendeninn NJ. Long term virological and immunological effect of the HIV protease inhibitor, Viracept (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC). 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September 1997.
90. **Saag** M, Alldredge L, Kilby M, Venetta T, DiMassimo B, Lambert D, Johnson MR, Hopkins S. A short-term assessment of the safety, pharmacokinetics, and antiviral activity of T-20, an inhibitor of gp41 mediated membrane fusion. 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September 1997.
91. Graybill JR, Sobel J, **Saag** M, van der Horst C, Powderly W, Cloud G, and the NIAID Mycoses Study Group and AIDS Clinical Trials Groups, Univ Texas Health Science Center, San Antonio, TX, and NIAID, Bethesda, MD. Cerebrospinal fluid (CSF) hypertension in patients with AIDS and cryptococcal meningitis (CM). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997 (Abstract #I-153)
92. **Saag** M, Knowles M, Chang Y, Yu G, Chapman S, Clendeninn NJ. Durable effect of viracept (nelfinavir mesylate, NFV) in triple combination therapy. 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997.
93. Childress KJ, **Saag** M, Clougherty C, Pham S, Tolson J, Simpson K, Mauskopf J. Annual cost estimation and resource utilization for treating opportunistic illnesses associated with AIDS. 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 1997.
94. Youle M, Franzetti F, **Saag** M, Childress J, Berto P, Trueman P, Lacey L. Impact of lamivudine (3TC) on healthcare costs: results from the Caesar study. 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany, October 1997.
95. Stewart KE, Raper J, Cloud G, **Saag** MS. CD4 count, but not viral load, is associated with current quality of life. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1998.
96. Torres R, **Saag** M, Lancaster D, Sonnerborg A, Feinberg J, Thompson M, Lang W, Schooley R, Mulder J, D'Aquila R, Santin M, Lafon S. Antiviral effects of Abacavir (1592) following 36 weeks of therapy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1998, #659.
97. **Saag** MS, Cloud GC, Raper J, Tolson JM, McKinnon S, Gum A, Call S. Predictors of success of antiretroviral therapy (ART) in a prospective clinic cohort. 12th World AIDS Conference, Geneva, Switzerland, June 1998, poster #22363.
98. **Saag** MS, Westfall A, Call S, Pham SV, Chatwood A, Cloud G, Raper J. Patterns of antiretroviral therapy (ART) use from 1988-1998 in a cohort of 120 HIV + patients. 12th World AIDS Conference, Geneva, Switzerland, June 1998, poster #22355.
99. Call SA, Westfall AO, Pham S, Chatwood A, Cloud GA, Raper JL, **Saag** MS. Patterns of Antiretroviral Therapy Use from 1988-1998 in a Cohort of HIV-Infected Individuals. 12th World AIDS Conference, 28 June – 3 July 1998, Geneva, Switzerland
100. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin D, Vaughn A **Saag** M. Controversies in AIDS Treatment. Proceedings from CME Conference Sponsored by Cornell University Medical College and the American Foudnation for AIDS Research (AmFAR). November 8, 1997. Question and Answer Session. *AIDS Patient Care STDS*. 1998 Jul; 12(7):557-566

101. Frost KR, Bellman P, Cohen CJ, Currier J, Dobkin J, El-Sadr W, Holodniy M, Leonard A, Merrick S, Pinsky L, Rubin DS, **Saag M**, Vaughn A, Controversies in AIDS Treatment. Proceedings from CME Conference Sponsored by Cornell University Medical College and the American Foudnation for AIDS Research (AmFAR). November 8, 1997. Faculty Roundtable Discussion. . *AIDS Patient Care STDS*. 1998 Jul; 12(7):543-55
102. Stewart KE, Greene PG, Call SA, Westfall AO, Chatwood A, **Saag MS**. Patterns of Self-reported Adherence to ART in a Prospective Clinical Cohort. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 24-27 September 1998, San Diego, CA
103. Call SA, Wilcox CM, **Saag MS**, Heudebert GR. Evaluation of chronic diarrhea in AIDS: A cost-effectiveness analysis. Society of Medical Decision Making, Boston, MA, October 1998.
104. Call SA, Klapow JC, **Saag MS**, Stewart KE, Centor RM. Health related quality of life in HIV positive patients - variations in outcome across instruments. Society of Medical Decision Making, Boston, MA, October 1998.
105. Call SA, Monkemuller K, **Saag MS**, Wilcox CM. The changing etiology of chronic diarrhea in ptiens with the acquired immunodeficiency syndrome (AIDS). American College of Gastroenterology, Boston, MA, October 1998.
106. Derdeyn CA, Kilby JM, Miralles GD, Sfakianos G, Li LF, **Saag MS**, Hockett RD, Bucy RP. Discrimination between active and inducible viral RNA transcription in peripheral blood mononuclear cells from human immunodeficiency virus type 1 infected subjects regardless of effective antiretroviral therapy. University of Alabama at Birmingham Comprehensive Cancer Center Annual Research Retreat, Birmingham, AL, October 1998.
107. Hoesley CJ, **Saag MS**, Chatham A, Kilby JM. Prolonged HIV-1 RNA suppression on dual therapy in clinical practice. 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, November 1998.
108. Tuazon CU, Powderly WG, Cloud GA, **Saag MS**, vanderHorst CM, Dismukes WE, and MSG. Utility of serum and CSF cryptococcal antigen in the management of cryptococcal meningitis in AIDS patients. 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, November 1998.
109. Deyton L, Levine AM, **Saag M**. Weekly dosing with epoetin alfa in Hiv-infected patients with anemia. 40th Annual Meeting of The American Society of Hematology, Miami Beach, FL, December 1998.
110. Hunter E, Kilby M, **Saag M**, Hopkins S, Sakalian M. Novel targets for antiretroviral therapies. First International Confrence on the Discovery and Clinical Development of Antiretroviral Therapies, St. Thomas, West Indies, US Virgin Islands, December 1998.
111. Wei X, Kilby M, Hopkins S, **Saag M**, Shaw G. HIV-1 selection in response to inhibition of virus fusion and entry. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January-February 1999. Abstract #611
112. **Saag M**, Demasi R, Ross L, Graham N, Pham S. Viral genetic heterogeneity of antiretroviral drug susceptibility in an HIV clinical cohort. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January-February 1999.
113. Stewart KE, Westfall AO, Ross D, Greene PG, Tolson J, Call S, **Saag MS**. Self-reported adherence is a robust predictor of viral load change. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January-February 1999.
114. **Saag MS**, Raper JL, Chatham A, Westfall AO, Cloud GA, Call SA. Optimal Design of Salvage Protocols: Lessons from a Clinical Cohort. 2nd International Workshop on Salvage Therapy for HIV Infection, 19-21 May 1999, Toronto, Canada
115. Call SA, Raper JL, Westfall AO, Chatham A, McKinnon S, **Saag MS**. HIV-Related Health Care Utilization Costs by Disease Status in the Era of HAART. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 26-29 September 1999, San Francisco, CA
116. Stewart KE, Call SA, Cloud GA, Westfall AO, McKinnon SL, Chatham AG, **Saag MS**. Prospective prediction of ARV adherence: the role of patient-perceived barriers. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999. Abstract #587.

117. **Saag** MS, Kilby M, Ehrensing E, Gizzi NA, Siemon-Hryczyk P, Buss N, Oo CY. Saquinavir systemic exposure and safety of once daily administration of fortovase™ (Saquinavir) soft gel capsule (FTV) in combination with low dose ritonavir (RTV). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999. Abstract #330.
118. Call S, Westfall A, Cloud G, Johnson V, Raper J, Stewart K, Hellmann N, **Saag** M. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999.
119. Levine AM, Deyton L, **Saag** M and the Community HIV Anemia Management Protocol Sites (CHAMPS). Weekly dosing with epoetin alfa in HIV-infected patients with anemia: interim data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1999. Abstract #1313
120. **Saag** MS, Kilby M, Ehrensing E, Buss N, Oo CY. Modulation of saquinavir steady-state pharmacokinetics with “baby” doses of ritonavir in healthy volunteers. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, Portugal, October 23-27, 1999. Abstract #829
121. **Saag** MS, Levine AM, Deyton L. Once-weekly dosing of epoetin alfa increases hemoglobin and quality of life in HIV-positive patients with anemia. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, November 18-21, 1999. Abstract #528.
122. Bucy RP, Kilby JM, Sillers ML, Hockett RD, **Saag** MS. Analysis of the second phase of viral load decline after HAART – macrophage clearance *versus* decline in antigen driven immune response. 4th International Workshop on HIV, Cells of Macrophage Lineage, and Other Reservoirs, Florence, Italy, December 1-4, 1999.
123. Bucy RP, Derdeyn CA, Keith K, Kilby JM, **Saag** MS. HIV-1 is not rapidly cytopathic for directly infected normal human T cells *in vitro*. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January/February 2000, #A191p.
124. Kilby JM, **Saag** MS, Goepfert PA, Hockett RD, Saha BK, Bucy P. Significant delay in plasma vRNA rebound during a scheduled treatment interruption in HIV-1 chronically infected patients previously on effective therapy. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January/February 2000.
125. Bucy RP, Kilby JM, Goepfert PA, Hockett RD, Saha BK, **Saag** MS. Persistent vRNA in PBMC from HIV infected patients on potent antiretroviral therapy is associated with rare vRNA + cells. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January/February 2000.
126. Smith B, Hunter G, Raper, J, **Saag** M, Barone J, Randazza L. Fat distribution in HIV-and HIV + women on protease inhibitor therapy. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January/February 2000
127. Johnson VA, Call SA, Westfall AO, Cloud GA, Acosta EP, Tolson JM, Larder BA, **Saag** MS. Comparison of Predictive Value of Phenotypic vs. Genotypic Susceptibility Testing (both Expert Interpretation and Virtual Phenotype) on Long-term Virologic Suppression in an ART Experienced Cohort. 4th International Workshop on HIV Observational Database Meeting, March 2000.
128. Ross LL, Liao Q, Johnson VA, Call SA, Pham S, Tolson J, Gao H, Larder B, Hertogs K, **Saag** MS. Impact of HIV-1 Drug-Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage Therapy in a Community Setting. 4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Stiges, Spain
129. Coghlan M, Sommadossi J-P, Many W. **Saag** M, Johnson V. Lactic acidosis in hospitalized HIV-infected patients treated with nucleoside reverse transcriptase inhibitors. 38th Annual Meeting of the Infectious Diseases Society of American, New Orleans, LA, September 2000.

130. Ross, LL, Liao Q, Johnson VA, Call S, Pham S, Tolson J, Gao H, Larder B, Hertogs K, **Saag MS**. Impact of HIV-1 drug-resistance mutations and phenotypic resistance profile on virologic response to salvage therapy in an observational cohort. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000.
131. Little SJ, Routy JP, Collier AC, Daar ES, Koup RA, Conway B, **Saag MS**. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in North America. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000.
132. Johnson VA, Call SA, Westfall AO, Cloud GA, Acosta BP, Tolson JM, Larder BA, **Saag MA**. Predictive value of genotypic resistance testing as interpreted by experts and a virtual phenotype. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000.
133. Call SA, Johnson VA, Westfall AO, Acosta EP, Cloud GA, Ross LL, Larder BA, **Saag MS**. Degree of agreement among interpretations of genotypic resistance testing results in a cohort of ART-experienced individuals. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000.
134. **Saag MS**, Chen RY, Westfall AO, Cloud GA, Raper JL, Chatham A, Call SA, Acosta EP, Heudebert GR. Immunologic and Virologic Consequences of Antiretroviral Treatment Interruption (TI) in Clinical Practice 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2000, Toronto, Canada
135. Chen RY, Westfall AO, Cloud GA, Call SA, Johnson VA, Raper JL, Stewart KE, Acosta EP, Chatham A, Taylor K, **Saag MS** (Tolson J, Pham S). Immunologic and Virologic Consequences of Antiretroviral Treatment Interruption (TI) in Clinical Practice. Strategic Treatment Interruption Workshop, October 2000, Chicago, IL
136. Montaner JSG, **Saag M**, Schwartz R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel capsules (SQV) in HIV infected anti retroviral naïve patients. Frontiers in Drug Development for Antiretroviral Therapies (DART), Puerto Rico, December 2000. Abstract #048
137. Ross LL, Liao Q, Johnson VA, Call S, Pham S, Tolson J, Gao H, Larder B, Hertogs K, **Saag MS**. The impact of HIV-1 drug-resistance mutations and phenotypic resistance profile on virologic response to salvage therapy in a community setting. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
138. Goepfert PA, Edwards BH, Ritter GD, Sfakianos G, Marshall G, Mulligan MJ, Bucy RP, **Saag MS**, Kilby JM. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 2001.
139. Montaner JSG, **Saag M**, Schwartz R. Pharmacokinetic and safety evaluations of a once daily regimen of saquinavir soft gel capsules (SQV) in HIV infected anti retroviral naïve patients. Third European Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, February 2001. Abstract #043
140. Chen RY, Westfall AO, Cloud GC, Chatham A, Acosta EP, Raper JL, Heudebert G, **Saag MS**. Long-term Survival After Initiation of Antiretroviral Therapy. 8th Conference on Retroviruses and Opportunistic Infections, 4-8 February 2001, Chicago, IL
141. Chen RY, Westfall AO, Raper JL, Chatham A, Taylor K, Acosta EP, Stewart KE, Carter J, Heudebert G, Cloud GC, **Saag MS**. Defining Virologic Failure: Getting into the GAPS. 5th International Workshop on HIV Observational Databases Meeting, April 2001, Monte Carlo, Monaco
142. Acosta EP, **Saag MS**, Montaner JSG. Pharmacokinetics and safety of once daily saquinavir soft gel capsules/ritonavir in HIV-infected anti-retroviral naïve patients. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2001. Poster #3.14
143. Shaw G, Weil X, Jones N, **Saag M**, Korber B, Nowak M, Borrow P. Dynamics of HIV-1 immune control and escape. AIDS Vaccine 2001, Philadelphia, PA, September 2001.
144. **Saag MS**, Levine AM, Leitz GJ, Bowers PJ. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV-positive patients. 39th Annual Infectious Diseases Society of America, San Francisco, CA, October 2001. Poster Presentation #201437

Revised 01/14/2020

Michael S. Saag, MD

145. Chen RY, Mugavero MJ, Westfall AO, Cloud GA, Raper JL, Chatham AG, Acosta E, Taylor K, **Saag MS**. Durability of HAART regimens over time. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001. Poster Presentation #1914
146. Chen RY, Mugavero MJ, Accortt NA, Westfall AO, Raper JL, Cloud GA, Stone BK, Carter J, Pisu M, Allison J, **Saag MS**. HIV Healthcare costs driven by CD4 count and medications, not physician fees. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002. Abstract H-157
147. Mugavero MJ, Chen RY, Westfall AO, Cloud GA, Raper JL, Taylor KH, Carter J, Pisu M, Allison J, **Saag M**. Increased Cost of Lipodystrophy in HIV Patients Due to Higher Physician, Laboratory, and Medication Costs. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, MA
148. Chen RY, Westfall AO, Hardin M, Vermund SH, **Saag MS**. Complete Blood Count (CBC) as a Surrogate CD4 Marker for HIV Monitoring in Resource-Limited Settings. 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, MA
149. Chen RY, Westfall AO, Hardin M, **Saag MS**. Red Alert: Identifying Predictors of Mortality in HIV-Infected Individuals. 7th International Workshop on HIV Observational Databases, March 2003, Fiuggi, Italy
150. Bedimo R, Accortt NA, **Saag MS**, Linn C, Chansolme D, Chen RY, Hoesley CJ. Trends in AIDS-defining and other HIV-associated malignancies among HIV-infected patients: 1989 to 2002. 41st Annual Infectious Diseases Society of America, San Diego, CA, October 2003. Poster Presentation #638
151. Bedimo JR, Westfall AO, Chen RY, **Saag MS**. Sustained HIV viral suppression following treatment interruption: an observational study. 41st Annual Infectious Diseases Society of America, San Diego, CA, October 2003. Oral Presentation
152. Chung SY, Accortt NA, Raper JL, Allison J, Chen RY, **Saag MS**. Prevalence and risk factors for hypogonadism in HIV-infected men. 41st Annual Infectious Diseases Society of America, San Diego, CA, October 2003.
153. Curtis JR, Bailey-Griffin J, Lopez R, Raper J, Smith B, **Saag M**, Venkataraman R, Weaver M, Saag KG. Ethnic differences in bone disease among HIV+ patients with lipodystrophy. The International Society for Clinical Densitometry, Miami, FL, January 2004.
154. Smith B, **Saag MS**. Double blind placebo controlled study of exercise and oxandrolone on lean mass, fat distribution, blood lipids, bone density and training markers in HIV infected men and women on HAART. XV International AIDS Conference, Bangkok, Thailand, July 2004. Oral Presentation #MoOrB1059
155. Fätkenheuer G, Pozniak A, Johnson M, Plettenberg A, Staszewski S, Hoepelman IM, **Saag M**, Goebel F, Rockstroh J, Dezube B, Jenkins T, Medhurst C, Sullivan J, Ridgway C, Abel S, Youle M, van der Ryst E. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist. XV International AIDS Conference, Bangkok, Thailand, July 2004. Poster Presentation, Abstract #TuPeB4489
156. **Saag M**, Lee D, Wanke C, Gertner J, Engelson E, Heymsfield S, Kotler D. Physical characteristics of patients with human immunodeficiency virus (HIV)-associated adipose redistribution syndrome (HARS). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October/November 2004. Poster Presentation, #2661
157. Rajagopalan P, Davey R, Gazzard B, Lalezari J, Mitsuyasu R, **Saag M**, Salata R, Schiess A, Pertel P, Choudhri, S. BAY 50-4798, a subcutaneously administered IL-2 selective agonist, exhibits dose-proportional pharmacokinetics in HIV patients. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October/November 2004.
158. Katlama C, Raffi F, **Saag M**, Wilkinson M, Chung J, Smiley L, Salgo M. Week 12 response as a predictor of week 48 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the TORO studies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October/November 2004.

159. Sklar P, **Saag** MS, et al. Predictive value of C-reactive protein versus traditional risk factors for cardiovascular events among HIV-infected patients. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October/November 2004.
160. Curtis JR, Smith B, Landers K, Lopez R, Raper J, **Saag** M, Venkataraman R, Weaver M, Saag KG. Metabolic bone disease among an ethnically diverse cohort of HIV+ patients with lipodystrophy. ASBMR Meeting 2004.
161. Stringer JSA, Zulu I, Chi B, Stringer E, Levy J, Chisembele-Taylor A, Mwale A, Bolton C, **Saag** M, Reid S, Wilfert C, Bulterys M, Goldenberg R, Luhanga D, Sinkala M. Rapid deployment of antiretroviral therapy (ART) services is feasible and effective in resource-limited settings in sub-Saharan Africa. 12th Conference on Retroviruses and Opportunistic Infections; Boston, MA, February 22-26, 2005. Abstract 638B
162. Jacobson J, **Saag** MS. Evidence that intermittent structured treatment interruption (STI) promotes immunologic control of HIV replication: The results of AACTG 5068. 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janeiro, Brazil, July 24-27, 2005. Poster TuPe13.2B01
163. Kempf MC, Pisu M, Maherya A, Westfall AO, **Saag** MS. Gender Differences in Discontinuation / Change in HIV Treatment. 6th Annual North American Cohorts Meeting, 9-10 November 2005, Washington, DC
164. van der Ryst E, Fatkenheuer G, Pozniak A, Johnson M, Plettenberg A, Staszewski S, Hoepelman IM, **Saag** M, Goebel F, Rockstroh J, Dezube B, Medhurst C, Sullivan J, Ridgway C, Abel S, Youle M, Jenkins T. Maraviroc (UK-427,857), a novel CCR5 antagonist, demonstrates antiviral activity during 10 day monotherapy studies. Targeting HIV Entry – 1st International Workshop; Baltimore, MD, December 2-3, 2005.
165. Kempf MC, Maherya A, Westfall AO, Cloud GA, **Saag** MS. Racial Differences in Discontinuation of Efavirenz Treatment. 10th International Workshop on HIV Observational Databases, 23-26 March 2006, Madrid, Spain
166. Pozniak A, **Saag** M, Bellos N, Chiliade P, Grinsztejn B, Molina J-M, Katlama C, De Meyer S, Vangeneugden T, Lefebvre E, Hill A. Efficacy of TMC114/r in treatment-experienced HIV patients: Factors influencing outcome in the pooled 24-week analysis of POWER 1, 2, and 3. Presented at the 12th Annual Conference of the British HIV Association (BHIVA), Brighton, UK, 29 March-1 April 2006.
167. Kempf M-C, Pisu M, Maherya A, Westfall AO, **Saag** MS. Gender differences in discontinuation/change of HIV treatment. 2nd North American Congress of Epidemiology; Seattle, WA, June 21-24, 2006.
168. Kauf TL, **Saag** MS, Kithahata M, Gazzard B, Earnshaw SR, Graham CN, Davis A, Shearer AT, Mauskopf J. Simulation modeling of adherence and resistance on long-term outcomes in HIV. 44th Annual Infectious Diseases Society of America Meeting, Toronto, Ontario, Canada, October 12-15, 2006.
169. **Saag** MS, Rosenkranz S, Becker S, Lkingman K, Kallungal B, Zadzilka A, Coakley E, Acosta E, Calandra G, Johnson V, and NIAID AIDS Clinical Trials Group, Bethesda, MD USA. Proof of concept of antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): Results of the 1st dosing Cohort A studied in NIAID AIDS Clinical Trials Group (ACTG) Protocol A5210. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Poster submitted.
170. **Saag** MS, Rosenkranz S, Becker S, Lkingman K, Kallungal B, Zadzilka A, Coakley E, Acosta E, Calandra G, Johnson V, and NIAID AIDS Clinical Trials Group, Bethesda, MD USA. Proof of concept of antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): Results of the 1st dosing Cohort A studied in NIAID AIDS Clinical Trials Group (ACTG) Protocol A5210. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Poster #J-132.
171. Hogg R, Mugavero M, **Saag** MS, for the Antiretroviral Cohort Collaborator (ART-CC). Life expectancy of persons at the time of initiating cART in high-income countries. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Poster #V-145.
172. Mocroft A, **Saag** MS for the Antiretroviral Cohort Collaboration (ART-CC). Clinical endpoints for randomized clinical trials: All AIDS defining conditions are not created equal. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007. Oral presentation #O-122.

173. Mugavero M, Willig J, Chang P, Raper J, Allison J, **Saag** M. When to Start HAAART: A Rhetorical Question for Many? 11th International Workshop on HIV Observational Databases, 23-24 March 2007, Monte Carlo, Monaco, abstract 10C773.
174. Jackson D, Willig J, Westfall A, **Saag** M, Chang P, Allison J, Raper J, Mugavero M. Management of hyperlipidemia in an HIV cohort: Clinical inertia and failure to meet LDL cholesterol goals. 11th International Workshop on HIV Observational Databases, 23-24 March 2007, Monte Carlo, Monaco, abstract 10C819.
175. Mugavero M, Willig J, Lin H, Marler M, Raper J, Allison J, Pisu M, Schumacher J, **Saag** M. Non-adherence to HIV Outpatient Treatment: Characterizing the "No Show" Phenomenon. 11th International Workshop on HIV Observational Databases, 23-24 March 2007, Monte Carlo, Monaco, abstract 10C772.
176. Willig J, Westfall A, **Saag** M, Chang P, Raper J, Mugavero M. NRTI Prescription Errors in an Outpatient HIV Clinic. 11th International Workshop on HIV Observational Databases, 23-24 March 2007, Monte Carlo, Monaco, abstract 10C829.
177. Willig J, Kumar M, Raper J, **Saag** M, Mugavero M. HTML and HL7: A case study of the transfer of clinic notes to a centralized online hospital system. TEPR May 19-23, 2007; Dallas, TX.
178. Willig J, Kumar M, Gupta S, Westfall A, **Saag** M, Raper J, Mugavero M. Provider Documentation Accuracy Rates: A Continuous Quality Improvement Initiative at the 1917 Clinic. TEPR May 19-23, 2007; Dallas, TX.
179. **Saag** M, Balu R, Brachman P, Brothers C, Stancil B, Mosteller M, Wannamaker P, Sutherland-Phillips D, Phillips E, Mallal S, Shaefer M. High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR). 4th International AIDS Society Conference, 22-25 July 2007, Sydney, Australia.
180. van der Ryst E, Cooper D, Konourina I, **Saag** M, Goodrich J, Tawadrous M, Simpson P, Sullivan J, Westby M, Mayer H. Efficacy of Maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. 4th International AIDS Society Conference, 22-25 July 2007, Sydney, Australia.
181. Kempf MC, Pisu MA, Maherya A, Westfall AO, Cloud G, **Saag** MS. Racial Differences in Discontinuation of Efavirenz Treatment. 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 19-22, 2007, Québec City, Canada.
182. Lalezari JP, **Saag** MS, Walworth CM, Larson PJ. Injection site reactions in the BOSS study: An open-label safety study of enfuvirtide (ENF) injection with a needle-free injection device (NFID) or needle-syringe (NS). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17-20, 2007; Poster H-370.
183. Martorell C, **Saag** M, Blick G, Corales R, Brachman P, Balu R, Stancil B, Sutherland-Phillips D, Wannamaker P, Brothers C. Clinical presentation of hypersensitivity reaction to abacavir (ABC HSR) by HLA-B*5701 status. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17-20, 2007.
184. Robison L, Westfall A, Mugavero M, Kempf M, Cole S, Allison J, Willig J, Wilcox M, **Saag** M. Factors associated with short-term discontinuation of HAART regimens due to GI toxicity. 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA; October 4-7, 2007; abstract 891.
185. Mugavero MJ, Lin HY, Allison J, Giordano TP, Willig JH, Chang PW, Raper J, Schumacher J, Wray N, Cole SR, Davies S, **Saag** MS. Expanding the Spectrum of HIV Adherence: Non-adherence to Clinic Appointments. 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, CA; October 4-7, 2007; abstract 1134.
186. Houser SH, Willig JH Raper, JL Patil, MA, **Saag** MS. Overcoming barriers to implementation of electronic health records in an HIV clinic. American Public Health Association (APHA) 2007 Annual Meeting, Washington, DC, November 3-7. Abstract 154564.

187. Heera J, **Saag** M, Ive P, Whitcomb J, Lewis M, McFadyen L, Goodrich J, Mayer H, van der Ryst E, Westby M. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naïve patients (MERIT). 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA February 1-6, 2008. Oral presentation #40LB.
188. Routman J, Willig J, Westfall A, Abroms S, Varshney M, Adusumilli S, Allison J, Savage K, **Saag** M, Mugavero M. Similar Responses Observed in ARV-naïve Patients Treated through Clinical Trials vs. Clinical Practice. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA; February 3-6 2008.
189. Ulett KB, Willig JH, Westfall AO, Routman J, Abroms S, Allison JJ, Chatham A, Raper JL, **Saag** MS, Mugavero MJ. Therapeutic Implications of Timely Linkage and Early Retention in Care. 3rd International Conference on HIV Treatment Adherence, Jersey City, NJ; March 17-18 2008.
190. Mugavero MJ, Lin HY, Willig JH, Ulett KB, Routman J, Abroms S, Chang PW, Raper JL, **Saag** MS, Allison JJ. Appointment Adherence Predicts Survival in Patients Establishing Initial HIV Care. 3rd International Conference on HIV Treatment Adherence, Jersey City, NJ; March 17-18 2008.
191. Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, Schumacher JE, Wray NP, Cole SR, Davies SL, **Saag** MS. Implications of Appointment Non-adherence in an HIV Clinic Cohort. Society of Behavioral Medicine, 29th Annual Meeting and Scientific Sessions, 26-29 March 2008, San Diego, California.
192. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Raper JL, **Saag** MS, Mugavero MJ. Increased regimen longevity in the era of once daily fixed-dose combination HAART. 12th International Workshop on HIV Observational Databases, 27-30 March 2008, Malaga, Spain, abstract 12C1083. (PMID: 18784459 PMID: PMC2828871)
193. Westfall AO, Willig JH, Mugavero M, Varshney M, Adusumilli S, Allison J, Raper J, **Saag** MS. Information integrity: A pernicious menace to clinical cohort research. 12th International Workshop on HIV Observational Databases, 27-30 March 2008, Malaga, Spain, abstract 12C1089.
194. Westfall AO, Adusumilli S, Raper JL, Willig JH, Allison J, Kumar M, Varshney M, Chang PW, **Saag** MS, Mugavero M. Symptom based versus routine screening strategy for anal Papanicolaou screening among MSM in an HIV infected cohort. 12th International Workshop on HIV Observational Databases, 27-30 March 2008, Malaga, Spain, abstract 12C1086.
195. Willig JH, Frazier C, Chang P, Patil M, Raper JL, **Saag** MS, Mugavero MJ. Focused decision support: A workflow sensitive methodology for dosing error reduction. Towards an Electronic Patient Record (TEPR) 2008. Ft Lauderdale, FL, May 2008.
196. Raper J, Lin H, Willig J, Mugavero M, Allison J, **Saag** M. The Hidden Costs of Prior Authorization: Uncompensated Efforts of Medical Providers. 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington, DC, October 25-28, 2008.
197. Mugavero M, Lin H, Willig J, Nevin C, McKinnell J, Savage K, Tennenberg A, Klaskala W, **Saag** M. The Impact of Darunavir/ritonavir (DRV/r) & Raltegravir in the Clinic: A New Era for Treatment-Experienced Patients? 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington, DC, October 25-28, 2008.
198. McKinnell J, Willig J, Westfall A, Allison J, Raper J, **Saag** M, Mugavero M. Contemporary Antiretroviral Therapy: Is it Time for the Generalist to Return? 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington, DC, October 25-28, 2008.
199. Vance DE, Mugavero M, Willig J, Raper JL, **Saag** MS. Clinical characteristics and co-morbidity prevalence associated with aging with HIV. Alabama State Nurses Association Annual Conference, Florence, AL. October 2009.
200. Vance DE, Mugavero M, Willig J, Raper J, **Saag** M. Co-morbidity prevalence and clinical characteristics of aging with HIV. 2009 Gerontological Society of America, Atlanta, GA. November 2009.
201. Vance DE, Mugavero M, Willig J, Raper JL, **Saag** MS. Co-morbidity prevalence and clinical characteristics associated with aging and HIV. University of Alabama at Birmingham Geriatric Education Conference, Birmingham AL. February 2010.

202. Rodriguez B, Lanzkron S, Haywood Jr C, Kitahata M, D'Aquila R, Eron J, Moore R, Kahn J, **Saag M**, Lederman M and CFAR Network of Integrated Clinical Systems (CNICS). Sick cell disease is associated with a decreased probability of HIV infection among black patients in the United States. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 2010.
203. Cropsey K, Willig J, Mugavero M, Crane H, McCullumsmith C, Lawrence S, Raper J, Kitahata M, Schumacher J, **Saag M**, and CFAR Network of Integrated Systems (CNICS). Psychological and smoking characteristics of patients at two large HIV clinics: implications for smoking cessation interventions for HIV+ smokers. CFAR Network of Integrated Clinical Systems (CNICS) Annual Meeting, San Francisco, CA, February 2010.
204. Mugavero M, Lau B, Crane H, Willig J, Kitahata M, Moore R, **Saag M**, and CFAR Network of Integrated Systems (CNICS). Relative effectiveness of preferred initial antiretroviral (ARV) regimens in the CFAR Network of integrated clinical systems (CNICS) cohort. CFAR Network of Integrated Clinical Systems (CNICS) Annual Meeting, San Francisco, CA, February 2010.
205. Napravnik S, Cole S, Eron J, Lau B, Crane H, Willig J, Kitahata M, Saag M, Mugavero M, and CFAR Network of Integrated Systems (CNICS). Viremia copy-years (VCY): a measure of cumulative HIV burden among patients initiating antiretroviral therapy (ART). 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 2010.
206. Achenbach A, Kitahata M, Willig J, Casper C, Porter D, Aban C, Beasley M, and **Saag M**. Incidence and novel risk factors for AIDS-defining and non-AIDS-defining malignancies in the CFAR network of integrated clinical systems (CNICS). 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 2010.
207. Poon A, Aldous JL, Mathews C, Kitahata M, Kahn J, **Saag M**, Rodriguez B, Boswell S, Frost SD, Haubrich R, and the CNICS 002 study team. Association with transmission of M184V/I and a reduced viral load in therapy-naïve patients in the CFAR network of integrated clinical systems (CNICS) cohort. 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 2010.
208. Vance DE, Mugavero M, Willig J, Raper J, **Saag M**. Clinical and psychological characteristics of adults with HIV by decade. The New Zealand Psychological Society 2010 Annual Conference, Rotorua, New Zealand. July 2010
209. Vance DE, Mugavero M, Willig J, Raper JL, **Saag MS**. Prevalance of co-morbidity and clinical characteristics associated with aging with HIV. Poster presented at the 2010 UAB Comprehensive Nursing Conference, Birmingham, AL.
210. Crane HM, Grunfeld C, Mugavero M, Willig J, **Saag M**, Schumacher M, Cropsey K, Mayer K, Mimiaga M, Boswell S, Mathews WC, Feldman B, Fredericksen R, Kitahata MM. Behavioral predictors of lipatrophy and lipohypertrophy in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. 18th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, CA, February 2011.
211. Vance DE, Mugavero M, Willig J, Raper JL, and **Saag MS**. (May, 2011). Prevalence of comorbidity and clinical characteristics of HIV across the lifespan. Poster presented at the HIV/AIDS 2011: The Social Work Response, The Twenty-Third Annual National Conference on Social Work and HIV/AIDS, Boston College Graduate School of Social Work, Atlanta, GA.
212. **Saag MS**. Treatment in resource-limited settings: Impact and challenges. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012.
213. **Saag, MS**. A cluster randomized trial of routine vs discretionary viral load (VL) monitoring among adults starting antiretroviral therapy (ART) in Zambia. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012.
214. Crane HM, Mimiaga M, Fredericksen R, Mugavero M, Willig J, Burkholder G, Safran S, Mathews WC, Christopoulos K, Haubrich R, Boswell S, Kitahata M, Saag MM, Mayer K on behalf of CNICS. Impact and patterns of substance use among patients in routine HIV clinical care at-risk for potentially transmitting HIV in the "test-and-treat" era of HIV prevention. 17th International Workshop in HIV Observational Databases (IWHOD), Cavtat, Croatia, April 11-13, 2013.

215. Yanik E, Napravnik S, Cole S, Achenbach C, Gopal S, Dittmer D, Kitahata M, Mugavero M, Saag M, Eron J. Timing and predictors of cancer incidence following initiation of ART., CFAR network of integrated clinical systems 1996-2011. 19th Conference on Retroviruses and Opportunistic infections, Atlanta, GA, March 3-8, 2013.
216. Crane HM, Mimiaga M, Drozd D, Frederickesen R, Mayer K, Nance R, Delaney JAC, Mugavero M, Cropsey K, Willig J, Burkholder G, Safren S, Mathews WC, Christopoulos K, Boswell S, Simoni J, Haubrich R, McCaul E, Hutton H, Chander G, Pantalone D, Williams E, Crane P, Merrill J, Kitahata MM, **Saag** MS on behalf of the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. Impact and patterns of alcohol and substance use with adherence behavior, HIV viral load (VL), and HIV transmission risk behavior among patients in routine clinical care. 18th International Workshop on HIV Observational Databases. Sitges, Spain, March, 2014.
217. Mgbemena O, Westfall A, **Saag** MS, Raper J, Overton ET, Norton W, and Merlin JS. Evaluation of a pilot physical therapy program for HIV-infected patients with chronic pain. Poster Session, American Pain Society, Tampa, FL, April 2014.
218. Reisner S, Mayer K, Grasso C, Crane HM, Kitahata MM, Mugavero M, **Saag** M, Schumacher J, Mathews C, Biell K, Mimiaga M. Correlates of substance use during sex among women living with HIV engaged in routine healthcare in four U.S. cities. 142nd Annual American Public Health Association Annual Meeting and Exposition. New Orleans, LA, November 2014.
219. Ingle S, Miro J, Furrer H, Justice A, **Saag** M, Manzardo C, Esteve A, Cain L, Sterne J, May M. (February 2015). Impact of ART on mortality in cryptococcal meningitis patients: high income settings. 22nd Conference on Retroviruses and Opportunistic infections, Seattle, WA, February 22-26, 2015.
220. **Saag** MS, Westfall A, Cole C, Mathews C, Haubrich R, Porter D, Boswell S, Drozd D, Kitahata M, Juday T, Rosenblatt L. Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. AMCP 27th Annual Meeting and Expo, San Diego, CA, April 9, 2015.
221. Hunt P, Crane H, Drozd D, Floris-Moore M, Moore R, Kitahata M, **Saag** M, Lederman M, Martin J. CRP, D-dimer and oxidized LDL predict myocardial infarction in treated HIV infection. 23rd Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2016.
222. Crane HM, Chow F, Becker KJ, Marra CM, Zunt JR, Ho EL, Kalani R, Huffer A, Nance R, Delaney JAC, Burkholder G, Moore R, Mathews WC, Eron J, Drozd D, Kitahata MM, **Saag** M, Tirschwell DL. Design, implementation, and findings of next generation stroke adjudication in HIV. 23rd Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2016.
223. Crane HM, Nance Rm, Delaney JAC, Drozd D, Heckbert S, Feinstein M, Young R, Moore RD, **Saag** MS, Kitahata MM. Optimal cardiovascular disease risk score for HIV-infection. 23rd Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2016.
224. Hahn A, Nance R, Delaney J, Frederickesen R, Crane H, Mugavero M, **Saag** M, Cropsey K, Mathews C, Tsui J, Simoni J, Chander G, Kitahata M, Jackson M, Mayer K, Merrill J. Effects of marijuana legal status change on use patterns among people living with HIV. 25th Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2018.
225. Williams-Nguyen J, Nance RM, Lindstrom S, Heckbert S, Peter I, Budoff M, Mathews WC, Eron JJ, Hunt PW, Moore RD, Mugavero MJ, Kitahata M, **Saag** M, Crane HM, Delaney J. Hepatitis C virus and incident Type 1 and Type 2 myocardial infarction in HIV. 25th Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2018.
226. Weibel A, Liu W, Liu J, Sattar A, Willig A, Boswell S, Crane H, Hunt P, Kitahata M, Mathews C, Moore R, **Saag** M, Lederman M, Rodriguez B. Physical activity intensity is associated with symptoms distress in the CNICS cohort. 25th Conference on Retroviruses and Opportunistic infections, Boston MA, February 21-26, 2018.
227. Crothers K, Harding BN, Whitney BM, Delaney J., Nance RM, Heckbert S, Budoff M, Mathews WC, Eron JJ, Moore RD, Mugavero MJ, **Saag** MM, Kitahata M, Crane HM. COPD and the risk for myocardial infarction by type in people living with HIV. 26th Conference on Retroviruses and Opportunistic infections, Seattle WA, March 3-7, 2019.

228. Whitney BM, Nance RM, Delaney J, Heckbert S, Budoff M, High K, Landay A, Feinstein, M, Moore RD, Mathews WC, Geng E, **Saag** MM, Kitahata M, Crane HM. Differences in types of myocardial infarctions among patients aging with HIV. 26th Conference on Retroviruses and Opportunistic infections, Seattle WA, March 3-7, 2019.
229. Achenbach CJ, Joyce B, Hou L, Hibler E, Martin JN, Mathews WC, Moore RD, Davy-Mendez, T, Rpdriquez B, Mayer KH, **Saag** MM, Kitahata M. CD4/CD8 ratio as a predictor of HIV-associated cancers in CNICS. 26th Conference on Retroviruses and Opportunistic infections, Seattle WA, March 3-7, 2019.
230. Amico KR, Modi R, Westfall A, Willig J, Keruly JC, Napravnik S, Crane HM, Quinlivan EB, Zinski AL, Golin CE, Long DM, Moore RD, **Saag** MM, Raper J, Mugavero MJ. Viral suppression among people initiating HIV care: outcomes from the iENGAGE trial. 26th Conference on Retroviruses and Opportunistic infections, Seattle WA, March 3-7, 2019.

MISCELLANEOUS

Newsletters:

1. **Saag** MS. Counseling AIDS patients: A new challenge for health care workers. *Alabama Health News* p 8, September 1989.
2. **Saag** MS. Opportunistic infections: Part I. *Questions* Spring, 1990.
3. **Saag** MS. AIDS update: More drug trials offered. *UAB Insight* 2(4):p 9,1990.
4. **Saag** MS. The ABCs of AZT. *Questions* Winter, 1990, p 3.
5. **Saag** MS. The HIV-infected physician. *Synopsis Forum* 10(13): 1991.
6. **Saag** MS. Will laws protect patients from health care workers with AIDS? *The Birmingham News* October 6,1991.
7. **Saag** MS. Testing for AIDS. *The Birmingham News* October 6,1991.
8. **Saag** MS. Toxoplasmosis. *Questions* 1(4):p 3,1991.
9. **Saag** MS. *Mycobacterium avium* complex. *Questions* 2(1):p. 3,1991.
10. **Saag** MS. Histoplasmosis. *Questions* 2(2):p 3,1991.
11. **Saag** MS. Answers regarding heterosexual transmission. *Questions* 3(1):p 3,1992.
12. **Saag** MS. UAB named as drug testing site. *Questions* 3(2):1,1992.
13. **Saag** MS. Editor's interview: Mike Saag. *UAB Magazine* No 3.: p 20-31, Winter, 1993.
14. **Saag** MS. The reach of AIDS. *The Birmingham News* (Review & Comment section) February 21, 1993.
15. **Saag** MS, Squires KE. A cure for AIDS by the Year 2000 -- Revisited. *UAB Insight*, Fall 1993.
16. **Saag** MS. Cryptococcus neoformans and the HIV patient: diagnosis, treatment, and prognosis. *Current Anti-Infective Therapy* Vol 13(4):p 3, 1993.
17. **Saag** MS. The protease inhibitors: A promising new approach to therapy. *HIV Newslines* 1(3):42-45,1995.
18. **Saag** MS. NIAID Refunds UAB's AIDS Clinical Trials Unit. *UAB Insight*, Spring 1996.

19. **Saag** MS. Impact of HIV viral load insights profound. *Current Anti-Infective Therapy*, Vol. 15, No. 6, 1995.
20. **Saag** MS. Disarray in health care: A call for physician leadership. *UAB Synopsis*, Vol. 15, No. 22, May 1996.
21. **Saag** MS. HIV now firmly established in the middle ages. *Clinical Infectious Diseases*, Editorial Commentary, October 2011.

Mongraphs/Handbooks:

1. **Saag** MS. Cryptococcosis. *Emerging Problems in the Management of Systemic Mycotic Infections*. Sponsored by the Division of Infectious Diseases and Division of Continuing Medical Education, University of Alabama at Birmingham; Published by Reiss Consultants, Inc., 1993.
2. **Saag** MS. Acute Antiretroviral Syndrome. *Comprehensive Management of HIV Disease*, (a Health Information Network Newsletter) published by World Health Communications Inc., p11-12, May 1993.
3. **Saag** MS. Cryptococcosis and histoplasmosis. *Management of Emerging Fungal Infections in AIDS*. Sponsored by the Division of Infectious Diseases and Division of Continuing Medical Education, University of Alabama at Birmingham; Panel discussions during the IX International Conference on AIDS in Berlin, Germany, 1993.
4. Benson C, Hughes W, **Saag** MS. New drugs for management of opportunistic infections. *Comprehensive Management of HIV Disease* (a Health Information Network Newsletter) published by World Health Communications Inc., p12-14, September 1993.
5. **Saag** MS. Cryptococcosis in patients with AIDS. *Opportunistic Infections of AIDS*, M. Pierce, ed., Norris Communications publisher, pp24-32, 1994.
6. **Saag** MS. Future directions in antiretroviral therapy: Waiting for Godot. *Clinical Care Options for HIV Quarterly*. Published by Healthcare Communications Group 1(2):13-15, August 1994.
7. **Saag** MS. Continuing antiretroviral therapy. *IAS-USA Improving the Management of HIV Disease* 2(2):4-6, August 1994.
8. **Saag** MS (session moderator). Pathogenicity and diversity of human immunodeficiency virus: Implications for clinical management. *Clinical Consensus*, published by World Health Communications Inc., January 1995.
9. Graham NMH, **Saag** MS (expert panelists). Initiation of antiretroviral therapy in HIV infection: a review of interstudy consistencies. *Clinical Consensus*, published by World Health Communications Inc., February 1995.
10. Graham NMH, Hardy WD, **Saag** MS (expert panelists). Combination therapy for HIV disease. *Clinical Consensus*, published by World Health Communications Inc., March 1995.
11. Volberging PA, Lagakos SW, Grimes JM, et al (CME Commentary based on an interview with Michael S. **Saag**). The Acquired Immunodeficiency Syndrome Clinical Trials Group: Extended analysis of Protocol 019. CME Reprints published by Grotelueschen Associates, Champaign, IL, 1995.
12. Expert Panel: Rinaldi MG, Graybill JR, **Saag** MS, Denning DW, Just-Nubling G, Berger T. Opportunistic fungal infections in AIDS patients: A Clinician's Handbook. Developed and produced for the Medical Mycological Society of the Americas by SynerMed, 1995.
13. **Saag** MS. *In vivo* dynamics of HIV infection. *Improving the Management of HIV Disease*, published by the International AIDS Society-USA, Vol 3, Issue 1, June, 1995.
14. **Saag** MS. Protease inhibitors. *Improving the Management of HIV Disease* published by the International AIDS Society-USA, Vol 3, Issue 2, August, 1995.
15. **Saag** MS, Kuritzkes DR. Strategies for continuing antiretroviral therapy. *Improving the Management of HIV Disease* published by the International AIDS Society-USA, Vol 4, Issue 2, June 1996.

16. Boucher C, **Saag M**. Viral load in HIV infection: Assays and clinical applications. Published by Adelphi Communications Ltd, United Kingdom, on behalf of F. Hoffman-La Roche Ltd, 1st ed., June 1996.
17. Schooley RT, Boswell SL, Coleman RL, Johnson SC, Kuritzkes DR, Markowitz MH, Mellors JW, Mildvan D, **Saag MS**. Roundtable discussions. *The Future of Antiretroviral Therapy: Targeting Hiv Reverse Transcriptase*. Published by World Health CME, a division of World Health Communications, Inc., 1997.
18. **Saag MS**. Issues in HIV Management: Clinical Applications of Viral-Load Testing. Published by Stratis-KPR, 1997.
19. **Saag MS**. Antiretroviral therapy: Select lesions from recent studies. *Topics in HIV Medicine*, a publication of the International AIDS Society-USA, 11(5): 164-168, 2003.
20. **Saag MS**. Initiation of antiretroviral therapy: Implications of recent findings. *Topics in HIV Medicine*, a publication of the International AIDS Society-USA, 12(3):83-88, 2004.
21. **Saag MS**. Ryan White Care Act reauthorization: We need help. *Topics in HIV Medicine*, 14(2):93-94, 2006.
22. **Saag MS**. Ryan White Care Act reauthorization: We need help. *AIDS Reader*. 2005 Nov; 16(11):594-6
23. **Saag MS**. UAB leads national AIDS research outcomes network. *UAB Insight*, Spring 2007
24. **Saag MS**. Ryan White: An Unintentional Home Builder. *AIDS Reader* 2009 May; 19(5): 166-8.